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ABSTRACT
CARDIOVASCULAR DISEASE IN DIABETIC WOMEN WITH BILATERAL
OOPHORECTOMY
Duke Appiah
April 16, 2013

Cardiovascular Disease (CVD) is the leading cause of death in women and the
risk is increased threefold in diabetics. In postmenopausal diabetics, the ovary responds
to hyperinsulinemia by increasing secretion of testosterone precursors which increases
the risk of CVD.
Data from the National Health and Nutrition Examination Survey (1988-2010)
and the Study of Osteoporotic Fractures were used to test the hypothesis that a history of
bilateral oophorectomy –surgical removal of both ovaries–would decrease the risk of
CVD among postmenopausal diabetic women due to reduced androgen levels. Logistic
regression, discrete time logit model, B-Spline regression and Cox proportional hazards
models were performed with adjusted estimates and 95% confidence intervals (CIs)
calculated.
Overall, the studies comprised of 17,549 postmenopausal women with
approximately 17.1 % having a history of diabetes Mellitus. Additionally, 24.1% of
diabetic women had undergone bilateral oophorectomy with 55% of these having the
surgery before age 45 years. Diabetics were more likely to be obese, live a more
sedentary lifestyle, have dyslipidemia and were more likely to report a higher prevalence
v

of stroke and myocardial infarction than non diabetics at baseline. Women who had
oophorectomy before age 45 years were more likely to be nulliparous and report a family
history of myocardial infarction.
Diabetic women with oophorectomy had lower levels of total testosterone compared to
diabetic women with intact ovaries or naturally menopausal non-diabetic women, which
was independent of age and body mass index (p=0.016). In multivariable regression
models, bilateral oophorectomy was predictive of prevalent CVD in diabetics (Odds
ratio: 1.63 (95% CI: 1.16 - 2.30) with the odds limited to women who had this procedure
before age 45 years (OR: 2.11, CI: 1.45-3.08). Although ovarian status did not influence
incident CVD in diabetic women (OR: 0.78, CI: 0.56-1.09), women with oophorectomy
before the average age at menopause (51 years), with or without diabetes were observed
to have elevated CVD risk in spline regression models. Furthermore, the risk of CVD
mortality was elevated for diabetic women irrespective of ovarian status, although
women with no ovaries had an increased risk (Hazard ratio: 2.57, CI: 1.18-3.67) than
those with intact ovaries (HR: 1.99, CI: 1.65-2.39).
This present analyses consisting of three different population-based samples of
postmenopausal women did not support oophorectomy having a protective effect on
cardiovascular health in diabetic women; however, our interpretation of these data is that
oophorectomy was performed more often in younger women who inherited a risk factor
for heart disease.
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CHAPTER ONE

INTRODUCTION

Type 2 diabetes is a metabolic disorder that is characterized by high blood
glucose levels and either insufficient insulin production or ineffective insulin action on
target cells (1). According to the International Diabetes Federation, 366 million (8.3%)
adults worldwide are living with type 2 diabetes mellitus, and this number is projected to
increase to 552 million (9.9%) by the year 2030; a number that has been attributed to the
concurrent obesity epidemic (2). In the United States, diabetes is the seventh leading
cause of death (3), and among diabetics aged 65 and older, heart disease accounts for
68% of all deaths (3). More than 12.6 million (11%) U.S. women over the age of 20 years
are estimated to have diabetes (4), and diabetes is thought to be a stronger risk factor for
CHD and cardiovascular disease (CVD) as whole, in women than men (5).
Women with diabetes are more likely to die of CHD compared to non diabetic
women or men with and without diabetes (5). Furthermore, diabetes has more debilitating
effects in women than men (6-9). For example, the estimate of mortality attributable to
CHD in men is 1 to 3 fold higher in diabetic than non-diabetic men while the risk in
women is 2 to 5 fold (8).
Additionally, the risk of CVD related-mortality among diabetic women with a
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prior history of CHD is 14 fold compared to 6.6 fold increased risk for women with a
prior history of CHD but no diabetes (10). Although women generally have poor
outcomes after coronary interventions namely percutaneous transluminal coronary
angioplasty (PTCA) and coronary artery bypass grafting (CABG), diabetic women are
reported to have far greater adverse outcomes compared to diabetic men or non-diabetic
women of same age (11).
Before menopause, women are 50% less likely to have a CVD event than men of
similar age. For example, among premenopausal women aged 35 to 39 in England and
Wales, the death rate from CHD was 30 per million compared to 194 per million persons
for men of same age (12). Diabetes eliminates the premenopausal gender related
differences in the prevalence of CHD (5, 7). In postmenopausal women, diabetes
increases the risk of a CHD event threefold compared to those without diabetes (5, 10,
13). Older diabetic women without CVD have a similar risk of cardiovascular mortality
compared to non-diabetic women with pre-existing CVD (14). Reasons why diabetes
increases CVD risk markedly in women compared to non-diabetic women is not well
understood. However, diabetes may induce a more adverse cardiovascular risk profile
and this may partially explain the greater excess CVD risk seem in them compared to
non-diabetic women (15). Traditional risk factors for CVD such as cholesterol, blood
pressure, and smoking which are also prevalent in diabetics do not fully explain the
gender difference in risk (6, 9).
While the loss of estrogens was previously thought to be the cause of the
increased CVD risk in women across the lifespan, current epidemiologic evidence
suggests that factors associated with the menopausal transition such as changes in
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cardiometabolic risk factors (hyperglycemia, dyslipidemia, insulin resistance and
abdominal obesity) play important roles and might rather explain the increasing CVD risk
(16-20). The poor CVD outcomes in diabetic women which maybe a reflection of
underdiagnosis or treatment bias that favors men (15), should also not be overlooked.
In most industrialized countries, the rate of mortality attributable to
cardiovascular diseases (CVD), namely coronary heart disease (CHD), has been declining
over the last 50 years. Since 1960, when mortality rates for CVD in the United States
were at their highest, a steady decrease has been observed which is believed to be a
reflection of the progress made in primary prevention especially smoking cessation, as
well as better diagnosis aided by novel imaging techniques, and finally improved
treatment due to great advances in thrombolytic therapy, pharmaceutical agents and
interventional devices such as percutaneous transluminal coronary angioplasty with a
drug-eluting stent and coronary artery bypass graft (21, 22). As an example, from the
period of 1998 to 2008, national estimates for CVD related mortality declined by 30.6%
(23). Despite this decline, cardiovascular disease related mortality accounts for 32.8% of
all deaths (24).
CVD is the leading cause of morbidity and mortality in women, and more than a
quarter of a million women aged 50 - 79 years in the United States die of heart diseases
each year (25). Contrary to popular belief, CHD claims more deaths compared to cancer,
chronic lower respiratory diseases and Alzheimer disease combined (23, 24). In fact,
compared to 1 in 31 deaths due to breast cancer, CHD results in 1 in 6.6 deaths in women
(23, 24). While high, these rates are projected to increase in the coming decade due to the
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debilitating effects of diabetes and obesity, coupled with an increasing aging population
(26).
It clearly is of substantial importance to understand the factors that contribute to
the gender disparity in CVD incidence and mortality. While some studies have reported a
gender bias in the utilization of percutaneous coronary intervention and CABG
procedures, others have found no such bias after correcting for age, differences in
severity of disease at time of surgery and comorbidities (27). Gender disparities,
however, exist in both medical care and outcomes of treatment procedures. Women
account for only 33% of the 1.2 million coronary interventions performed annually
nationwide (28). Additionally, women are less likely than men to receive the
recommended cardiovascular standards of care (29), undergo extensive evaluation of
cardiac symptoms (30) and be prescribed common prevention pharmaceutical agents
(such as aspirin, beta blockers, heparin, statins) (31). They also receive delayed
thrombolytic therapy (31). Furthermore, with regards to high-risk patients, as classified
by Thrombolysis in Myocardial Infarction (TIMI) scores, only 47.6% of women received
angiograms, angioplasty and CABG procedures compared to 60.5% of men (31, 32).
Additionally, women who have both CVD and other comorbidities such as diabetes and
dyslipidemia are less likely to receive frequent prescriptions to control these
comorbidities (31, 33). As highlighted earlier, this may well explain a large component of
the excess risk in cardiovascular disease related mortality associated with diabetes in
women compared to men (15)

4

RATIONALE AND SIGNIFICANCE OF THE STUDY
While the epidemiology, symptoms and prognosis of CVD differs in women and
men, the basis for these differences is not well understood. In addition, CVD risk factors
seem to have different impacts on the incidence of disease in the two sexes. For instance,
while cholesterol is a major predictor of disease in men, diabetes and hypertension are
more predictive of CVD in women (34). Moreover, the roles of sex specific
characteristics, such as endogenous hormones (androgens and estrogens), pregnancy and
menopause, together with genetic mechanisms and comorbidities, such as diabetes, in the
risk of CVD in women are not well understood.
Women on average develop CVD when they are about 10 years older than men,
and typically after the onset of menopause (34). Menopause is the transitional period after
which the ovaries stop producing eggs, and there is a cessation of menstruation. During
this period the levels of both estrogens and androgens are lower than in premenopausal
women due to follicular depletion and age-related atrophy of the adrenal cortex (35).
However, the postmenopausal ovaries remain hormonally active, secreting significant
amounts of androgens (35). In women with bilateral salpingo-oophorectomy (BSO),
which is the surgical removal of the ovaries, the levels of androgens are lower than in
women with natural menopause (36, 37). This was confirmed by a recent study using
liquid chromatography-tandem mass spectrometry (38). Contrary to the idea that the
majority of the testosterone produced by the postmenopausal ovary is converted into
estradiol thereby resulting in no significant difference in testosterone levels between
women with and without ovaries, testosterone is approximately 50% lower in women
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with BSO than naturally menopausal women with this difference persisting throughout
the menopausal years (39).
Understanding the influence of the hormonal milieu at menopause on
cardiovascular health remains elusive (40). Furthermore, there exists a debate in the
literature as to whether chronological aging or biological ovarian aging (follicular oocyte
depletion resulting in menopause which also causes reduced ovarian estrogen production)
is the reason for of the increased CVD risk in postmenopausal women compared to
premenopausal women, and for the delayed in CVD onset in women compared to men
(12). Depending on the type of statistical analyses employed, a rise in coronary disease
risk after menopause may or may not be observed. A rise/inflection in coronary disease
risk after menopause depicts ovarian aging contributing to CVD risk while no rise in
coronary disease risk at or after menopause gives evidence to chronological age
predisposing women to CVD. Displaying crude CHD rates compared with age-specific
rates or male to female age-specific death rates or semi-logarithmic graphs alternatively
support the idea that menopause or chronological aging affect CHD risk (41). Such
discrepancies have caused many to argue that the increase or no increase in CVD risk
after menopause maybe an artifact of the way vital statistics data are presented (41).
Studies of women with early natural menopause and CVD risk present equivocal
results. Although inadequate control for smoking (which is known to decrease the age of
natural menopause by 2 years) can confound results, most (41-45) but not all (46, 47)
studies which made adequate adjustment for current smoking status still found an
association between early natural menopause and CVD risk. Interestingly, the
Framingham Heart Study cohort reported that premenopausal CVD risk factors (smoking,

6

increased weight, blood pressure and decreased total cholesterol levels) determines age
at natural menopause with the authors concluding that such observations offers novel
explanation for the inconsistent findings on cardiovascular disease rate and its
relationship to menopausal age (48).
Hysterectomy is the second most common surgery performed on women of childbearing age after Cesarean section, and more than half of all women having a
hysterectomy also have both ovaries removed (BSO) most often as primary prevention
for ovarian cancer (49). But bilateral oophorectomy eliminates ovarian hormones, and
might be expected to influence CAD risk. Women who undergo hysterectomy (regardless
of oophorectomy status) have an adverse CVD risk profile compared to those without
hysterectomy, and BSO is linked to increasing CVD risk in some (41, 50-54) but not all
studies (55-59). However, the increased CVD risk among women with BSO is limited to
women who have the procedure before the average age at natural menopause (or an
arbitrary age of 45 years) and those not receiving hormone therapy (51-54).
Methodological issues, namely inappropriate comparison groups, small sample size and
lack of multivariable models have contributed to the conflicting results concerning how
BSO affects CVD (57, 59).
Assuming that the postmenopausal estrogen decline predisposes to increased
CVD risk, then hormone therapy (HT) during menopause would be expected to reduce
this risk. However, controlled clinical trials have refuted previously accepted conclusions
from observational studies that exogenous hormones are protective in the primary
prevention of heart diseases (60-62). The use of postmenopausal HT, which has been
suggested to have a short term beneficial effect when initiated immediately after BSO in
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premenopausal women (63), does not provide any protective effect against CVD in
women who have BSO after the expected natural age at menopause (64). Furthermore,
data from controlled trials provides little or no support for the timing hypothesis of
favorable effects from CVD among women who initiate postmenopausal HT soon after
menopause, either in women with hysterectomy only or intact uterus (65).
The failure to demonstrate a protective effect of estrogens in the primary
prevention of CVD in clinical trials has brought an increasing scientific interest how
thyroid-stimulating hormone and BSO are related to CVD risk, and to the possible role of
androgens and insulin resistance. Results from the largest U.S study on the menopausal
transition based on 10 years of follow-up indicate that changes in the lipid profile during
menopause tend to favor the progression of atherosclerosis (40). Across women of
different ethnicity, total cholesterol, low-density lipoprotein (LDL) cholesterol and
apolipoprotein-B levels increase during the menopause (40), while variation in HDL
subclass is observed with a decrease in HDL2 levels concurrent with an increase in
HDL3 level (66). Additionally, an increase in visceral adiposity during this transitional
period has been noted (67). These changes in the lipid milieu and adiposity result in a
more atherogenic profile. Moreover, women with visceral adiposity have increased
endogenous androgens (67) which increase levels of total and LDL cholesterol, reduce
HDL cholesterol and increase lipogenesis (68-70). Visceral fat may directly influence
atherosclerosis by accelerating the progression of coronary calcification (71).
Not only is there is much greater decline in estradiol than in testosterone
production following menopause, but also the effect of estrogen to increase sex hormone
binding globulin (SHBG) and thereby decrease the free bioactive component of
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androgens in circulation falls (72). Therefore the failure of estrogens to oppose the
activity of testosterone during the menopausal transition results in a state of relative
androgen excess (73). As testosterone progressively dominate the hormonal milieu during
the menopausal transition, the occurrence of other cardiometabolic disorders as well as
the effect of visceral adipose tissue (VAT) increase, independent of age (74). For instance
the Study of Women's Health Across the Nation (SWAN) established that the risk of
developing metabolic syndrome was associated with an increase in bioavailable
testosterone or a decrease in sex hormone-binding globulin (SHBG) levels (74).
Postmenopausal women with diabetes are especially susceptible to CVD. While HT was
found to reduce the incidence of diabetes (75-77), other trials enrolling diabetics reported
that even though HT improved lipid profile of diabetic women, it however predisposed
them to a faster progression of coronary atherosclerosis (78).
Testosterone levels are higher in postmenopausal women with diabetes than in
non-diabetic controls either matched on age and body mass index (BMI) (79-81), age and
years since menopause (82), or regression adjustment for age, BMI and waist to hip ratio
(83, 84). Even among diabetic women with similar total fat mass, android adiposity,
waist circumference and upper body fat as nondiabetics, the same relationship is
observed (85). These results tend to suggest that independent of age or adiposity;
hyperandrogenemia may play a role in the link between diabetes and CVD in women and
may as well explain the gender difference in diabetes-associated CVD (36, 82, 86).
Lower sex-hormone binding globulin (SHBG) levels in diabetics further increase the
circulating non-SHBG bound (bioavailable) testosterone and this further amplifies the
effect of testosterone independent of overall adiposity (body mass index) and central
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adiposity (as measured by the ratio of waist to hip circumferences) (87). Although some
studies have found low levels of SHBG and high androgenicity to be associated with
dyslipidemia and increased carotid artery intima-media thickness, which in turn is
associated with an adverse CVD risk factor profile in postmenopausal women (88-90),
evidence for an association with hard cardiovascular endpoints especially among diabetic
women in longitudinal studies is lacking. While the source of the excess androgens in
diabetic women has not been studied in detail, results in women with polycystic ovary
syndrome (PCOS), who are also more likely to be obese and insulin resistant (91, 92),
suggest an ovarian source of androgens in diabetics, although increased adrenal steroid
production might also contribute in part to the higher androgen levels reported in diabetic
women (93). Moreover, the ovaries in diabetics may have a reduced ability to convert
androgens to estrogens due to a reduction in ovarian aromatase activity (94).
Based on these observations, if increased testosterone levels raise the risk for
CVD in diabetic women, then reducing androgens should decrease this risk. A means of
assessing this hypothesis is by studying women with BSO.
An alternative possibility is that a sizeable portion of women whose ovaries are removed
are prediabetic with insulin resistance and anovulation, representing a group of women
with increased CVD risk (95) independent of ovarian hormones, and that BS0 in these
women will produce the same outcomes as they grow older and develop diabetes as in
nondiabetics. Furthermore, if estrogens limit visceral fat accumulation, and thereby
insulin resistance, then the removal of the ovaries at an early age may have a more
adverse effect than if this procedure is performed after the time of natural menopause.
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CVD is a complex process that includes genetic, inflammatory, and immune
factors as well as endocrine components. An added complexity is the influence of
diabetes on cardiovascular health especially among women. A great deal of research has
been done to improve our understanding regarding the roles cardiovascular risk factors
play to influence disease as well as interaction between these factors. Despite numerous
investigations into the moderating effect of gender on the etiology of CVD, as well as
improving our understanding as to why diabetes increases CVD disproportionately across
gender, much remains to be learned (96). Additionally, with research lacking on the
consequences of BSO in diabetic women, the aim of this present study is to contribute to
the understanding of the association between diabetes and cardiovascular disease, and to
investigate the moderating role oophorectomy may play on this relationship. Findings
from this study will help identify if a causal association exists, and will shed more light
on the roles androgens play on the increased risk for CVD in postmenopausal women
with diabetes. Furthermore results from this study will provide evidence and add
information to the current debate in the scientific community; as to whether the ovaries
should be removed or conserved during hysterectomy.

SPECIFIC AIMS OF THE STUDY

The aims of this study are twofold: first, to investigate whether bilateral salpingooophorectomy (BSO) has a moderating effect on cardiovascular disease risk in diabetic
women, including all cause mortality and CVD-related mortality using data from a
national survey; and, second to examine, using a large prospective observational study of
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postmenopausal women, the association of baseline levels of testosterone (free and total),
sex hormone binding globulins and estradiol with CVD-related mortality in diabetic as
well as nondiabetic postmenopausal women, and to determine if BSO influences the
association.

HYPOTHESES

We hypothesize that

1. Postmenopausal diabetic women without ovaries will have lower androgen levels
compared to postmenopausal diabetic women with intact ovaries and this
difference will significantly influence the risk of CVD.

2. Among postmenopausal women with diabetes, the risk of CVD events will be
lower in those who have undergone bilateral oophorectomy compared to those
without a history of oophorectomy.

3. If estrogens oppose visceral fat accumulation, then the removal of the ovaries at
an early age may have a more adverse effect on cardiovascular health than if this
procedure is performed after the time of natural menopause.
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CHAPTER TWO

BACKGROUND AND SIGNIFICANCE

Introduction
The 20th century observed a transition in the burden of disease in industrialized
countries as infectious/communicable diseases gave way to chronic diseases especially
CVD as the leading cause of morbidity and mortality in the adult population. While
improvement in the diagnosis of acute events such as MI increased in the early part of
that century, leading to a better understanding of this chronic condition, the underlying
causal factors were debated. However a growth in observational epidemiology by the
middle of the 20th century brought to light certain lifestyle factors which influence heart
disease, as researchers sought to study trends across countries and populations. This work
continues today: epidemiologic studies identify traditional and novel risk factors
associated with the prevention/control of CVD, while translational and interventional
studies seek new and better therapies. Despite substantial progress, CVD continue to
affect and negatively impact health and quality of life in men and women universally.
Several epidemiologic studies reveal that clinically relevant differences exist
between men and women in terms of incidence, prevalence, management and outcomes
of CVD, but less is known about why CVD affects women and men differently (97)
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Historically, heart disease has been perceived as a male disease, a belief that is fueled by
the media representation of patients with MI being men and the underrepresentation of
women advertisements for cardiac drugs (98, 99). This has contributed to fewer women
being enrolled in CHD trials. However it is worth mentioning that exclusion and
underrepresentation of women in heart disease trials was not necessarily an overt
discrimination perpetuated deliberately (98). Rather, the atypical presentation or
symptoms of CHD in women made them less likely to be referred to Cardiologist who
could, in turn, invite them to enroll in clinical trials. This has resulted in a shortfall of
evidence concerning sex-specific outcomes as well as CVD treatment in women (97).
While this knowledge gap may explain why cardiovascular health in women is not
improving as fast as that of men, gender differences in cultural, behavioral, psychosocial,
socioeconomic status and the endocrine- metabolic milieu may be contributory factors
(97).
This review outlines the epidemiology of CVD in women with emphasis on
gender differences and attempts to provide reasons why these differences exist.
Traditional modifiable risk factors will be briefly described. In recent years there has
been an increase in research into the effect of androgens on CVD, against the backdrop of
estrogens showing no protective effect on primary prevention of CVD, and an increasing
awareness of the connection between the attributes of the Metabolic Syndrome and CVD
In view of this, the review will include a comprehensive discussion on the roles
sex-specific characteristics and sex hormones on cardiovascular health. Finally, a detailed
discussion of the epidemiology of CVD in diabetic women, and how sex-specific
characteristics and sex hormones influence CVD risk in this high risk population.
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EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE

CVD is the leading cause of morbidity and disability in industrialized countries as
well as the leading cause of mortality worldwide. Current estimates from the World
Health Organization show that 17.3 million people around the globe die from CVD each
year, representing 30% of all deaths (100). Alarmingly, this figure has been estimated to
reach 25 million by the year 2030 (100). Additionally, 7.3 million and 6.2 million deaths
that occur annually are attributable to coronary heart disease and stroke respectively
(100). Low-and middle-income countries bear the greatest burden of CVD mortality with
80% percent of all deaths taking place in these countries, where deaths occurs almost
equally in men and women (100). In 2004, CVD alone caused approximately 32% (8.6
million) of deaths in women worldwide compared to 27% in men (101).
Recent reports from the United States estimate the overall annual rate of death
attributable to CVD to be 236.1 per 100,000 (age-standardized rate 237.1 per 100,000)
(102), representing 32.3% (787,931) of the total number of 2,437,163 deaths documented
(102). Furthermore, 2,150 Americans die of CVD each day, which is an average of one
death every 40 seconds (102). Moreover 34% of all CVD deaths occur in people who are
less than 75 years old (102).
Gender differences in the incidence and prognoses (short term and long term) of
CVD are well recognized. For instance since 1984, the number of deaths attributable to
CVD in American women has exceeded that of men (24). In 2009, 51 % (401,495) of all
CVD deaths occurred in women (102). Interestingly, 2 out of 3 women who die suddenly
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of CHD are asymptomatic (103). In addition, women are somewhat more likely to die
within one year of suffering a myocardial infarction (MI) compared to men (23% vs.
18%) (104), and nearly half of those women who survive are disabled by heart failure
(105). The burden of CVD mortality is also disproportionately distributed by
race/ethnicity as Blacks/African American women have a higher rate of CVD mortality
(267.9 per 100,000) than Non-Hispanic whites (190.4 per 100,000) (102). Among women
aged 20 years and older, the prevalence of CVD is highest among Blacks/African
American (48.9%), followed by Non-Hispanic Whites (32.4%) and Mexican Americans
(30.7%) (102).
With regards to the prevalence of CVD nationwide, 83.6 million American (1 in
3) are estimated to be living with one or more types of CVD, of whom 42.2 million are
aged 60 years and older (102). Of the total number of Americans living with some form
of cardiovascular disease, 42.9 million are women (102). The distribution of disease
prevalence according to the various CVD are as follows; 15.4 million (6.6 million
women) adults have coronary heart disease, 7.6 million (2.6 million women) have
myocardial infarction and 6.8 million (3.8 million women) have stroke (102). Before age
75, a higher proportion of CVD events attributable to CHD occur in men while in
women, a higher proportion of events is attributable to stroke (102).
Estimates based on data from the Framingham Heart Study (1980 to 2003)
indicate that the annual incidence rates for a first CVD event increases with age, with
men aged 35 to 44 years having a rate of 3 per 1000 compared to 74 per 1000 in those
aged 85 to 94 years (102). Rates are comparable in women; but 10 years later in life, with
this gap narrowing with advancing age (102). The older age at onset of CVD in women
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correlates with an increase in comorbid conditions namely hypertension and diabetes,
which in turn results in poorer prognoses and consequentially increased mortality (98).
Information based on a pooled analysis of five NHLBI funded community based cohorts
shows that the lifetime risk of developing CVD (defined as fatal and nonfatal CHD,
stroke, congestive heart failure, and all other CVD related deaths) after age 45 is 60.3%
for men and 55.6 % for women (106).
Despite these alarming statistics and the increased awareness over the past
decade, CVD is still viewed by many women as a remote health risk. In 2009, a survey
conducted by the American Heart Association reported that almost half (54%) of women
(which is an improvement over the 30% reported in 1997) recognized heart disease as a
significant cause of mortality in women (107). Alarmingly only 16% in 2009 (7% in
1997) identified heart disease as the single greatest health problem facing women
compared to 28% who were most concerned about breast cancer (107, 108).

EXPLAINING THE GENDER DISPARITY

Reasons for the observed gender disparity are no doubt multifactorial, but may be
explained in part by the following. First, there are difficulties in the diagnosis of CHD in
women. Results from several observational studies confirm that the accuracy of
diagnostic tests differs between men and women (31). For instance, the standard exercise
stress test which is the most commonly used method for diagnosing coronary artery
disease (CAD) has lower sensitivity and specificity in women compared to men (31,
109). Menopausal status, hormone therapy use and a lower prevalence of obstructive
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CAD in women may be contributory factors (31). In addition, women undergoing
exercise stress tests tend to have lower functional capacity which limits the induction of
myocardial ischemia and in turn decreases the diagnostic ability of the standard exercise
stress test to detect CAD (28). All these factors also limit the use of stress
echocardiogram in women, necessitating the use of non-imaging tests to detect vascular
obstruction (28, 30, 109). Furthermore, complimenting standard exercise stress testing
with other specialized diagnostic instruments such as myocardial perfusion Single Photon
Emission Computed Tomography (SPECT) or dobutamine stress echocardiography,
which all have relatively higher specificity, may aid in better diagnosis and prediction of
future adverse events in women, but at an added expense (28, 30).
Second, women may not experience the typical symptoms of angina. Rather, their
pain may be located in the right arm associated with fatigue, abdominal pain, nausea,
sweating and shortness of breath (27, 30, 110). Women who experience signs and
symptoms of angina and MI tend to delay seeking medical care, and when they do may
not be evaluated as aggressively as men, or may be misdiagnosed (27, 30). Women
respond to CHD treatment drugs differently than men, and have more adverse drug
reaction (29, 30). This is further compounded by the hindering of inclusion, if not
exclusion, of women from clinical drug trials. For example, of the over 30,000
participants enrolled in randomized trials to study the effectiveness of statins in primary
and secondary prevention of CVD, only10% and 23%, respectively, were women (98).
Moreover, between 1997 to 2006, 27% (range:10% to 47%) of the total enrollment in
phase 3 or 4 cardiovascular disease randomized clinical trials funded by the National
Heart, Lung, and Blood Institute were women (NHLBI) (111). The underrepresentation
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of women in clinical drug trials impedes determination of the benefits of drug therapy for
women because of low statistical power (28, 31). Therefore clinicians cannot be certain
whether results with new drugs apply to women, since drug absorption and metabolism
may differ in women and men due to lower body weight, higher body fat and differences
in circulating hormone levels (30, 31, 98).
Third, women who undergo percutaneous coronary interventions and CABG have
more fatal complications related with these procedures than do men (27). For example,
women are twice as likely to die during surgery from CABG, and are more likely to
undergo repeated revascularization procedures (112). On average, women undergoing
coronary revascularizations are older and tend to have higher burden of comorbidities
(27). It’s now recognized that women have smaller coronary arteries independent of
body size (113, 114). Furthermore, compared to men, women with established CHD,
have coronary vasculatures characterized by smaller luminal diameter, stiffer vessels as a
result of fibrosis or positive remodeling, and contain more diffuse atherosclerosis with
the tendency for plaque erosion as opposed to rupture (31, 115-117) . These factors all
lead a greater susceptibility for complications during revascularization procedures
compared to men (27).
Recognition of the gender disparity in clinical trials enrollment, and a growing
awareness in the scientific community, as well as women’s advocacy groups, of the
differences in pathophysiology, presentation, treatment and outcomes of CVD in women,
led to the enactment of a series of federal mandates aimed at increasing enrollment by
women in CVD trials to bridge the knowledge and disparity gap (118). This led to the
creation in 1990 of the Office of Research on Women’s Health by the U.S Congress to
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ensure fair representation of women in CVD clinical trials (118). Backed by the NIH
Revitalization act (Public law 103-43), large single sex trials sponsored by the NHLBI–
namely the Women’s Health Study and the Women’s Health Initiative–were commenced,
enrolling thousands of women in the study of primary prevention of heart diseases (118).
Over the past 30 years, the enrollment of women (42.6% in primary and 26.6% in
secondary prevention) in all cardiovascular trials, either government/foundation-funded
or industry-funded has increased worldwide (119). In 1970 only 9% of all trials included
women but this increased to 41% in 2006. Nevertheless, among clinical trials conducted
in the United States, lower estimates were reported with women making up only 26.7%
(119). Also no significant increase in enrollment of women in mixed sex trials was seen
over this period. Improvement was seen in NHLBI-sponsored mixed-sex CVD clinical
trials, with women forming 38% and 26% of CAD trials and congestive heart failure
(CHF) trial participants respectively (118). When these large multicenter single sex trials
are included, however, the estimates increase to 57% for all CAD trials but estimates
remains the same for studies of CHF (118).
While these figures and statistics are encouraging, improvement is needed to
ensure that trials generate the information necessary for evidence-based medicine
involving women, to aid clinicians in making informed decisions, to reduce or avoid the
negative side effects of therapy and to tailor treatment to this patient group to achieve the
desired outcomes in clinical care. Additionally, a gender-sensitive approach to research
should be incorporated, with more women enrolled in drug and intervention trials as well
as increasing the education for women about the symptoms of heart diseases. Lastly,
increased research is needed that focused on women with comorbidities such as diabetes,
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which has been demonstrated to be a stronger risk factor for CVD in women compared to
men. A better understanding of the effect of such comorbidities in women, especially
during menopause, will help elucidate why such women are at high risk for CVD
disability and mortality compared to men.

THE NEED FOR PREVENTION

Aside from morbidity and mortality, CVD has a tremendous impact on the
economy of nations. CVD costs the United States $312.6 billion each year (192.1 billion
due to direct costs of expenditures and $120.5 billion due to indirect costs of lost
productivity), compared to the estimated cost $228 billion for all cancer care (102).
Although enormous, this figure has been forecasted to increase to $818 billion by the
year 2030, primarily due to population aging and the detrimental effects of diabetes and
obesity (120). During the period 2000 to 2004, CVD accounted for approximately 17% of
all national health expenditures and nearly 30% of all Medicare expenditures (121).
These figures stress the importance of improving cardiovascular health and quality of life
through risk factor modifications, particularly among women since they have longer life
expectancy and are more likely develop and dye from CVD.
Although an increasing number of women (48%) are proactively discussing heart
disease risk with their primary care physicians (107), unfortunately, preventive therapies
are less often recommended to women (66). This is largely explained by lower perceived
risk of CVD among women by healthcare providers leading to under-identification and
under-treatment of modifiable risk factors (66). For instance, in a national survey of 500
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randomly selected physicians (300 primary care physicians, 100
obstetricians/gynecologists, and 100 cardiologists) to identify awareness and adherence to
cardiovascular disease prevention guidelines, only 20% reported knowing that more
women than men die each year from CVD (122). Also, primary care physicians were
more likely to assign intermediate risk women—as assessed by the Framingham risk
score—to a lower risk category than men with identical risk profiles, while reassigning
men with intermediate risk to a higher risk category (122).
The need for early identification of women at high risk for CVD and
implementation of appropriate lifestyle modifications and treatment are immense public
health issues of importance. Currently, the commonly used risk prediction algorithm to
identify women at high risk for CHD is the Framingham risk score (123). However this
risk estimation method does not include reproductive factors that increase a women’s risk
for a CHD event, and therefore may not be entirely appropriate for women. Although the
Reynolds score system does not include reproductive risk factors, it has been
recommended by some researchers to be used in women for risk estimation since it
reclassified 40 to 50% of women enrolled in the Women’s Health Study at intermediate
risk into higher or lower risk categories (124). While this risk algorithm holds promise, it
needs to be validated in other populations (123).

RISK FACTORS

One of the largest studies of MI risk factors in women, the INTERHEART study,
a global case control study which included participants from 52 countries reported that
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nine traditional risk factors collectively explained more than 90% of acute MI in both
men and women across all major ethnic groups (125). These nine modifiable risk factors
are dyslipidemia, psychosocial stress, hypertension, smoking, diabetes, physical
inactivity, obesity (especially abdominal), poor diet (with insufficient fruit and vegetable
intake), and excessive alcohol consumption. These risk factors however impacted acute
MI risk differentially with regard to gender. Among women, the population attributable
risk of psychosocial stress, hypertension, diabetes and physical inactivity were greater
compared to men (125). While the direct effects of age and family history of heart disease
were not addressed in this study, they are important non modifiable risk factor for CVD
in both men and women. Certain subgroups of women are known to have a significantly
higher risk of CVD which cannot be entirely explained by these aforementioned
traditional risk factors. These include women with systemic autoimmune diseases namely
systemic lupus erythematosus and rheumatoid arthritis (126). Other sex specific factors
such as life-cycle changes (puberty, menstrual cycle, polycystic ovary syndrome,
pregnancy, and menopause) and sex hormone (estrogens and androgens) are suggested to
impact the incidence of CVD; howbeit the possible biological or genetic mechanisms
underlying their effect are not well understood (31).
Aside from these traditional CVD risk factors, other novel risk markers have been
identified. In an effort to improve risk prediction, over 100 risk markers (i.e. C-reactive
protein, lipoprotein (a), homocysteine, etc) have been proposed to predict CVD
particularly in intermediate-risk populations as assessed by existing risk algorithms.
However these biomarkers are not accepted for populations screening by consensus
conferences since they are either not causally related to CVD, or statistical and
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epidemiological evidence indicate that they add little to traditional risk factors in risk
estimation (123, 127).
The following paragraphs describe some of the important modifiable risk factors and
their effects on atherosclerosis progression and CVD among women. Gender differences
that may exist will be highlighted.

Traditional Risk Factors
Smoking
Smoking is the single most important preventable cause of heart disease in
women and the leading cause of heart disease in women less than 50 years old (123).
Cigarette smoking was uncommon among women until the 1920’s (128). Since 1965,
when 33% of women (51% of men) were smokers, the rate has significantly decreased,
although the rate of decline has been lower for women (128). One reason for this reduced
decline is that women may smoke cigarettes for weight control (66). As of 2009, 16.7%
(19.6 million) of women aged 18 years and older were reported to be current smokers
(102). A dose response relationship exists between the number of cigarettes smoked per
day and the incidence of non fatal CHD. Smoking 1 to 4 cigarettes daily raises the risk of
CHD in women by as much as threefold, while smoking 25 or more cigarette increased
the risk six fold (129). Additionally smoking has a more harmful effect on women than
men, with women smokers having almost 60% increased risk of first admission to a
hospital or death caused by MI (Hazard Ratio: 1.57, 95% Confidence Interval: 1.25-1.97)
compared to men (130). Furthermore, women who smoke and use oral contraceptives
have a twofold risk of MI (Odds Ratio: 2.0, 95%CI: 1.5 to 2.8) mainly due to venous

24

thrombosis (131). Exposure to passive smoking also raises the risk of CHD by 24% (22%
in men) (Relative Risk, 1.24; 95%CI: 1.15-1.34) (132). Regardless of age or gender,
smoking cessation reduces heart disease risk, with one year of cessation resulting in a
reduction of approximately 50% (128). After 10 years of smoking cessation, the risk of
CHD approaches that of never smokers (128). Smoking influences heart disease risk in
women through several mechanisms. These include endothelial dysfunction, increased
LDL oxidation, vascular inflammation, platelet aggregation, reducing levels of
endogenous estrogens and causing menopause to occur at an earlier age (66, 133),

Hypertension
Numerous epidemiologic and interventional studies have long shown that
hypertension is associated with CVD, especially CAD, stroke and heart failure.
Hypertension and stroke cause the greatest morbidity in women (66). In adults,
hypertension is defined as a systolic and/or a diastolic blood pressure measurement which
is consistently above 140/90 mmHg (134). The prevalence of hypertension is low in
premenopausal women but increases with age. The lifetime risk of hypertension for
women after age 55 is more than 90% (66). Currently 1 in 3 women (40.7 million) aged
20 years and older is hypertensive, with those aged 75 years and older bearing the
greatest burden of disease (80.1%) (102).While hypertension was associated with a
threefold increase in CHD risk in men aged 65 to 74 in the Framingham Heart Study, a
fourfold increased risk was observed among women of the same age (112). In the
INTERHEART study of acute MI, the population attributable risk for hypertension was
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36% in women compared to 19% in men, underscoring a greater impact of high blood
pressure in women (125).
There are several pathophysiologic mechanisms by which hypertension influences
cardiovascular heath. High blood pressure induces endothelial dysfunction, remodeling of
coronary arteries and increased resistance at the microvascular level (135). All these
processes promote and exacerbate the atherosclerotic process by making plaques formed
in the arteries more unstable (135). Unstable atherosclerotic plaques are prone to rupture
which exposes thrombogenic material, such as collagen to the circulation resulting in
thrombus formation in the lumen of coronary arteries (136). These intraluminal thrombi
either occlude coronary arteries resulting in infarctions, or more often detach and occlude
other smaller vessels causing thromboembolisms (136). An ischemic stroke occurs when
thrombi occlude the carotid artery (136). Additionally, hypertension leads to left
ventricular hypertrophy which promotes a decrease of coronary reserve while increasing
myocardial oxygen demand, which collectively contributes to the incidence of MI by the
action of ischemia (135). Additionally, hypertension is frequently associated with other
metabolic disorders such as dyslipidemia and hyperinsulinemia which are all risk factors
for CVD (135).
In pregnant women, hypertension is the most common medical problem
encountered, accounting for 15% of all complications (137). This complication includes a
spectrum of conditions including preeclampsia-eclampsia, preeclampsia superimposed on
chronic hypertension, chronic hypertension and gestational hypertension (138).
Compared to normotensive women, hypertensive women have an increased risk of
incident preeclampsia during pregnancy as well as increased complications resulting from
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this condition (25% vs. 6%) (137). Preeclampsia which most commonly occurs during
the first pregnancy is defined as the development of hypertension and proteinuria after 20
weeks of gestation in previously normotensive persons. (137), When it occurs in women
with preexisting hypertension, its termed chronic or superimposed preeclampsia (137). In
industrialized countries preeclampsia affect 2-8% of first pregnancies and results in about
15% of maternal mortality globally (139). Aside pregnancy complications, preeclampsia
further increase the risk of CVD events (66). At the turn of the century, a Norwegian
which assessed the effect of preeclampsia on CVD risk reported that among women with
preeclampsia and who also had a premature delivery (< 36 weeks), the risk of CVD
mortality was a staggeringly eightfold compared to women who had a normal delivery
without preeclampsia. Furthermore, a Meta analysis of 25 prospective and retrospective
cohort studies including 198,252 women with preeclampsia showed that a history of this
condition increased the risk of incident ischemic heart disease (RR: 2.16, 95% CI:1.862.52) after 11.7 years, stroke (RR: 1.81, 95% CI:1.45-2.27) after 10.4 years, and venous
thromboembolism (RR:1.79, CI:1.37- 2.33) after 4.7 years (140). Preeclampsia amplifies
the effect of hypertension on cardiovascular health by increasing free radical derived
oxidative stress and various inflammatory markers which results in severe endothelial
dysfunction and subclinical vascular damage (138).

Dyslipidemia
An estimated 53.6 million (44.9%) American women aged 20 years and older
have total serum cholesterol levels greater than or equal to 200 mg/dL, a figure higher
than the 41.3% (45.3 million) reported for men (102). Furthermore, 30.0% (31.9% in
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men) of women are reported to have low-density lipoprotein (LDL) Cholesterol levels
greater than or equal to 130 mg/dL, as well as 12.3% (31.8% in men) having less than 40
mg/dL of high-density lipoprotein (HDL) Cholesterol (102).
Dyslipidemia is a significant independent risk factor for CVD in both women and
men, however there are considerable differences in lipoprotein particle with regards to
gender exists (66). Women generally have higher levels of total cholesterol, secondary to
more HDL cholesterol throughout their lifespan (66). Beginning at puberty, women have
consistently higher HDL levels than men although during the menopausal transition, a
slight reduction (about 10%) is observed (66). Conversely, LDL and very-low-density
lipoprotein (VLDL) cholesterol tend to be lower in women compared to men until about
age 60, when levels begin to rise and surpass those of men (66). Triglycerides, on the
other hand, increases with age in both genders, howbeit at a slower rate in women, but
after age 79, women have similar levels to men (66).
While higher levels of HDL are associated with a lower CVD risk and other
comorbid conditions including hypertension, obesity and diabetes, the opposite is
observed with triglycerides, LDL and total cholesterol (66).
Hypertriglyceridemia and low HDL cholesterol levels are more important risk factors for
women than men (112). A meta-analysis of 17 prospective studies which included 46,413
men and 10,864 women found that with each 1 mmol/l increase in fasting triglyceride
levels, there is a corresponding 30% increased risk of CVD in men compared to a 76%
increase risk in women. Further adjustment for HDL cholesterol levels attenuated the risk
but remained significant, with women (RR: l.37, 95%Cl: 1.13-1.66) still having an
increased risk compared to men (RR: 1.14, 95%CI: 1.05-1.28) (141). The Framingham
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Heart Study as well as the Lipid Research Clinics Prevalence Mortality Follow-up Study
published similar results showing that each 0.025mmol/L increase in HDL cholesterol
levels reduced CVD events to a greater extent in women than men (97). In the former
study, a 3% (2% in men) decrease in the incidence of CAD in women was observed
(142), while the latter study reported a 4.7% (3.7% in men) reduction in CVD mortality
among women (143).
Reduction in cholesterol levels (excluding HDL) by lipid-lowering therapies has
been shown in several intervention trials to substantially influence cardiovascular health
(133). Although some have found comparable effectiveness in both genders, a few
studies reveal greater effectiveness in women. One of those studies is the cholesterol and
recurrent events (CARE) trial which assessed the effect of Pravastatin in the secondary
prevention of CHD (144). After five years of follow-up, postmenopausal women in the
treatment arm had a reduced risk of 43% for coronary events (which was defined as
coronary death, nonfatal MI, PTCA or CABG) and 56% for stroke (144). Although men
showed a similar reduction in risk, the magnitude was less than that reported for post-MI
women with average cholesterol levels. Data from another meta-analysis of 27
randomized trials which included approximately 26% of women to assess the effect of
statins on CVD in persons with low risk of vascular events, showed a 21% reduction in
non-fatal myocardial infarction or coronary death (RR: 0·79, 95% CI: 0·77-0·81) with
each 39 mg/dl reduction in LDL level (145). This significant finding was independent of
age, sex, baseline LDL cholesterol or previous vascular disease. However in participants
without a history of any vascular disease, the risk of non-fatal myocardial infarction or
coronary death and all-cause mortality was statistically significantly reduced by 15% and
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9% respectively, with each 39 mg/dl reduction in LDL cholesterol (145). The
Justification for Use of statins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER) trial which enrolled 17,802 participants (38% women) also
confirmed the effectiveness of statins in the primary prevention of CVD in women. After
a median follow-up of 1.9 years, rosuvastatin use (20 mg daily) was associated with a
54% reduction in MI, 48% reduction in stroke, 46% reduction in revascularization, 43%
reduction in venous thromboembolism, and 20% reduction in total mortality (146). This
reduction in risk was similar among men and women, but overall women had a greater
reduction (46% vs. 42%) in the composite endpoint of nonfatal MI, nonfatal stroke,
hospitalization for unstable angina, arterial revascularization, or cardiovascular mortality
(146). Recently, another meta-analysis of all primary prevention statin trials in women
with 13,154 participant (mean age of 63 to 69 years), also found a significant reduction in
CVD events with statins by a third (RR: 0.63, 95%CI: 0.49-0.82) (147). While such
results lend support to the conclusions of the JUPITER trial that statin therapy is effective
in the primary prevention of CVD in women, it’s uncertain if the same effect will be
found in younger women since most primary prevention trials included only older
postmenopausal women
Despite the years of research on cholesterol and CVD risk, the underlying
mechanisms are still not entirely understood (96). LDL cholesterol when high
accumulates in the arterial walls and is oxidized, and taken up by foam cells, initiating as
well as progressing atherosclerotic process (148). HDL cholesterol on the other hand
directly opposes atherosclerosis by removing cholesterol from foam cells, inhibiting LDL
oxidation as well as limiting the inflammatory processes that underlie atherosclerosis
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(148). Furthermore HDL has antithrombotic properties that prevent the formation of
blood clots in the arteries preventing vascular occlusions (148). The action of statins on
cardiovascular health is achieved via its effects on lowering arterial inflammation and
inhibiting cerebral cholesterol synthesis (96). Aside from cholesterol lowering, statins
also exert pleiotropic properties such as increasing endothelial nitric oxide formation as
well as suppressing vascular inflammation which inhibits atherosclerosis (149).

Obesity, Diet and Physical inactivity
Obesity is a growing public health problem worldwide and has been shown to
increase CVD risk as well as exacerbates numerous other chronic diseases (102). In
epidemiologic studies, body mass index (BMI) is used to measure general obesity, but
this index does not account for variation in body fat distribution and abdominal fat mass.
To capture central or abdominal adiposity, other anthropometric measures such as waist
circumference (WC) and waist-to-hip ratio (WHR) have been recommended (150). A
BMI ≥ 30 kg/m2 defines obesity with values of 25.0 - 29.9 kg/m2 define overweight
(150). Unlike BMI which uses the same categorization for both men and women, WC and
WHR have different cutoff values for abdominal obesity. In women WC of ≥ 88.0 cm
and WHR of ≥ 0.80 defines central obesity (150). In the United States, 64% of women
are reported to have a BMI ≥ 25 kg/m2, while 36% are obese (102). Blacks/African
American women are more likely to be obese (54%), compared to Mexican-Americans
(45%) and non-Hispanic whites (33%) (102). Forecast, using the Behavioral Risk Factor
Surveillance System (BRFSS) estimates that by 2030, 51% of the population will be
obese, with 11% having severe obesity (102). This database further shows that the

31

number of quality-adjusted life-years lost as a result of obesity is similar to or greater
than those lost as a result of smoking (102)
Several studies reveal that obesity increases the risk of CVD. In the a metaanalysis of 58 cohorts, with 221,934 participants and 14,297 first-onset CVD events, a
minimal increased risk of 7%, 10% and 12% using BMI, WC and WHR respectively in
CVD was reported (151).An earlier meta-analysis (152), however reported a greater risk
of CHD event in both overweight men and women. Summarizing information from
302,296 participants with 18,000 events, the authors reported an 18% and a 50%
increased risk for CHD among overweight and obese individuals (152). In contrast, the
Framingham Heart Study reported that obesity infers a greater effect on cardiovascular
health in women than men, with obese women having a 64% (46% in men) increased risk
of first CVD as well 2.75 fold (2.21 in men) risk for hypertension (153). Despite these
figures illustrating that obesity increases CVD, an obesity paradox exists with regards to
certain cardiac diseases (154). Among patients with a history of various types of CVD,
those who are overweight or obese have been reported to have better outcome than their
normal weight counterparts. This paradox has been reported for outcomes including heart
failure (155), peripheral arterial disease (156), acute coronary syndrome (157) and
cardiovascular mortality (158).
An increase in caloric intake and physical inactivity is closely tied to the current
obesity epidemic. A well balanced diet with adequate fruits and vegetables coupled with
increased physical activity has been shown to aid in weight management and to reduce
the risk of CVD in the long run (128). A single-blind randomized trial of 130 severely
obese (class II or III) adults without diabetes, followed for 12 months reported that both
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intensive lifestyle intervention of diet and physical activity achieve clinically significant
weight loss and improvement cardiometabolic factors namely waist circumference,
visceral abdominal fat, hepatic fat content, blood pressure and insulin resistance (102,
159). Moreover, physical activity promotes greater reductions in waist circumference and
hepatic fat content (159). These reported benefits of diet and physical activity are less
marked though in women compared to men (133).
The Nurses’ Health Study (160) and the Women’s Health Initiative (161) both showed a
strong, graded inverse association between physical activity and the risk of coronary
events. Additionally, they report that brisk walking showed similar effect on
cardiovascular health as vigorous exercise; reducing CVD risk by as much as 40% (160).
In spite of these benefits from physical activity, 33.2% of women (29.9% in men) report
no physical activity, with minority populations (Blacks: 41.1% and Hispanics: 42.2%)
having higher age adjusted estimates compared to non-Hispanic whites (27.7%) (102).
Obesity increases the risk of CVD through several mechanisms. For instance
adipose tissue produces cytokines such as leptin and adiponectin, while increasing levels
of inflammatory markers and endothelial cell products namely intercellular adhesion
molecule-1 (162). These bioactive mediators affect body weight homeostasis and
predispose to insulin resistance (162). Additional effects of these bioactive mediators are
alteration in lipid profile and blood pressure as well as increased oxidative stress,
coagulation, and fibrinolysis which all lead to endothelial dysfunction and atherosclerosis
(162). Furthermore, an obesity induced insulin resistance state is characterized by
increased levels of non-esterified fatty acids which promote lipotoxicity and in the long
run initiates atherosclerosis (162).
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CARDIOVASCULAR DISEASE IN DIABETIC WOMEN

Epidemiology of diabetes
About 23.6 million (7.8%) Americans have diabetes mellitus with 5.7 million of
this number being undiagnosed (3). Among the various ethnic/racial groups, 12.6% of
non-Hispanic blacks, 11.8% of Hispanics, 8.4% of Asian Americans and 7.1% of nonHispanic whites aged 20 and over are reported to be living with diabetes (102). Each
year, about 1.9 million new cases of diabetes are diagnosed in US adults (102). Diabetes
is the seventh leading causes of death with rates of 23.3 per 100,000 for white males, 44.2
per 100,000 for black males, 15.7 per 100,000 for white females and 35.9 per 100,000 for
black females (102). Furthermore 68% and 16% of deaths in persons diagnosed with
diabetes are due to heart diseases and stroke respectively (102). Moreover, diabetes is
associated with a cluster of CVD risk factors. For instance the prevalence of
hypertension, elevated LDL cholesterol and obesity in diabetics is 75% to 85%, 70% to
80%, and 60% to 70% respectively (102). Results from the Framingham Heart study
show that the lifetime risk for CVD among women with diabetes is 54.8% among
normal-weight women (78.6% in normal-weight men) and 78.8% among obese women
(86.9% in obese men) (163). The annual total cost (direct and indirect) of diabetes care
grew to $245 billion in 2012 from $174 billion in 2007, with the medical care cost per
each diabetic person estimated to be $7,900 (164). With the increasing obesity epidemic
and aging of the population, diabetes will undoubtedly place a great burden on the future
healthcare system.
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The Impact of Cardiovascular Disease in Diabetic women
One of the most important risk factors for heart disease in women is type-2
diabetes. Compared to persons without diabetes, the risk of CVD among diabetics is
about 3-fold (102). Among diabetics aged 65 and older, heart disease accounts for 68% of
all deaths (3), and diabetes is a stronger risk factor for CHD in women than men (10).
The risk of fatal and non fatal CHD events for diabetic women is reported to be as high as
9.5 fold compared to 2.8 fold for diabetic men (9). Furthermore, women with diabetes are
more likely to die of CHD compared to non diabetic women or men with and without
diabetes (5). A twenty year follow-up of the Nurses’ Health Study cohort reported an 18
fold risk for CHD mortality among women with both a history of diabetes and CHD,
compared to an 8 fold increase risk among women with a history of CHD as well as those
with a history of diabetes (10). Additionally, diabetes has more debilitating effects in
women than men (6-9). Inflammatory factors due to diabetes in women are proposed to
interact with female hormones, resulting in a decreased effect of estrogen on the coronary
vasculature, insulin actions and body fat distribution thereby abolishing the gender gap in
heart disease rate among premenopausal women and men of similar age (9). The presence
of diabetes in postmenopausal women increases the progression of atherosclerosis as well
as the incidence of heart disease (165).
With recent progress in reducing the prevalence of many CVD risk factors such as
smoking, hypercholesterolemia, etc, a reduction in all-cause and CVD-related mortality
has been observed among diabetics. During the period of 1997 to 2006, the CVD death
rate declined by 40%, while all-cause mortality declined by 23% among diabetics (166).
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However, there was a greater magnitude of decline among men than women (166). While
the decline in mortality among diabetics is encouraging, the increasing incidence of
diabetes will result in a greater burden of disease in the future. The lack of improvement
in survival among diabetic women compared to men is disturbing, and progress seems
unlikely until the reasons for this gender difference are determined. While some have
attributed this to the lesser improvement in CVD risk factors, others point to a less
aggressive medical management and worse outcomes after coronary revascularization in
diabetic women (167).
The treatment of diabetes and CVD is complex and certain factors including
disease status, comorbidities, self-management capabilities and patient’s compliance are
all considered before therapy is prescribed (168). Although diabetes treatment is
intensified if risk factors for CVD or CVD itself is present, gender differences in diabetes
care in the presence of heart disease has been reported. The DIANA study found that
diabetic women are less likely to be prescribed angiotensin-converting-enzyme (ACE)
inhibitors and calcium channel blockers compared to men with CHD (168). These gender
disparities exist even after controlling for confounding factors such as age, diabetes
duration, glycosylated hemoglobin (HbA1c) level, medication adherence, and the
prevalence of CVD, diabetic nephropathy and depression (168). Similar studies also
report that among diabetics who are eligible for statin therapy based on recommendations
by American Diabetes Association, women are less likely to receive adequate lipid
lowering treatments compared to men (169). Some researchers have argued that this
disparity in treatment which favors men is not necessarily intentional but that the control
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of hyperglycemia and major CVD risk factors are less satisfactory in women than men
(170).
Although women undergoing coronary intervention in general have a higher
frequency of adverse outcomes than men, those with diabetes have increasingly worse
outcomes primarily due to diffuse small-vessel disease leading frequently to diabetic
cardiomyopathy (171), A register linkage analysis of outcomes among diabetic patients
with acute MI who have undergone coronary interventions (171) reports that after 2
years of follow-up (which began on the date of PCI during the index hospitalization) the
incidence of adverse outcomes was significantly higher in women. Diabetic women were
44% more likely to encounter a non-fatal acute MI, repeat revascularizations and allcause mortality than men. This excess risk was largely driven by a high (12.0% vs. 3.9%)
mortality during hospitalization of diabetic women. These results do not only warrant
special attention in treatment strategies of diabetic women, especially during
hospitalization (171), but also stress the importance of preventing diabetes as well as
CVD in women to improve their quality of life.

PATHOPHYSIOLOGY OF DIABETES AND CARDIOVASCULAR DISEASE

Diabetes is a common endocrine disorder. There are two major types. Type-1
diabetes, known previously as Juvenile-diabetes, is an autoimmune disorder which occurs
when the pancreatic beta cells (in the islets of Langerhans) are destroyed thereby causing
severe insulin deficiency. Also known as juvenile-onset diabetes since its common in
children, there are no means of prevention. Type-1 diabetes accounts for at least 10% of
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all cases, and prevalence differs markedly by racial group with Non-Hispanic white
having the highest rate of disease (172).
On the other hand, Type 2 diabetes accounts for approximately 90% of all
diabetes nationwide (173). Unlike type 1 diabetes which occurs as a result of absolute
insulin deficiency, type 2 diabetes is characterized by insulin sensitivity or peripheral
insulin resistance, impairments in the regulation of hepatic glucose production as well as
pancreatic beta cell dysfunction (173). Formerly considered as an adulthood disease,
type 2 diabetes accounts for 15% of all cases of diabetes in children between the ages of
10 to 19 years, however the prevalence of diabetes in the children aged 10 to 19 years in
the general population is very low (0.4%) (173). Although the specific mechanisms
underlying the development of type 2 diabetes are complex not well understood, the
familial occurrence suggests genetic predispositions which are influenced by
environmental factors to result in the onset of clinical disease (173). Some environmental
factors that place increased secretory burden on the pancreatic beta cells include puberty,
pregnancy, sedentary lifestyle and obesity (173), while acquired risk factors for insulin
insensitivity include advancing age, overweight, increased abdominal fat, hypertension,
lack of physical activity, decreased HDL cholesterol and medication (173, 174). For
brevity “diabetes” will denote type 2 diabetes–which is the focus of this review.
Insulin resistance often always occurs before the onset of diabetes and indicates
the presence of an impaired biologic response to either exogenously administered or
endogenously secreted insulin (173). It is manifested by decreased insulin-stimulated
glucose transport and metabolism in adipocytes and skeletal muscle as well as impaired
suppression of hepatic glucose output (173). Hyperglycemia occurs because of
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inadequate utilization by insulin target tissues and also elevated gluconeogenesis. The
mechanisms controlling the interplay of these two impairments: hyperglycemia and
insulin resistance, are unclear.

Genetic factors involved in the pathogenesis of diabetes
Clearly, the development of diabetes is associated with a family history of the
disease. While concordance rates between monozygous twins for type 1 diabetes is
reported to be approximately 50% or less (175), those for type 2 diabetes is about 90%
(176). Genetic mutations or abnormalities in glucokinase genes, mitochondrial genes, and
insulin receptor genes have been observed to influence several processes including the
regulatory system of glucose metabolism and insulin action, as well as glucose-stimulated
insulin secretion of pancreatic beta cells, which independently lead to the development of
diabetes (177). Current evidence show that these genetic abnormalities collectively
explain about 30% of the genetic factors for diabetes (177).
Genetically, diabetes consists of monogenic and polygenic forms, with the genes
involved in the common polygenic forms of diabetes being far more difficult to identify
and characterize compared to those for monogenic forms (173). Unlike the monogenic
forms of diabetes in which environmental factors do not greatly influence the risk of a
genetically predisposed person developing clinical diabetes (but genes being the main
cause), the polygenic form has both environmental and genetic factors equally
influencing the incidence of disease (173).
The mongenic forms are relatively rare and account for only a small percentage of
all diabetes cases, however, recognizing these forms are of tremendous importance since
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it will aid in the determination of the best choice of therapeutic agents as well as enhance
genetic counseling (178). They are usually diagnosed in the first 2 to 3 decades of life,
however if only mild, asymptomatic elevations in blood glucose occur, their diagnosis
may be missed until later in life (173).
In monogenic forms associated with insulin resistance, mutations in insulin
receptor gene occurs which impair their function, resulting in a decrease in the number of
receptors expressed on cell surfaces, accelerating the rate of receptor degradation or
inhibiting the transport of receptors to the plasma membrane (173). Insulin resistance
associated with insulin receptor mutations manifest during the neonatal period as
leprechaunism and Rabson-Mendenhall syndrome, while in adulthood they result in
diabetes with marked hyperinsulinemia, acanthosis nigricans, and hyperandrogenism
which collectively are referred to as type A insulin resistance (173). Furthermore,
mutations in the transcription factor Peroxisome Proliferator-Activated Receptor-γ
(PPARγ) also results in diabetes of early onset (familial lipodystrophy type 3) (173).
Finally, insulin resistance which is associated with lipoatrophy, lipodystrophy and
characterized by a paucity of fat and hypertriglyceridemia results in lipoatrophic diabetes,
another monogenic form of diabetes (173).
With regards to insulin deficiency, several mutations occur which result in
defective insulin production. These include mutations in insulin or proinsulin genes, and
mitochondrial gene which leads to diabetes (173). Maturity-onset diabetes of the young
(MODY) which is also a monogenic form of diabetes with an autosomal dominant mode
of inheritance is a genetically heterogeneous group of disorders characterized by
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nonketotic diabetes mellitus (173, 178). It is common in children and adolescents with
onset usually before age 25 years (173, 178).
The interactions of several genetic and environmental factors through complex
mechanisms result in common polygenic form of diabetes in predisposed persons.
The phenotypic manifestations of polygenic form of diabetes include resistance to the
action of insulin in muscle, fat, and liver; defects in insulin secretory responses from the
pancreatic beta cell (173).

Roles of environmental factors
As mentioned earlier, aging, obesity, alcohol intake, smoking, and sedentary
lifestyles are all independent risk factors for diabetes (177). Since majority of diabetics
have central obesity, abdominal obesity is thought to play a crucial role in the
pathogenesis of diabetes. Additionally, the mechanism for the cause in reduction in
insulin secretion –which is progressive–is not fully known, and may not also be a gradual
consequence of insulin resistance since not all insulin resistance subjects develop
diabetes. However impaired insulin secretion by pancreatic beta cells generally involves
glucose toxicity and lipo-toxicity (177). The impairment of insulin action in major target
organs such as liver and muscles to sensitize the absorption of glucose by cells due to
either a defect in cell receptors or an absorption effect results in a state termed insulin
resistance (172, 177). Investigations into the molecular mechanism for insulin action has
clarified how insulin resistance is associated to genetic and environmental factors namely
hyperglycemia, free fatty acids, inflammatory mechanism, etc (177).
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Abdominal adipose store especially visceral fat, is known to be resistant to the
antilipolytic effects of insulin, including alterations in lipoprotein lipase activity which
results in increased lipase activity and a greater flux of fatty acids into the portal
circulation and to the liver (173). This increased influx of free fatty acids to the liver
promotes gluconeogenesis and hepatic insulin resistance, and lead to an accelerated
synthesis of very-low-density lipoprotein and increased triglyceride levels (179).
To maintain metabolic homeostasis, excess nutrient intake (carbohydrate, protein, or
lipid) are stored as fatty acids in the form of triglycerides in adipose tissues(173). If the
storage capacity of adipose tissue is exceeded, triglycerides are usually diverted from
adipose tissues and stored in non-adipose tissues such as hepatocytes, vascular cells, beta
cells and skeletal muscle, which interferes either directly or indirectly, with insulin
signaling pathways leading to insulin resistance and cellular dysfunction (173, 179).
Additionally, adipose tissues secrete proinflammatory cytokines and other factors such as
leptin, plasminogenactivator inhibitor-1 (PAI-1), tumor necrosis factor (TNF)-α, and
interleukin-6 (IL-6) which alter the action of insulin at target cell sites via pathways that
interfere with the transduction of glucose transporter 4 (GLUT-4) to plasma membranes
(179). Additionally, these proinflammatory cytokines result in local or systemic
inflammation which leads to disruption of beta cell function (173), thus resulting in
decreased insulin production.
Diabetes is diagnosed based on fasting plasma glucose test (FPG) results of 126
mg/dL or above, oral glucose tolerance test (OGTT) results of 200 mg/dL and above or
random plasma glucose test results of 200 mg/dL or higher, in the presence of increased
urination, increased thirst and unexplained weight loss (1).
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Table 2.1: Disorders of Glycemic Homeostasis

Insulin resistance

Definition
A condition characterized by decreased tissue sensitivity
to the action of insulin

Impaired glucose
tolerance

Elevated blood glucose of 140-199 mg/dL on oral
glucose testing (blood glucose measured 2 hours after a
75-gram oral glucose load).

Impaired fasting
glucose

Fasting blood glucose of 110-125 mg/dL

Diabetes Miletus

fasting plasma glucose (FPG) of ≥126 mg/dL or blood
glucose levels of ≥ 200 mg/dL on an oral glucose
tolerance test (OGTT)

Diabetes accelerates atherosclerosis through a myriad of processes including
endothelial dysfunction, increased vascular oxidative stress, dyslipidemia and
abnormalities of platelet function, fibrinolysis, and coagulation (5, 25). The vascular
dysfunction created by these processes is known to be intimately related to visceral
adiposity, insulin resistance and hyperglycemia (25). The mechanism by which diabetes
influences hemostasis, resulting in platelet and coagulation abnormalities and endothelial
cell dysfunction are complex.

Lipoprotein
Diabetes, through the action of hyperglycemia and hyperinsulinemia influences
changes in lipid profile through several mechanisms which predisposes to atherosclerosis.
These include peripheral actions of insulin on adipose tissue and muscles, insulincontrolled apoprotein production in the liver, regulation of lipoprotein lipase (LPL), and
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the actions of cholesteryl ester transfer protein (CETP) which results in elevated
production of small, dense atherogenic triglyceride-rich LDL particles (180).
Plasma Levels of non-HDL lipoprotein cholesterol and chylomicrons are
increased in diabetics. Oxidation of lipoproteins is enhanced by hyperglycemia and
hypertriglyceridemia (5). Oxidized lipoproteins are cytotoxic to endothelial cells and
smooth muscle cells and accelerate atherogenesis (5). Additionally, hyperglycemia
accelerates the conversion of LDL particles to smaller, perhaps more atherogenic,
lipoproteins termed 'small-dense LDLs' (180). Furthermore, hyperglycemia facilitates the
glycation of apolipoprotein B which results in impaired recognition of LDL cholesterol
by its receptors on hepatocyte (5). This abnormality increases the LDL half life and
thereby increases their susceptibility to oxidation and also prolongs the exposure of the
endothelium to atherogenic lipoproteins (5, 180).
On the other hand, the glycation of HDL cholesterol during hyperglycemia
reduces its half life (5). The clearance of HDL alter the lipid profile in diabetics, resulting
in increased levels of VLDL, LDL and liproprotein (a)–which is a modified form of
LDL(5). Lipoprotein (a) is an established risk factor for premature atherosclerotic
vascular disease. Apart from it binding to endothelium and components of the
extracellular matrix, it also interferes with fibrinolysis since it has a similar structure to
plasminogen and competes for binding sites (5). This interference in fibrinolysis leads to
the occurrence of thrombosis, which may result in vascular occlusion. furthermore, HDL
cholesterol in its basal state possess enzymes that destroys oxidized lipids, but in
diabetics this is mechanism is impaired by the action of acute-phase reactants (180).The
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increased glycation or inactivation of serum paraoxonase 1 (PON1) enzyme in diabetic
also diminishes the ability of HDL to protect LDL from oxidation (180).
Another mechanism by which diabetes causes dyslipidemia is through the
increase in production of stored fatty acids (FAs) which inhibit glucose uptake by muscle
cells as well as causing increased glucose output by the liver (180, 181). Triglycerides
levels are markedly elevated in uncontrolled diabetics or persons with hyperinsulinemia.
In insulin resistance, activation of hormone-sensitive lipase (HSL) occurs, the enzyme
that catalyze the conversion of stored triglycerides from adipocytes into FAs and
monoglycerides which can be transferred across the plasma membrane of the cell (180,
181). The activation of HSL leads to increased production of free fatty acids (FFAs) to
the liver, giving rise to hepatic overproduction of large VLDL particles and
hypertriglyceridemia (180). Additionally, insulin resistance reduces the effectiveness of
Lipoprotein lipase (LPL), an enzyme that plays a major role in the breakdown of
triglycerides present in chylomicrons and VLDL particles, resulting in diminished
triglyceride clearance from the circulation (180). The elevation of triglycerides in
circulation facilitates the transport of cholesteryl esters and triglycerides between
lipoproteins (180). Here, Cholesteryl ester transfer protein (CETP) modulates the
collection of triglycerides from VLDL or LDL particles and exchanges them for
cholesteryl esters from HDLs, and vice versa (180). However, the increased activity of
CETP drives the production of small, dense triglyceride-rich LDL particles which are
atherogenic (180).
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Platelet and coagulation anomalies
In diabetics, platelet adhesion and platelet aggregation are often enhanced and the
balance between coagulation and fibrinolysis is greatly affected. About 80% of all
premature deaths in diabetics are secondary to thrombotic events with 75% of such cases
occurring in the cardiovascular system (182). Platelets in diabetics have increased
expressions of activation markers, and platelet surface receptors or surface adhesion
molecules including P-selectin , glycoprotein (GP) Ib and GP IIb/IIIa, which mediate
binding to von Willebrand factor and platelet-fibrin interaction (183). Furthermore, in
diabetics the production of nitric oxide, prostacyclin and other vasodilator prostanoids by
platelets and vascular tissues, which inhibits platelet aggregation and adhesion are
reduced (183).
The impaired regulations of calcium metabolism in diabetics result in increased
intracellular calcium levels (183). This alteration in calcium homeostasis which leads to
elevated concentration of cytosolic calcium, enhance platelet reactivity and aggregation
(183). This process is suggested to provide explanation for the elevated platelet
sensitivity and the increased response to variety of aggregating agents such as adenosine
5′-diphosphate (ADP), thrombin, or collagen, observed in diabetic (182).
Hyperglycemia is thought to influence platelet reactivity through several
mechanisms. One of such is the non-enzymatic glycation of platelet membrane proteins
that decrease membrane fluidity which may in turn also increase platelet adhesion (183).
Hyperglycemia in the presence of elevated reactive oxygen species enhance the
production of advanced glycation end products (AGEs) which may contribute to
atherosclerosis by activating AGEs receptors (RAGE) and also by enhancing platelet
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aggregation through the serotonin receptor (183). Another possible mechanism is the
activation of protein kinase C, a mediator of platelet activation (183). Other platelet
abnormalities in diabetics that increase their risk of atherosclerosis include decreased
platelet survival, increased platelet generation of vasoconstrictor prostanoids, and
increased glycosylation of platelet proteins (182).
Both hyperglycemia and hyperinsulinemia are known to influence coagulation.
Hyperglycemia activates coagulation by raising concentrations of procoagulant factors
such as tissue factor and von Willebrand factor, while inhibiting fibrinolysis by
increasing concentrations of plasminogen activator inhibitor which together promotes
thrombosis (183). Moreover, the increased concentration of plasminogen activator
inhibitor (PAI-1) mainly due to hyperinsulinemia as well as decreased levels of
antithrombin III, protein C, and protein S in diabetics predisposes them to thrombosis
since (PAI-1) block fibrinolysis (5).

Endothelial dysfunction
Recent advances using in vivo studies have improved our understanding of the
mechanisms underlying the vascular dysfunction that leads to cardiovascular disease in
persons with diabetes. The endothelium plays a vital role in vascular homeostasis by
modulating vascular tone, caliber and blood flow in response to hormonal, mechanical
and neural stimuli by synthesizing and secreting substances that influence vascular
constriction and dilation (184). In the presence of diabetes, however, these functions are
adversely impaired. Apart from maintaining vascular tone and reactivity, nitric oxide
opposes the action of endothelium-derived contracting factors, inhibits leukocyte and
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platelet activation and maintains vascular smooth muscles in a non proliferative state
(184). In diabetics, however, nitric oxide is either destroyed or the endothelium is
insensitive to nitric oxide signaling (5). Additionally, hyperglycemia delays endothelial
cell replication through both increased oxidation and glycation, causing endothelial cell.
Furthermore, hyperglycemia increases the synthesis, and thereby plasma concentrations
of endothelin-1, a vasoconstrictor which causes arterial blood pressure to increase (5). All
these processes lead to reduced vascular elasticity or stiffness, which in itself is an
independent risk factor for cardiovascular mortality in persons with diabetes (5).
All together, these abnormalities of platelet adhesion and aggregation, coagulation and
endothelial dysfunction which occur in diabetes are proposed to abolishes the cardioprotective effect of estradiol in premenopausal women (5).

THE EFFECT OF SEX-SPECIFIC CHARACTERISTICS ON CVD IN WOMEN

Menopause
Although the incidence and prevalence of CVD has been shown to increase as
women enter the menopause, the mechanisms by which menopause affect cardiovascular
health remains incompletely understood (40). The projected increase in the number of
postmenopausal women worldwide from 467 million in 1990 to 1.2 billion by 2030 (47
million women enter the menopause each year) makes this a significant public health
issue (185). Compared to men of similar age, premenopausal women have a lower risk of
CVD and develop the disease 10 years later than men. Attempts to resolve this
knowledge gap have resulted in several debates in the scientific community. While some
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researchers have attributed this to a chronological aging effect (12, 186, 187), others have
invoked an effect of ovarian ageing (menopause resulting in estrogen depletion) (188).
This issue is further complicated by investigators suggesting that the timing of
menopause– natural or surgical –influences CVD risk in women (41, 42, 189).
Evidence for an association between the menopause and CHD originated from
case-control studies in which CHD mortality was compared between age-matched groups
of pre- and postmenopausal women (190). Later, prospective studies reported that the
removal of the ovaries at an earlier age increased the risk of CHD, compared to women
who attained natural menopause (190). Earlier, an autopsy study among 80 young
oophorectomized women, compared to 80 age-matched women with intact ovaries dying
from accidents or cancer reported more extensive coronary atherosclerosis and
myocardial infarction in the women with oophorectomy (191) .CHD risk was reduced in
oophorectomized women who used estrogen therapy (191). These observations provided
the basis for the widely held theory that menopause is a risk factor for heart disease, and
proposal that estrogen therapy might protect women from CVD. However, a rigorous
demonstration of whether menopause is a risk factor for heart disease will be to follow-up
women throughout the menopausal transition and compare the incidence and mortality
rates in those who become menopausal with women remaining pre-menopausal (190).
Two studies which attempted this were the Framingham heart study and the Nurses’
health study. The Framingham heart study which followed 2873 women for 24 years,
suggested that women with menopause at a younger age had an increased risk for CHD
than women whose menopause occurred later in life, although most of the women in the
younger age-group had surgical menopause (192). Among women with natural
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menopause, who were aged 45 to 54 years, there was a significant increase in CHD
compared to premenopausal women of similar age (190, 192). While the Framingham
study supported menopause as a risk factor for CHD, the Nurses’ Health Study, which
followed 121,700 women aged 30 to 55 years for 6 years found that those women who
had had a natural menopause and had never taken replacement estrogens had the same
incidence of fatal and non-fatal MI as the premenopausal women (190, 193). In
multivariable adjusted models, oophorectomy but not natural menopause increased CHD
risk, and the use of estrogens appeared to eliminate this risk.
Ecological studies, which have fallen out of favor with most epidemiologists,
conducted in England and Wales (12), United States (194), and Japan (186), using vital
statistics data report that menopause is not a risk factor for cardiovascular disease. These
cross sectional analyses of age-specific mortality do not show any proportional
acceleration in heart disease at the time of menopause on a semi-logarithmic scale, and
conclude that age effect rather explains the delay of CHD in premenopausal women.
Cross sectional associations between age and mortality are difficult to interpret and infer
association since both the exposure and outcome of interest are ascertained at the same
time. Furthermore, they do not take into account the effect of changing lifestyles and
treatment environments over a person’s lifespan (187). Such deficiencies prompted a
recent longitudinal analysis of mortality data using birth cohorts from United States,
England and Wales (187). Again this birth cohort analyses did not identify any shift in
CHD mortality rates at menopause but reported a linear trend, denoting an effect of
chronological age (187). Such conclusions dispel the presence of an ecological fallacy
playing a role in previous mortality studies.
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Other researchers have refuted such claims, and argued that the use of a semilogarithmic scale is not justifiable for the analysis of a menopausal effect on CHD
mortality (188). Using mortality rates from the UK, the Framingham risk function, and
estimates of relative risks at young ages from the MRFIT Study, and using a simulation
model–which the authors assert makes more reasonable assumptions, Witteman et al
(188), reported an increase in CHD mortality during the menopausal period, and argue
that menopause indeed raises the risk of CHD in women, but did not comment whether
depletion of endogenous estrogens play a role. Because all these studies analyzed only
vital statistics data and therefore did not analyze individual cardiovascular risk factors or
individual timing of menopause, these conclusions maybe speculative and further
illustrate that vital statistics data are not a source that provide easy answers on this issue
(41, 187).
Whether the increased risk of CVD in women is a function of chronological age,
ovarian aging associated with depletion in endogenous estrogens or both is
methodologically challenging since these two concurrent processes are intimately linked,
and will continue to be a debated issue (195). This significant gap in knowledge has
grave consequences in the prevention and care of women with heart disease.
During the menopausal transition, several changes in the lipid profile occur which
tend to favor the atherosclerotic process (figure 2.1). Results from the Study of Women's
Health across the Nation (SWAN) show that total cholesterol, low-density lipoprotein
(LDL) cholesterol and apolipoprotein-B levels rise slowly through the premenopausal
years, and increase rapidly during perimenopause until plateauing after menopause, a
pattern consistent with menopause-induced changes but not chronological age (40). This
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observation is similar across ethnic groups. Additionally, after menopause, LDL particle
distribution shifts to smaller particles which are denser and more atherogenic (66). At the
same time, changes in HDL subclass are observed, with a decrease in HDL2 levels
concurrent with an increase in HDL3 levels (66). These HDL particles, even in healthy
postmenopausal women, have been observed to have redacted ability to inhibit LDL
oxidation (196).
Besides these modifications in lipid profile of women transitioning to menopause,
current evidence confirms that changes in body fat distribution occur during this time
period (197). This is characterized by a shift of fat mass from the legs towards the upper
body even in the absence of significant changes in total body fat (197). In healthy
premenopausal women, fat is deposited mainly in the gluteofemoral region–termed
gynoid adiposity (198, 199). However, during menopause, fat is accumulated in the
abdominal region–termed android adiposity (198, 199). Data from 1988-1994 show that
the national prevalence of abdominal obesity (as defined by waist circumference > 88
cm) was reported to be 22.8% among women aged 20-29 compared to 67.3% among
those aged 60-69 (200).These changes in lipid profile and body composition are thought
to be initiated and moderated by sex hormones and insulin resistance hyperinsulinemia.
The influence of sex hormones on these processes will be described in detail.

Surgical Menopause
While the gradual loss of ovulation , estrogen and progesterone production,
known as the climacteric occur over about 10 years and culminate in the cessation of
ovulation known as menopause at a median age of 51 years, induced/surgical menopause
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occurs when the ovaries are surgically removed by bilateral oophorectomy or are
damaged by radiation- or chemo-therapy. This more abrupt loss of ovarian function and
decline in plasma estrogen levels is proposed to influence long-term health outcomes.
Bilateral salpingo-oophorectomy (BSO) is commonly offered concomitant with
hysterectomy as a prophylactic procedure to prevent ovarian cancer, or as a treatment for
premenstrual syndrome and symptomatic endometriosis or other conditions (201). When
normal ovaries are removed at the time of another procedure, it is termed prophylactic or
elective oophorectomy (202). Hysterectomy, the removal of the uterus is the most
common major surgery performed among non pregnant women in the United States (49,
203). Of the more than 600,000 hysterectomies performed annually, approximately 54%
include BSO (49, 203). The proportion of women with BSO increased from 25% in 1979
to 45% in 2004 (202). However at the turn of the century, an overall decrease in the rate
of BSO has been observed nationwide. Since, hormone therapy was commonly
prescribed for all women undergoing oophorectomy, this declining trend in BSO rate
may reflect the impact of recent publications about the adverse effects of hormone
therapy on patients' and physicians' decision-making (202).
During the period of 2001 to 2006, an 8% overall reduction in the incidence of
oophorectomy was reported , with a relative reduction of 35% among women younger
than 55 years (204). However, 63% of BSO were performed in women aged 45 to 49
years compared to 30% in women aged 35 to 39 years (205) Women who live in the
South are more likely to undergo oophorectomy (42%), an observation that reflects
geographic variation in practice patterns and/or patient preferences (202).

53

Fig. 2.1 The mechanism of menopause and cardiovascular disease

Although race is not a significant factor for BSO, a greater proportion of women with
BSO are non-Hispanic Whites, while black/African American women are more likely to
undergo hysterectomy (202). Regardless, socioeconomic status plays a role in the choice
and age of BSO (204). In younger women, those who are uninsured or are enrolled in
Medicaid programs are more likely to undergo BSO. On the contrary older women with
private or self-paid for insurance are more likely have an oophorectomy. Younger women
who choose to have an oophorectomy before the average age at natural menopause may
not all be truly undergoing prophylactic surgery, but instead may partly represent a select
group of women with high risk for worse health outcomes, since they more likely to have
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a family history of breast or ovarian cancer, as well as a personal history of breast cancer,
ovarian cysts, or endometriosis at the time of surgery (202).
Results from prospective studies suggest that there is equipoise about the risks
and benefits of bilateral oophorectomy especially in women with normal ovaries. Despite
its benefits in decreasing the risk of epithelial ovarian cancer, breast cancer, and a
decrease in pelvic pain and future pelvic surgery risk, oophorectomy is asserted to have
deleterious effects on cognitive function, cardiovascular and bone health (202, 204). The
debate about risks and benefits of prophylactic oophorectomy has led to several revisions
in recommendations by the American College of Obstetricians and Gynecologists (204).
Furthermore, the effect of elective oophorectomy on cardiovascular outcomes remains
controversial and existing evidence is inconclusive to determine risk or benefit (58). In
our view, several methodological limitations exist among studies conducted to
demonstrate whether there is an association between BSO and CVD (58). Notably,
women who undergo hysterectomy (regardless of ovarian status) have adverse CVD risk
profile compared to those without hysterectomy (57), and a number of studies have failed
to control for these factors. Additionally, others did not control for the use of HT, which
has been suggested to have a short term beneficial effect when initiated immediately after
the surgical procedure in premenopausal women (63). Other methodological factors that
have resulted in conflicting conclusions concerning the effect of BSO and CVD include
inappropriate comparison group, small sample size and inadequate methods to address
confounding (63). These methodological differences among studies limit their synthesis
for meta-analysis (63). Nevertheless, in a meta-analysis by Atsma et al (41), the risk of
CVD was reported to be 4-fold among women with oophorectomy. In view of the small
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sample size (3 studies) and substantial heterogeneity among studies in their stratified
analyses of bilateral oophorectomy, care should be taken in interpreting these results.
Two of the largest cohorts to address the effect of BSO on incident cardiovascular
disease and mortality were the Nurses’ Health Study and the Women’s Health Initiate.
Parker et al (53) examined the records of 29,380 women followed for 24 years in the
Nurses’ Health Study, and reported that compared with ovarian conservation, BSO at the
time of hysterectomy increased the risk for all cause mortality (HR: 1.12, 95% CI: 1.031.21), as well as fatal and nonfatal CHD (HR: 1.17, 95% CI: 1.02-1.35) but this increased
risk was limited to women with their ovaries removed before age 45 years. The strength
of that study does not only lie in the appropriate comparison group for BSO, but also the
extensive adjustment for confounders (age, age at hysterectomy, diabetes, high blood
pressure, smoking status, hypercholesterolemia, family history of myocardial infarction
before age 60 years, body mass index, use of estrogen therapy, duration of oral
contraceptive use, parity, average daily alcohol consumption, total hours of weekly
physical activity, and acetylsalicylic acid use)
Contrastingly, Howard et al (57), using data from 89,914 participants of the WHI
Observational Study reported no significant association between BSO and fatal and
nonfatal CVD after adjusting for several confounding variables (HR: 1.11, 95% CI: 0.99 1.24) when compared to women with no hysterectomy or oophorectomy. These results
were later confirmed by Jacoby et al (59) using a sample of 25,448 women aged 50 to 79
years with a history of hysterectomy from the same cohort. Comparing participants with
both hysterectomy and BSO to women with ovarian conservation, BSO was not
associated with an increased risk of fatal and nonfatal coronary heart disease (HR:1.00,

56

CI: 0.85 – 1.18), stroke (HR:1.04, CI: 0.87-1.24) or total cardiovascular disease
(HR:0.99, CI: 0.91-1.09) after adjusting extensively for confounders such as age,
race/ethnicity, educational level, medical insurance, parity, body mass index, HT status,
smoking, alcohol use, physical activity, hypertension, diabetes mellitus,
hypercholesterolemia and personal or family history of angina, myocardial infarction,
stroke or any percutaneous coronary intervention procedure. The same outcome was also
seen among women with BSO and no history of HT use, suggesting that BSO of itself
may not incur additional risk for CVD, especially among the WHI cohort.
Several differences among these two cohorts are worth mentioning which might
influence the divergent results reported. While both enrolled a greater proportion of NonHispanic whites, the Nurses’ Health Study had 94% compared to 85% in the WHI study
(53, 57). Furthermore the Nurses’ Health Study cohort were homogeneous with regard to
education, socioeconomic status and access to care, while the WHI cohort was
heterogeneous for these above mentioned factors, older (mean age of 63 vs. 51 years) and
had less follow-up time ( 8 years vs. 24 years) (53, 57).
One hypothesis is that the abrupt reduction in endogenous estrogen levels without
HT therapy among women with oophorectomy raises their risk for CVD. This idea is
supported by results from a sub-study of the WHI estrogen alone trial in which no
significant associations between BSO and subclinical coronary artery disease was
reported (50). In women with BSO without hormone therapy, however, a 2 fold increased
risk (OR: 2.0, 95%CI: 1.2–3.4) for atherosclerosis, as assessed by coronary artery
calcium (CAC) scores was identified independent of traditional CVD risk factors. This
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underscores the complex biologic effects and multiple pathways by which estrogen
influences the atherosclerotic process.

Polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is an incompletely understood hormonal
disorder which is characterized by enlarged cystic ovaries, chronic hyperandrogenemia,
irregular or absent menstrual cycles, hirsutism, insulin resistance and obesity (206). It is
the most common endocrinopathy in women of childbearing age (207). The prevalence of
PCOS varies depending on the diagnostic criteria used (207). PCOS prevalence of 6-10%
is reported when applying the National Institute of Health criteria, while this estimate
increases to 20% when using the Rotterdam criteria; however, this number may
significantly under represent the prevalence since many cases are not recognized (207,
208). Apart from hyperandrogenemia, several other CVD risk factors are common in
women with PCOS including hypertension, low HDL cholesterol, as well as elevated
levels of triglycerides, LDL cholesterol, and homocysteine (207, 208), and as many as
70% of women with PCOS are obese (209). Numerous studies have reported that PCOS
is associated with diabetes, atherosclerosis and CVD.
Using electron beam computed tomography measure coronary artery calcium
noninvasively, Christian et al (210), reported that women with PCOS have a greater
prevalence of subclinical coronary artery disease than obese or non-obese women of
similar age. Compared to age-and BMI-matched healthy, ovulatory controls, the risk of
atherosclerosis in women with PCOS aged 30 to 45 years was five-fold (OR: 5.89, 95%
CI: 2.46–13.97) (210), even after excluding participants with diabetes and prevalent
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CHD. Additionally, other studies reported that body weight and obesity do not fully
explain the increased atherosclerosis risk in women with PCOS as assessed by carotid
intima-media wall thickness (211). Furthermore, reports from the Coronary Artery Risk
Development in Young Adults (CARDIA) study demonstrates that PCOS women have
higher left ventricular mass index and left atrial diameter (212) compared to healthy
controls. Likewise the Women’s Ischemia Syndrome Evaluation (WISE) Study reported
an increased risk of angiographic CHD (OR 1.88, 95%CI: 1.06–3.40) in women with
PCOS compared to controls (213).
On the other hand, observational studies to assess the incidence of cardiovascular
morbidity and mortality in PCOS patients have produced conflicting results. Iftikhar et al
(207), found no statistically significant risk in the incidence of MI, CVD or stroke related
mortality, among 309 women with PCOS followed for 24 years in Olmsted County,
Minnesota. On the contrary, a 20 year follow-up of 2,301 multiethnic British women
including 29% Asians with PCOS identified a higher incidence of diabetes, MI and
angina in women with PCOS than in the national female population (214). Additionally,
the increased risk was limited to women aged 45 years and older with over a quarter
having MI or angina after age 65 years (214). To try to resolve the ambiguity in the
association of PCOS with CVD hard endpoints and to assess if obesity mediated this
relationship, a meta-analysis of controlled observational studies was conducted by de
Groot et al (209). Using a random effects model, the relative risk for CHD or stroke was
2.02 comparing women with PCOS to women without PCOS (95% CI: 1.47-2.76).
Although the risk was attenuated by controlling for the effect of BMI, it still attained
statistical significance (RR: 1.55, 95%CI: 1.27-1.89).
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Statistical adjustment for traditional risk factors of CVD does not fully explain the
excess risk of CVD among women with PCOS. However, women with PCOS are more
likely to have central adiposity, insulin resistance and hyperandrogenemia as do women
with diabetes (215). Since both groups of women share these risk factors and have more
CVD, these factors may explain the excess CVD risk in these two specialized
populations.

SEX HORMONES AND CARDIOVASCULAR DISEASE

The role of sex hormones in women’s cardiovascular health is an emerging field
of interest (96). Failure to demonstrate that exogenous estrogens are effective in the
primary or secondary prevention of CVD in both the HERS and WHI trials, has brought
increasing attention to the role of other hormones in cardiovascular health outcomes. One
idea is that testosterone predisposes older women and those with PCOS or diabetes to
increased CVD risk. Accordingly, among younger women, estrogen opposes the
detrimental effects of testosterone on chronic cardiac remodeling and function (216) by
direct effects and by increasing the production of SHBG which reduces the portion of the
circulating testosterone that affects target tissues (bioavailable testosterone). After
menopause estradiol levels are dramatically reduced whereas testosterone levels fall only
modestly allowing testosterones and other androgens to adversely impact CVD risk.
Furthermore, estrogen deficiency in women predisposes to visceral fat accumulation
which is strongly associated with insulin resistance. Following the menopause, women
show a steeper increase in visceral fat than men, perhaps because of estrogen deficiency,
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and the increase in androgen production that occurs with increased visceral fat may
increase CVD risk especially in women with PCOS and diabetes.

ESTROGEN
Estrogen production and metabolism
The ovaries are the main source of estrogen production in premenopausal women,
and estradiol is the major and most important circulating estrogen which acts on target
tissues throughout the body (217). Estrogens are produced from cholesterol by a series of
biotransformations which culminate in bioconversion of testosterone to estradiol by the
enzyme aromatase (217). This enzyme is expressed in other tissues, however, allowing
for estrogen production in the liver, adipose cells in the breast and other parts of the body,
osteoblasts , chondocytes, muscle cells and skin cells and the placenta during pregnancy
(217). In postmenopausal women, these sites of peripheral production of estrogen
become the major source of estrogen since the ovaries cease producing estrogens (217).
At this time, estrone is the primary estrogen in the circulation and is produced by the
bioconversion of androstenedione from the adrenal cortex (218). A very small amount of
estradiol is formed through the extragonadal conversion of testosterone (218). Adipose
tissue is a significant site for the conversion of androstenedione to estrone in
postmenopausal women, and the level of estrone in plasma is directly proportional to
BMI (218).
After release from the ovaries and peripheral tissues, estradiol circulates bound to
albumen (60%), sex hormone binding globulin (SHBG) (38%), or unbound (2%)
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(219). Estrogens are metabolized primarily in the liver in two phases (220, 221). Phase I
is hydroxylation of molecule at the 2nd , 4th and 16th alpha carbon position by the
addition of a hydroxyl ion yielding 2-hydroxyestrone, 4-hydroxyestrone and 16-alphahydroxyestrone respectively (220, 221). It’s now known that 2-hydroxyestrone has
beneficial effect while 4-hydroxyestrone and 16-alpha-hydroxyestrone lead to tissue
proliferation which promotes carcinogenesis (220, 221). These hydroxyestrones (catechol
estrogens) are then oxidized to quinones (phase II). Quinones from 2-hydroxyestrone and
4-hydroxyestrone are also known to have a deleterious effect on DNA either directly or
indirectly through the generation of reactive oxygen species (220, 221). They are
methlylated by catechol-O-methyltransferase (COMT) to detoxify them for excretion
(220, 221). Methylated catechol estrogens are conjugated with glucuronic acid to
facilitate their excretion in the feces and urine (220, 221). In the intestines, certain
bacteria produce the glucuronidase enzymes which break the bond between the estrogen
and glucuronic acid, allowing the estrogens to re-enter the blood stream (220, 221).

Protective Effects of Estrogen on the Cardiovascular System
Endogenous estrogens have a cardio-protective effect via several mechanisms.
Estrogens increase HDL cholesterol levels and reduce LDL levels (96). However,
estrogen- induced changes in the lipid profile account for only about one third of its
cardio-protective effects (222). Additionally, estrogen activates the release of the
vasodilators nitric oxide and prostacyclin from vascular endothelial cells to inhibit
vascular constriction and thereby reduce arterial blood pressure (96). The increased
production of nitric oxide also reduces platelet aggregation (96). Furthermore, estrogen
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inhibits endothelial cell apoptosis, promotes increased endothelial cell proliferation and
angiogenesis. The route of administration of exogenous estrogens has differential effect
on lipid levels, with estrogens administered transdermally having less effect on plasma
lipids compared to orally administered estrogen (96). Estrogens administered
transdermally produce higher concentrations in plasma with a more rapid onset of action
than estrogens administered orally as a result of the first pass effect, however estrogens
administered orally increased the expression of many genes in liver, clotting factors, and
sex hormone binding globulin (223)..

Hormone Therapy and Cardiovascular disease
Earlier autopsy studies in oophorectomized women receiving hormone treatment
or none reported that estrogen has a positive effect on the coronary vasculature (191).
Supported by experiments in vitro and in experimental animal, it was asserted that
endogenous estrogens might have a protective effect on the primary prevention of CVD
in women. This idea seems plausible since premenopausal women are less likely to have
a CVD event compared to men of similar age, and CHD risk is increased in
postmenopausal women (224). A meta-analysis of observational studies published up
until 1996 reported a protective effect of HRT among ever users from CHD and CHDrelated mortality, with Barrett-Connor et al (225), reporting a statistically significant
reduced risk of 30% and 34% for unopposed and opposed therapy respectively. However
two large randomized clinical trials, the WHI Study and the HERS study, reported results
that were contrary, and refuted the theory that estrogens are protective in the primary
prevention of CVD in postmenopausal women (60-62).
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The publications of the results of those trials lead to extensive debate with many
scientists arguing that women enrolled in the primary prevention trial (WHI) were older
and initiated hormone therapy years after the onset on menopause, unlike earlier
observational studies which enrolled women closer to the time of menopause.
This notion was supported by experimental studies in monkeys in which hormone therapy
was effective in slowing atherosclerosis when administered soon after surgical
menopause whereas the benefit was lost if therapy was delayed until plaques had
developed (226) This prompted further analyses of the combined data from both the
observational and clinical trial arms of WHI according to age and years since menopause.
While women who initiated therapy closer to menopause were observed to have reduced
CHD risk compared to increase CHD risk among women more distant from age at
menopause, these results did not meet statistical significance (227).
The National Heart, Lung, and Blood Institute-sponsored Women's Ischemia
Syndrome Evaluation (WISE) study which followed 654 postmenopausal for a median of
6 years reported lower prevalence of obstructive CAD (OR: 0.44, 95%CI: 0.30-0.73) and
CVD (HR: 0.60, 95% CI: 0.41-0.88) among hormone therapy users who had natural
menopause and were less than 55 years (228). Similarly, three meta-analyses of
randomized controlled trials seem to affirm the timing hypothesis by concluding that a
significant reduction in CHD and mortality was observed in women who were
randomized to HT before age 60 or within 10 years of menopause (229-231). One of such
was a Bayesian meta-analysis that included women at a mean age of 55 years and
reported a 27% reduced risk of mortality by HT (RR:0.73, 95%CI: 0.52- 0.96) in younger
postmenopausal women (231). Recently, a clinical trial which enrolled 1006 healthy
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newly postmenopausal women aged 45-58 who were randomized to either triphasic
estradiol and norethisterone acetate (if they had intact uterus) or 2 mg estradiol a day if
they had undergone hysterectomy, reported a 52% reduced risk of CVD events (a
composite endpoint of mortality, MI, or heart failure) by hormone therapy (HR: 0.48,
95%CI: 0.26- 0.87) (232). Although this is the first randomized trial to study healthy
women treated early in menopause with 17-β-estradiol and norethisterone acetate, as well
as the longest HT intervention with 10 years of follow-up, it was however an open label
trial with no placebo or blinding (232).
The timing hypothesis remains controversial; however the protective effect of
estrogens in perimenopausal or early postmenopausal women for the treatment of
menopausal symptoms which may in turn slow down the progression of atherosclerosis
seems convincing (226). Taken together, these observations seem plausible since newly
menopausal women have fewer thrombotic modifications to their vasculature due to
healthier vascular endothelium which is also more resistant to thrombosis (96), and
thereby might benefit from the protective effect of estrogen.

ANDROGENS

Androgens production
The postmenopausal ovary is an ongoing site of androgen production. While both
circulating estrogens (mainly estradiol) and androgens levels fall with menopause due to
ovarian follicular depletion and age-related atrophy of the adrenal cortex, there is a
drastic reduction in estradiol compared to testosterone, resulting in a more androgenic
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milieu in older women (35). A reduction in SHBG levels during menopause also fosters
this excess androgenic state (233). Although postmenopausal ovaries cease producing
estradiol, the ovarian stroma, however, continues to produce testosterone (234). Thus
women with bilateral oophorectomy have lower levels of androgens (50% less) compared
to women with natural menopause (36, 37), which persist even after age 65 years (234).
Meanwhile, postmenopausal women with unilateral oophorectomy have significantly
higher levels of androstenedione and testosterone than menopausal women with bilateral
oophorectomy (202). Certain factors promote reduced circulating levels of testosterone.
Estrogen therapy administered orally increases SHBG production (approximately 75%)
which results in reduced levels of free and total testosterone (233). Evidently, transdermal
hormone therapy has to be administered at very high dose to achieve this same effect
(233). Other conditions and therapies including Addison’s disease, corticosteroid therapy,
chronic illness, and premenopausal ovarian failure are all known to decrease circulatory
levels of androgens resulting in androgen deficiency (233).
There are five major androgens produced in women. Listed in descending order of
serum concentration, they are dehydroepiandrosterone sulphate (DHEAS),
dehydroepiandrosterone (DHEA), androstenedione, testosterone, and dihydrotestosterone
(DHT) (233). DHT and Testosterone are the most potent androgen (233), while DHEAS,
DHEA, and androstenedione can be converted to testosterone (233). The biosynthesis of
androgens is modulated by two cytochrome P450 enzymes. P450 SCC modulates
cholesterol side chain cleavage, while P450 c17 catalyzes 17-hydroxylation and 17-20
bond cleavage to form DHEA and androstenedione (233). The conversion of DHEA to
androstenedione is catalyzed by the enzyme 3β -hydroxy steroid dehydrogenase (3β -
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HSD), and 17β-hydroxy steroid dehydrogenase (17β-HSD) catalyzes the conversion of
androstenedione to testosterone (233). About 65% to 75% of testosterone in the plasma is
bound to SHBG, 1-2% is unbound, and the remaining 25% to 35% is bound loosely to
albumin (235).
In women, androgen production takes place in three compartments: the ovary,
adrenal cortex and in peripheral tissue (236). In premenopausal women, 25% of
testosterone is derived from the ovaries (35). Another 25% is produced by the adrenal
cortex through the stimulation of adrenocorticotropic hormone (ACTH), and 50% is from
peripheral conversion of androstenedione, DHEA and DHEA-S (35). In postmenopausal
women, however, the sources of testosterone changes with 50% from the ovaries, 10%
from the adrenal cortex and 40% from peripheral conversion (35). (Figure 2.2)
Follicular depletions results in reduced estradiol secretion which leads to loss of
negative feedback to the hypothalamus and pituitary gland, leading to increased
production of luteinizing hormones (LH) which stimulates ovaries to produce
testosterone (235).
There is a positive association between the levels of insulin and testosterone in
plasma, which is exaggerated in women with PCOS or diabetes. Insulin stimulates
ovarian production of testosterone, and insulin resistance is associated with low levels of
SHBG such that diabetics having higher circulating levels of testosterone compared to
normal women of the same age (36). Furthermore, in the ovaries of premenopausal
diabetic women, conversion of androgens to estrogens less effectively due to decreased
ovarian aromatase activity (94), perhaps because of increased mullerian inhbitory
hormone..
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Fig 2.2 Sources of testosterone production in postmenopausal women

This imbalance between estradiol and testosterone may be one mechanism for the
increase in CHD risk in diabetic women (94). It is insulin that stimulates elevated ovarian
androgen production and not androgens causing insulin resistance and hyperinsulinemia
(94), since in hyperinsuulinemic hyperandrogenic women with PCOS, suppression of
luteinizing hormones with a gonadotropin-releasing hormone (GnRH) analogues reduced
androgen levels without altering insulin sensitivity or circulating insulin levels (94).
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However, among PCOS women whose insulin levels declined through diet or drugs, a
fall in serum androgens was observed (94, 237).

Androgens as a Cardiometabolic risk factor
Adiposity and fat distribution
There is a large body of scientific literature on the influence of androgens on the
connection between androgens and the accumulation and distribution of fat in
postmenopausal women independent of age, total fat mass and other CVD risk factors
(67, 198, 199, 238-240). In the Study of Women’s Health Across the Nation (SWAN) Fat
Patterning Study, the level of bioavailable testosterone was associated with the amount of
visceral fat even after adjusting for insulin resistance, suggesting that testosterone is
linked to regional fat distribution (67). This is an important relationship since both factors
are associated with higher cardiovascular risk in women (figure 2.3). Obese women have
elevated circulating androgens levels, especially bioavailable testosterone, and DHEAS,
as well as an increased androgen production rate (94, 241). Furthermore, testosterone
clearance is accelerated in obese individuals due to lower SHBG (239), while the causeand- effect relationship between androgens and visceral adiposity is complex. Female-tomale transsexuals, testosterones treatment increased BMI and visceral adiposity (35).
Android obesity is associated with a greater risk for metabolic syndrome, diabetes
and CVD in women than is gynoid obesity (242). The action of visceral fat and its
deleterious effect on CVD is poorly understood. However, the amount of abdominal
obesity correlates positively with small dense LDL particles, reduced HDL, insulin
resistance, hyperinsulinemia, growth hormone deficiency and hypertension, independent
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of age and total body fat or body mass index (BMI) (74, 243-246). Visceral adipose
tissue (VAT), is known to be more metabolically active than subcutaneous adipose tissue
(SAT) and is linked to increased insulin resistance.(16, 242, 247, 248). Additionally,
VAT secretes larger quantities of pro-inflammatory cytokines such as TNF -  and
interleukin-6 which increase the level of the acute phase reactant C-reactive protein (242,
247), and contributes to atherothrombosis through the activation of intravascular
coagulation and fibrinolysis (249). Finally VAT may directly influence atherosclerosis by
accelerating the progression of coronary calcification (71).

Fig. 2.3 Actions of elevated testosterone on cardiovascular risk and disease
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Several studies have found that bilateral oophorectomy, when performed in
premenopausal women, increases their risk for CVD, but the explanation for this
important association is uncertain. While no statistically significant relationship between
BSO and all-cause and cause-specific mortality was reported among participants in the
third National Health and Nutritional Examination Survey obese women who underwent
BSO before 40 years of age had an increased risk of mortality, with the lack of HT use
compounding this effect. Studies in rodents reveal that BSO increases visceral fat content
(250-252), LDL cholesterol, and produced a hyperinsulemic response to glucose
tolerance implying insulin resistance which is partially reversed with estrogen
supplementation (251, 252). While no comparable data are available in humans, if
estrogens decrease visceral fat accumulation in humans, then removal of the ovaries at an
early age may have a more adverse effect on CVD risk than if this procedure is
performed after the time of natural menopause when estrogen production is low (234,
253). Moreover, the increase in visceral fat may stimulate androgen production to further
increase CVD risk.

Lipid Profile
Clinical observations suggest that testosterone plays an important role in lipid
metabolism. For instance among female-to-male transgender patients who were receiving
testosterone therapy, a reduction in HDL cholesterol was identified, coupled with
elevated triglycerides. When obese postmenopausal women were administered nandolone
deconoate (an anabolic steroid) in a 9-month randomized placebo-controlled trial (254),

71

HDL cholesterol levels were reduced but no significant change in fasting glucose or
insulin sensitivity was observed (254).
Androgens may influence lipid metabolism through several mechanisms. These
include increasing the activity of lipoprotein lipase and hepatic triglyceride lipase which
results in elevated levels of triglyceride in adipose tissue, as well as a decrease in total
circulating high-density lipoprotein levels (255). Furthermore, androgens may decrease
catabolic removal of low-density lipoproteins from circulating plasma (255).
A study to characterize the cross-sectional relationship between endogenous
hormones and lipid parameters in 328 postmenopausal women with prevalent carotid
atherosclerosis in the Atherosclerosis Risk in Communities Study reported a positive
correlation between free androgen index and increased levels of triglyceride, LDL and
total cholesterol (69). Although free androgen index was associated with a more
atherogenic lipid profile independent of demographic, metabolic factors and health
behaviors, SHBG on the other hand was statistically significantly associated with a more
favorable lipid profile (69). Another study of 598 healthy Greek postmenopausal women
not on hormone therapy demonstrated that compared to women in the lowest testosterone
quartile, women in the highest testosterone quartile had higher levels of total cholesterol,
LDL cholesterol, apolipoprotein B and decreased HDL cholesterol, independent of the
effect of age, BMI, insulin resistance and social habits (70). Interestingly, the free
estrogen index exhibited similar associations with lipid profiles as the free androgen
index (70).
Although, endogenous androgens, namely testosterone has been shown to also
increase levels of total and LDL cholesterol, reduce HDL cholesterol in most
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observational studies (68-70), results from other studies do not support a major role of
testosterone in lipid metabolism. Stork et al (256), studying 889 healthy postmenopausal
participating in the PROSPECT study did not identify any association between total
testosterone and lipid metabolism, however free androgen index was weakly inversely
correlated with HDL cholesterol levels. Furthermore, a more androgenic profile was
associated with high levels of C-reactive protein (CRP), after adjustment for age,
traditional cardiovascular risk factors and markers of body composition. Adipose tissue is
known to produce inflammatory mediators that increase CRP-production in the liver (1).
However, a positive association between androgens with a nonspecific inflammation
marker like CRP independent of adiposity was still reported (1). This suggests that
androgens may independently influence the inflammation process during atherosclerosis.

Subclinical coronary disease
The impact of androgens on subclinical coronary artery disease is largely
unexplained; however, experimental studies suggest that androgens may promote several
mechanisms of the atherosclerotic process. Recent evidence acknowledges that
testosterone influence the process of inflammation by increasing the level of endothelin 1
(ET-1) which is a vasoconstrictor and is usually present at early stages of endothelial
dysfunction, while 17β-estradiol reduces ET-1 levels (257). Testosterone leads to
apoptotic damage of the endothelial cells under serum deprivation, leading to endothelial
leakage, increased platelet adhesiveness and thrombus formation (258). This results in
clot formation that block narrow arteries, cutting off oxygen supply to the heart and
myocardial infarction when the coronary arteries are occluded (258). In vitro studies also
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demonstrate that testosterone increases monocyte adhesion to the vascular endothelium
(259). Similar to aging, hyperandrogenicity results in increased oxidative stress and
advance glycation end-products (AGE) which are well-documented atherogenic
molecules that interact with the transmembrane receptor RAGE, leading to the activation
of inflammation, oxidative stress and proatherogeneic cascades (260).

The Effect of Androgens on Cardiovascular disease outcomes
Little is known about the association of androgen levels with cardiovascular
disease outcomes in postmenopausal women, and the few studies conducted reveal
conflicting results. In some instances, both J and U-shaped relationships have been
proposed, while in others, either a reverse association of testosterone with CVD outcomes
or null associations have been reported. Table 2.2 summarizes the reported association of
androgens with cardiovascular events.
The Rancho Bernado study (261), reported no association between bioavailable
testosterone levels and CVD mortality in 651 post-menopausal women while another
cohort study of 2914 German women in primary care reported that women with low total
testosterone levels had increased CVD mortality (262). The risk of CVD-related mortality
was elevated for participants with total testosterone levels in the lowest quintile (Q1),
with patients in the collapsed quintiles (Q2-Q5) having a 32% reduced risk (HR 0.68,
95%CI: 0.48-0.97) (262). Three were no results for SHBG or bioavailable testosterone.
Conversely, Shaw et al (213) reported a 59% increased risk of CVD mortality
among postmenopausal women with a history of irregular menses as well as clinical
features of PCOS. These women were both hyperandrogenic and insulin resistant.
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A large nested case control study, the Women's Health Study, found that among women
not using hormone therapy, there was a higher calculated free androgen index (FAI)
among postmenopausal women who developed CVD events. This did not attain statistical
significance after controlling for the independent effect of body mass index and other
cardiovascular risk factors, however (263). The study by Juutilainen et al (9) which
examined free testosterone levels– the biologically active form– found no association
with either CVD or all cause mortality, except among diabetic women. However the
external validity of that study is limited since it was not population based but was instead
conducted among women referred for coronary angiography, and results may not be
generalisable to women with low cardiovascular risk.
It is necessary to highlight some of the limitations in studies undertaken to
demonstrate association between androgens namely testosterone and CVD. In non
prospective studies (i.e. cross-sectional studies), reverse causality cannot also be ruled
out. Additionally study populations were heterogeneous and selection criteria were
diverse (35). Adjustments for confounders were not always adequate in some studies to
control for spurious associations. Furthermore in case control studies, bias may be
introduced since atherogenic changes may cause a decline in testosterone levels in
participants diagnosed with CVD (35).

THE EFFECT OF ANDROGENS ON CVD IN DIABETIC WOMEN

Considerable attention has been focused on androgens in diabetic women because
of their increased risk for CVD. Postmenopausal women with diabetes have elevated
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levels of testosterone compared to non-diabetic controls. Stoney et al (79), in a study
among 42 postmenopausal diabetic women compared with 42 normoglycemic women
matched for age and BMI, reported that diabetics had significantly elevated levels of
androgens. Another study of 126 postmenopausal diabetic patients with 7.8 years
average duration of diabetes, matched for age and BMI with 126 healthy postmenopausal
controls also demonstrated that diabetics have elevated levels of testosterone than
controls (1.7+/-0.1 vs. 1.4+/-0.2 pmol/l; P<0.05) (80). Furthermore diabetic women have
a higher ratio of testosterone/estradiol than controls (80). The association was also
confirmed by a meta-analysis of 43 prospective and cross-sectional studies in which
women with diabetes had higher testosterone (mean difference, 6.1 ng/dL; 95% CI, 2.3 to
10.1) and estradiol levels compared to age and BMI matched controls (81). Even among
diabetic women with similar total fat mass, android adiposity, waist circumference and
upper body fat as non diabetic controls, the same relationship is observed (85). Other
studies of diabetic women matched with non-diabetics either on age and years since
menopause (82), or regression adjustment for age, BMI and waist to hip ratio (83, 84)
concluded that testosterone levels are indeed elevated among diabetics.
It has been proposed that the ovaries of Women with diabetes have a reduced
ability to convert androgens to estrogens due to a reduction of aromatase activity (94).
Although the source of the excess androgens in diabetic women has not been studied in
detail, results in women with PCOS, who are also more likely to be obese and insulin
resistant (91, 92), and to develop diabetes suggest an ovarian source of androgens
although increased adrenal steroid production might also contribute in part to the higher
androgen levels reported in diabetic women (93).

76

Table 2.2: Studies of endogenous testosterone and risk of cardiovascular disease (CVD) outcomes in postmenopausal women
Study

Study
design

N

Mean
age

Mean
BMI

Risk estimate

Total Testosterone

Free Testosterone

CS

651

66.7

–

HR:1.00 (0.99-1.01)

Rexrode et al 2003 (263)

NCC

400

63.1

26.4

Q4 vs.Q1
OR:1.16 (0.48-2.78)

Braunstein et al 2008 (264)

C

284

64.8

30.0

OR:1.02 (1.00-1.04)

OR:1.13 (1.201.25)

Patel et al 2009 (265)

C

344

74.4

26.9
Q4 vs. Q2
OR: 2.95 (1.2-7.3)

Q4 vs. Q2
OR:1.41 (0.6-3.2)

Barrett-Connor et al 1995

Outcome

Bioavailable T
RR:0.98 (0.95-1.02)

CVD death

(261)
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Sievers et al 2010 (262)

CS

2914

58.0

26.7

Q5 vs. Q1
HR:0.64 (0.38-1.07)
Q2-Q5 vs. Q1
HR:0.68 (0.48-0.97)

Laughlin et al 2010 (266)

CS

639

73.8

24.3

Q5 vs. Q3
HR:1.84 (1.06-3.19)

Q1 vs. Q2-Q5
HR:1.72 (1.15-2.57)

Q1 vs. Q3
1.93 (1.09–3.43)
Wehr et al 2011 (267)

CS

875

67.3

26.9

HR:1.03 (0.78-1.37)

HR:1.01(0.89-1.15)

nonfatal MI,
PCI, CABG,
nonfatal stroke, or
stroke death,
CAD (≥ 50%
Stenosis)
Prevalent CHD
(angina, MI,
coronary
angioplasty,
or CABG
angina , MI,
PCI, CABG,
stroke, transient
ischemic attack,
CV death.
coronary artery
revascularization,
nonfatal MI,
or fatal MI.
CVD death

T: Testosterone, C: Cross-sectional study, CS: Cohort study, NCC: Nested case control study, OR: odds ratio, HR: Hazard ratio, CAD: coronary
artery disease, MI: myocardial infarction, PCI: Percutaneous coronary intervention, CABG: Coronary Artery Bypass Grafting

Lower sex-hormone binding globulin (SHBG) levels in diabetics further increase
the non-SHBG (bioavailable) testosterone in the circulatory system, and amplify the
effect of testosterone independent of overall adiposity (body mass index) and upper body
adiposity (as measured by the ratio of waist to hip circumferences) on CVD risk (87).
Although some studies have found low levels of SHBG and high androgenicity to be
associated with dyslipidemia and increased carotid artery intima-media thickness which
in turn is associated with an adverse CVD risk factor profile in postmenopausal women
(88-90), evidence for an association with incident hard cardiovascular endpoints
especially among diabetic women in longitudinal studies is lacking. A case control-study
of 120 (40 cases and 80 controls) postmenopausal diabetic women from the Wisconsin
Epidemiologic Study of Diabetic Retinopathy reported no association between
endogenous testosterone and 5 year risk of ischemic heart disease mortality (268). This
same study reported that low levels of dehydroepiandrosterone sulfate predicted ischemic
heart disease mortality. However this study included women with type-1 and type-2
diabetes, and no stratification was made for type of diabetes in the analysis. Wehr et al
(267), followed 875 postmenopausal women for a median of 7.7 years and found no
association between total testosterone or free testosterone levels with either CVD or all
cause mortality. Interestingly, in a subsample of 302 women with diabetes, comparing
women in the fourth quartile to the first quartile, free testosterone but not total
testosterone predicted all-cause (HR: 0.38, 95%CI: 0.08-0.90) and cardiovascular
mortality (HR: 0.28, 95%CI:0.08-0.90). This association was not linear thought, as there
was no significant association of one standard deviation increase in free testosterone with
all-cause mortality or cardiovascular mortality.
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Low androgen levels among postmenopausal women may be caused by illness or
weight loss which also has adverse impact on mortality or health (267). Besides this, the
external validity of the study is limited since it was not population based but was instead
conducted among women referred for coronary angiography, therefore results may not be
applicable to women with low cardiovascular risk.
To resolve the ambiguity in the scientific literature as to whether low or high
levels of androgens are associated with CVD events in diabetic women may require
assessing levels of androgens among postmenopausal women with and without intact
ovaries since the latter are known to have relatively low levels of androgens. If low levels
of androgens somehow predispose to CVD among diabetics, then a decreased risk should
be found among diabetic women with intact ovaries compared to diabetic women with
oophorectomy. On the other hand, if elevated levels of androgens contribute to increased
CVD risk in diabetics, then diabetic women with oophorectomy will have a relatively
reduced risk compared to diabetic women with intact ovaries.
Further, if accumulation of visceral fat due to estrogen deficiency is an important
predictor of CVD risk and androgen levels then the removal of the ovaries at an early age
may have a more adverse effect on CVD risk than if this procedure is performed after the
time of natural menopause. An alternative possibility is that some women whose ovaries
are removed at an early age are insulin resistant and anovulatory (95), representing a
group of women with increased risk of CVD.
Summary
The relative importance of testosterone to women’s cardiovascular health remains
a matter of great speculations. While some studies have found no statistical relationship
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between testosterone and CVD events in women, other which found a significant
association reported either a linear, J- or U-shaped relationship. Although much progress
has been made in the prevention of cardiovascular disease, it remains the leading cause of
morbidity and mortality in women. The presentation, diagnosis and treatment of CVD
differ between women and men leading to gender related disparities in outcomes.
Moreover, the impact of type 2 Diabetes on CVD differs substantially by gender. With
the diagnosis of diabetes, the relative risk of CVD is greater in women than men, with
women having more adverse outcomes than men. Although, it is controversial that
menopause increases the risk of CVD in women, this transitional period is associated
with several changes in both lipid profiles and body composition which is thought to be
influenced by sex hormones. During menopause, women experience a significant decline
in estrogen levels compared to androgens, which creates a more androgenic profile.
These excess androgens are suggested to modulate endothelial function, resulting in a
more deleterious effect on the coronary vasculature thereby predisposing postmenopausal
women to an increased risk of cardiovascular diseases. Evidently, diabetic women have
elevated levels of androgens and if androgens have adverse effect on women’s
cardiovascular health, then this might explain why diabetic women are at greater risk of
CHD events. Despite some studies indicating that BSO increases cardiovascular disease
risk, studying women with oophorectomy remains a good model to investigate and
understand the effect of hyperandrogenemia and cardiovascular outcomes among
postmenopausal diabetic women.
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CHAPTER THREE

RESEARCH DESIGN AND METHODS

NATIONAL HEALTH AND EXAMINATION SURVEY (1988-2010)
Description and source of study population
The National Health and Nutrition Examination Survey (NHANES) is a national
survey conducted by the National Center for Health Statistics to assess the health and
nutritional status of children and adults residing in the United States. Its aim is to monitor
health trends and provide national estimates of certain health risk factors and outcomes.
Authorized by the National Health Survey Act of 1956 passed by the 84th Congress,
which stipulated that health information be continuously collected to monitor the health
status of the civilian non-institutionalized population, this health survey has been
conducted since 1960 (269). The first three National Health Examination Surveys (NHES
I, II, and III) conducted from 1960 to 1970 did not collect any information on nutritional
status. All subsequent surveys since that time have included a nutritional and an
environmental health component. As such, the name of the survey was changed to the
National Health and Nutrition Examination Survey and data collection was also
broadened to include ages 1-74 years. NHANES I was conducted from 1971 to 1975;
adult participants aged 25 years and older were subsequently followed longitudinally
until 1992 in the NHANES I Epidemiological Follow-up Survey (NHEFS).
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NHANES II was conducted between 1976 and 1980, and NHANES III between 1988 and
1994 (269). After this time, the periodic collection of data was discontinued, and since
1999 data have been collected annually. Due to disclosure issues, continuous survey data
are released in two-year increments. Mortality data for persons who were 17 years or older

at the time of interview in the various surveys conducted between 1971 and 2004 were
obtained by the NCHS using a probabilistic match of participants information to the
National Death Index records (269).

Sampling procedure
Both NHANES III and the continuous NHANES surveys employ a complex
multistage design to obtain a probability sample of the civilian, non-institutionalized U.S.
population. Certain subpopulations such as adolescents aged 12 to 19, African
Americans, Mexican Americans, low income White Americans, and adults over the age
of 60 are oversampled to increase reliability and precision of estimates of health
indicators for these subgroups.
The complex multistage sampling begins with primary sampling units (PSU)
which includes single counties or groups of contiguous counties with probability
proportional to a measure of size (269). The PSUs are then divided into segments–usually
city blocks–and households within each segment are randomly sampled, with individuals
in those households chosen within designated age-sex-race/ethnicity screening subdomains (269). On average 1.6 persons are selected per household (269). The Survey
consisted of a detailed in-person home interviewer-administered questionnaire using
Computer-Assisted Personal Interview (CAPI) technology, physical examination and

82

specimen collection performed in a set of specially-designed and equipped Mobile
Examination Centers (MEC).(269). All adult participants provided written informed
consent and all procedures and surveys were approved by the National Center for Health
Statistics Institutional/Ethics Review Board. During the period of 1988 to 2010, the
response rate for the home interview ranged from 78.4% to 86.0% while that for the
medical examination ranged from 75.4% to 80.0% (270).

Study eligibility criteria
Inclusion criteria
Analyses for the current study were restricted to NHANES III since it was the
first wave to ask reproductive health questions pertaining to oophorectomy status, and
also NHANES 1999-2008. While NHANES 1999-2008 provided cross-sectional
information for assessing cardiovascular disease in diabetic women with oophorectomy,
NHANES III allowed the evaluation of the prospective association of the effect of
oophorectomy in diabetic and cardiovascular mortality. NHANES III was linked with
mortality follow-up data from 1988 through to December 31, 2006. Mortality was
ascertained based on National Death Index death certificate records. Previous versions of
the International Classification of Diseases (ICD) codes were recoded into comparable
ICD-10 codes based on underlying cause of death.
Of the 39,695 persons selected to participate in NHANES III, 33,994 (86%) were
interviewed in their home with 30,818 (78%) of them receiving a clinical examination.
Female participants who were ≥ 40 years old and not pregnant (n = 6,050) were eligible
for this study. For the six waves of NHANES data (1999-2010), 15,644 female
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participants aged 20 years or older who received a clinical examination were eligible for
this study.

Exclusion criteria
From the 6,050 women in NHANES III eligible for the study, the following
exclusions were made, in order: 1,984 pre- and perimenopausal, 356 with partial or
unilateral oophorectomy, 384 with missing age at menopause, 18 with missing values for
either height or weight or both, 100 with missing values for important covariates, and 2
women with missing mortality status. In addition, women who were underweight (n=82)
based on BMI were excluded due to the small number, yielding an analytic sample
comprising of 3,224 postmenopausal women. In NHANES 1999-2010, analyses were
restricted to 7,139 women who were postmenopausal. Of this number, 359 with partial or
unilateral oophorectomy, and 405 women with unknown or missing age at menopause
were excluded, resulting in a sample size of 6,375 for the cross-sectional analysis.

Definition of exposure variables
Diabetes
Both fasting and 2 hour oral post-glucose (using 75g oral dose in adults)
concentrations were determined by an enzyme hexokinase method. Diabetes was defined
as a fasting (at least 8 hours) plasma glucose of ≥ 126 mg/dl or < 126 mg/dl with a 2-hour
value of ≥11.1 mmol/L (200 mg/dL) in accordance to the Expert Commission on
Diagnosis and Classification of Diabetes recommendations for epidemiologic studies
(271). In addition, current use of an antihyperglycemic medication (including insulin) or
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a self-reported medical history of diabetes was also included in the definition of prevalent
diabetes.
Oophorectomy
The detailed home interview questionnaire ascertained both oophorectomy status
and age at surgery. Oophorectomy status was ascertained through questions such as
“have you had one or both of your ovaries removed”, “were only one or both ovaries
removed” and “how old were you when ovaries were removed” Women who answered
“both ovaries were removed” were considered to have bilateral oophorectomy.
Participants were not asked about the indication for oophorectomy.

Definition of outcome variables
Prevalent cardiovascular disease (CVD) was defined as a self-report of physician
diagnosis of angina pectoris, stroke and myocardial infarction. In NHANES III, angina
was assessed using the WHO Rose angina questionnaire (272). For prospective analyses,
deaths were classified as incident CVD mortality when the underlying or primary cause
of mortality on the death certificate was coded with ICD 10 codes (I00 - I78). A
dichotomous variable with categories for CVD mortality and no-CVD mortality was
created.

Definition of relevant covariates
Sociodemographic
Information about age, race/ethnicity, and educational status was self-reported.
Age was specified as continuous. Race/ethnicity was defined as Non-Hispanic White,
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Non-Hispanic Black, Mexican American and Other. Educational status was reported as
years of education, and further categorized into either college degree or higher and less
than a college degree. Socio-economic status was assessed using the poverty income
ratio. This is the ratio of a family's income to the poverty threshold defined by the U.S.
Census Bureau appropriate to the family's composition (273). A cutoff point of less than
1.00 means living below the federal poverty level while a cutoff point of 1.00 or more
means living at or above the federal poverty level.

Anthropometry
Body mass index (BMI) was calculated as weight in Kilograms divided by the
square of height in meters, after which it was categorized into underweight (less than
18.5), normal weight (18.5 to 24.9), overweight (25 to 29.9) and obese as 30.0 or greater,
without any modification/adjustment being made for any racial/ethnic group. Waist
circumference was measured to the nearest 0.1 cm at the level of the iliac crest. Women
who had a waist circumference of >88 cm were considered to have abdominal obesity.
Hip circumference was measured at the level of the maximum posterior protrusion of the
buttocks. Waist-to-hip ratio (WHR) was calculated by dividing waist circumference by
hip circumference.

Health behavioral/lifestyle factors
A subject was be said to be a “never smoker” if she reported smoking fewer than
one hundred cigarettes over her entire life. “Former smoker” was defined as reporting
smoking at least one hundred cigarettes over a participant’s lifetime, but answered “no”

86

when asked if she smoked at the present time. Finally participants were categorized as
“Current smoker” if they reported smoking at least one hundred cigarettes over their
lifetime and answered “yes” when asked if they smokes at the present time.
For physical activity, participants were asked about the frequency with which they had
participated in the following activities during the preceding month: walking a mile
without stopping, jogging or running, swimming, regular dancing, aerobic exercise or
aerobic dancing, riding a regular bicycle or exercise bicycle, calisthenics, garden or yard
work, and weight lifting. Only frequency of events and not duration were asked. The
frequency of physical activity in the previous month was divided into 3 levels based on
their distribution: low if frequency of activity was less than 5, medium (5-28 times) and
high (29 or more times).

Health history and conditions
During the home interview, participants were asked whether any family member
had a heart attack before age 50. A family member was defined as an immediate blood
relations living or deceased, which would include grandparents, parents, brothers and
sisters. Participants who responded “yes” were considered to have a family history of
heart attack before age 50. Additionally, participants were asked if they had been
informed by a physician or were told to be diagnosed with cancer. A history of female
cancer was defined as having a physician diagnosis of breast, uterus or ovarian cancer.
Blood pressure was measured by trained staff using a mercury
sphygmomanometer with an appropriately sized arm cuffs. Participants had their blood
pressure measured while seated. A participant was said to have hypertension if there was
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a systolic blood pressure above 140 mm Hg, diastolic blood pressure of above 90 mm
Hg, a physician diagnosis of hypertension, or current medication use for elevated blood
pressure.
Non-fasting serum levels of HDL-cholesterol and C-reactive protein were
measured using the Roche/Boehringer-Mannheim Diagnostics direct HDL method and
the latex-enhanced nephelometry on a Behring Nephelometer respectively (274).
In NHANES III, fasting measures of triglycerides, plasma glucose, and insulin
were obtained in a subsample of participants (~50%) who attended the morning
examination. Hypercholesterolemia was defined as a serum total cholesterol level ≥240
mg/dl.

Reproductive heath
Questions on reproductive health were collected by a trained interviewer.
Participants with no history of reproductive surgery were classified as postmenopausal if
they reported not having had a menstrual period during the previous 12 months;
consistent with WHO criteria (275). Additionally, women with no history of
hysterectomy or oophorectomy who were current users of postmenopausal hormone
therapy (HT) and were ≥ 51 years were classified as postmenopausal. HT use was also
obtained by asking the following questions: “have you ever taken estrogen or female
hormone pills by mouth other than oral contraceptives”, “have you ever used female
hormones in the form of vaginal creams, suppository, injections or skin patches”.
Duration of HT was also obtained. Current HT users were women who answered “yes” to
using female hormones in the form of pills, vaginal cream, suppository, injections or
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patches placed on the skin, and were currently using them. Former users were those who
had used female hormones after menopause but were not currently using them. Never
users of HT were those who answered “no” to any of the above questions. Oral
contraceptive use was assessed by asking “have you ever taken birth control pills for any
reason” with a response of “Yes” indicative of ever use. Women were also asked about
their age at menarche, and this was reported in whole years. Finally, participants were
asked about the number of pregnancies resulting in live births. Based on response, parity
was categorized as none, 1-2 live births, 3-4 live births and ≥ 5 live births.

Power Calculations
A previous study which examined the incidence of CVD in diabetic men and
women reported that among diabetic women aged 50-79 and free of heart disease,
approximately 37% developed CVD at the end of 10 years of follow-up (276). Likewise,
another study examined the impact of diabetes on CHD among 121,046 women in the
Nurses’ Health Study aged 30 to 55 years, and followed from 1976 to 1996, reported that
40% of diabetic women developed coronary heart disease (10). A power calculation for
the current study was made based on these results (277).
For NHANES III which had an accrual interval of 6 years, and additional followup of approximately 12 years for mortality, if the true relative risk of CVD in diabetic
women with a history of BSO (N=211) relative to diabetics without BSO (N=812) is
0.74, we will be able to reject the null hypothesis that the exposed and unexposed
survival curves are equal with a power of 0.84 (α =0.05) (277). For the cross sectional
association in NHANES 1999-2010, the sample size was sufficient to detect an odds ratio
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of 0.76 among 369 diabetic women with BSO and 1,034 diabetic women without BSO,
based on prior data indicating that the average proportion of diabetics with CVD is 38% ,
resulting in a power of more than 85% (α =0.05) (278).

THE STUDY OF OSTEOPOROTIC FRACTURES (SOF)
Study population and sampling
The study of osteoporotic fractures (SOF) is a multi-center prospective
observational study of women age 65 or older with clinical sites at University of
Maryland, Baltimore; University of Minnesota, Minneapolis; Kaiser-Permanente Center
for Health Research in Portland, OR; and the University of Pittsburgh, Pittsburgh (14,
279). It was funded by the National Institute of Arthritis and Musculoskeletal and Skin
Diseases to describe the risk factors for osteoporotic fractures and falls in
postmenopausal women. However, its aims have grown to include factors that influence
successful aging. Originally, 9704 women who were predominantly non-Hispanic whites
were recruited from September 1986 to October 1988 through population-based listings,
and enrolled into the study.
Women were recruited from several sources. In Minneapolis, women were
identified from Group Health Incorporated, a large health maintenance organization; list
of Minnesota residents produced for the Hypertension Detection and Follow-up study as
well as the Systolic Hypertension in the Elderly study; and jury-selection lists for
Hennepin County (280). In Pennsylvania, women were identified from the 1985 voter’s
registration list for the Monongahela Valley (280). In Portland, women were identified
from membership lists for the Kaiser-Permanente Health Plan, which is also a large
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Health Maintenance Organization (280). Finally, in Baltimore women were selected from
lists of holders of driver’s license and identification cards within Baltimore County (280).
Participants received a letter and a brochure inviting them to join the study. Data
were collected from all four clinical sites using a common protocol and detailed manuals
of operation. At the baseline clinic visit, physical examination, health status
questionnaires, dietary history, medical history, lateral lumbar radiographs, and blood
specimens were collected. Study participants were contacted every four months by
postcard or telephone to ascertain the occurrence of falls, fractures and changes in
residential address. Participants returned every two years for clinical visits. To date, rates
of follow-up have exceeded 98% (281).
Since African American women are known to have a low incidence of hip
fracture (which was the main outcome), they were excluded from the initial recruitment.
Additionally, women were excluded if they had a history of bilateral hip replacement or
were unable to walk without assistance (282). From 1996 to 1998, the original cohort was
enhanced by the addition of 662 African American women recruited at the Maryland and
Pennsylvania clinical centers, yielding a total cohort of 10,366 women (281). All
participants provided written informed consent and human subjects research approval
was obtained by each clinical center's institutional review board.

Eligibility criteria
Inclusion criteria
Incident cardiovascular disease related mortality was not available for the African
American cohort. Therefore, two analytic cohorts were created. The first, which included
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10,366 women, was to assess the incidence of CVD disease while the second was
comprised of the original cohort of 9,704 women enrolled between 1986 and 1988 was
used to evaluate CVD deaths. Prevalent cardiovascular disease was evaluated at the
second visit; therefore, this time was used as baseline for studying incident nonfatal
CVD.

Exclusion criteria
Women were excluded from the analytic cohort if they had missing or unknown
age at last menstrual period (N= 2,004). Furthermore, women who had unilateral or
missing values for oophorectomy status (N=412) were also excluded resulting in a cohort
of 7,950. Analyses of time to CVD deaths was restricted to the Caucasian cohort
(n=7540) since cardiovascular disease related mortality was not ascertained in the
African American cohort.

Definition of exposure variables
Diabetes
History of diabetes was determined by means of a questionnaire at baseline. A
diagnosis of diabetes was established by a positive response to the question “has a doctor
ever told you that you had diabetes or sugar diabetes”. Women identified to be diabetic
were further asked about age at diagnosis and current use of insulin.
Oophorectomy
By means of a questionnaire, women were asked “Have you ever had an ovary
removed”. Those who responded “yes” were further asked if one or both ovaries were
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removed. Women who had both ovaries removed were defined to have bilateral
oophorectomy. Age at which this surgical procedure was performed was also ascertained.

Definition of outcome variables
At every subsequent clinic visit after the baseline assessment, participants were
asked about incident physician diagnosed cardiovascular disease, which was defined as
angina, myocardial infarction, stroke and other heart diseases. During the twenty years of
follow-up, the coordinating center obtained copies of the original death certificates of all
subjects who died and cause-specific mortality was coded according to the International
Classification of Diseases, Ninth Revision Clinical Modification. Cause of death was
physician-adjudicated and based upon death certificates and discharge summaries.
Cardiovascular mortality was defined using ICD-9 Codes (402,404,410–414,426–445)
which represented mortality from atherosclerosis, stroke, coronary heart disease or other
heart diseases.

Definition of relevant covariates
Sociodemographic
Self-reported data on age, race/ethnicity, highest grade or years of education
completed, and marital status were obtained. Age was defined as continuous. Education
was categorized into either a high school education or less, or otherwise. With regards to
race/ethnicity, all participants identified themselves as non-Hispanic whites. No
information about household or annual income was ascertained at baseline.
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Anthropometry
Body weight was obtained using a beam balance scale by weighing women while
they wore indoor clothing without shoes. Height was measured using a portable wall
mounted Harpenden stadiometer. Body mass index (BMI) was calculated as weight in
kilograms divided by the square of height in meters, after which it was categorized into
underweight (less than 18.5), normal weight (18.5 to 24.9), overweight (25 to 29.9) and
obese as 30.0 or greater. Waist circumference was measured with a steel measuring tape
at the midpoint between the highest point of the iliac crest and the lowest part of the
costal margin in the midaxillary line. Hip circumference was measured at the level of
maximum protrusion of the buttocks to the nearest 0.1 cm. Waist-to-hip ratio was
calculated by dividing waist circumference by hip circumference

Health behavioral/lifestyle factors
Smoking status was assessed using self-administered questionnaires. Smoking
status was classified as never, former and current. The average number of cigarettes
smoked per day as well as lifetime pack year smoked was also ascertained.
Recreational and sports activities from the previous 12 months were recorded using a
modified version of the Harvard Alumni Questionnaire and converted into weekly caloric
expenditure by intensity level. The sum of kilocalories from high, medium and low
intensity activities, stair climbing and walking was used to estimate total kilocalories per
week expenditure during the previous year. Physical activity was defined as a continuous
variable of total kilocalories expended per week.
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Health history and conditions
A personal history of cardiovascular disease was assessed by asking, “has a
doctor ever told you that you have or had a stroke, a blood clot in the brain, or bleeding in
the brain” (at baseline) and “has a doctor told you that you had a heart attack, coronary or
myocardial infarction” (at second clinic visit). Women who responded “yes” were
identified as having a physician diagnosis of cardiovascular disease. Questions were also
asked to identify a personal history of angina, and congestive heart failure.
A systolic blood pressure reading of 140 mmHg and or a diastolic blood pressure of
above 90 mm Hg was used for the diagnosis of hypertension. Hypercholesterolemia was
defined as a serum total cholesterol level ≥240 mg/dl.

Biochemical Analyses
Blood samples were drawn from all participants according to the protocol of the
Study of Osteoporotic Fractures. Blood was drawn between the hours of 8:00 a.m. and
2:00 p.m. Participants were not required to fast but were instructed to avoid fatty foods to
minimize lipemia on the morning of the examination, which may interfere with assays.
Blood was drawn after the participant had been seated for at least 10 minutes and was
immediately frozen to −20°C for up to 2 weeks and stored in liquid nitrogen at −190°C
until assays were done (283-285). Total cholesterol, triglyceride, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol and sex hormones were measured in a
subsample of participants. Sex hormone measurements were restricted to women not
taking postmenopausal hormone therapy.
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Total testosterone was measured by radioimmunoassay after extraction and
aluminum oxide column chromatography, with an interassay coefficient of variation of
6.1 to 13.4 percent (283-285). Free testosterone was measured with an ammonium sulfate
precipitation procedure with an interassay coefficient of variation of 10.7 to 15.5 percent
(283-285). Calculation of free testosterone was adjusted for albumin concentration
(coefficient of variation for intra-assay and total assay, 5% and 5.4%, respectively;
sensitivity, 34.7 pmol/L)(286). Estradiol and estrone were measured in serum by
radioimmunoassay after extraction and separation by liquid chromatography. The
interassay coefficient of variation for estradiol ranged from 8 percent to 12.5 percent, and
from 6.2 percent to 7.0 percent for estrone (283-285). The testosterone-binding capacity
of SHBG in serum was measured by means of a displacement technique (283-285).
All biochemical Analyses were carried out at Coming Nichols Institute (San Juan
Capistrano, CA) and Endocrine Sciences Esoterix (Calabasas Hills, Calif.). In both
laboratories, the intra-assay and interassay coefficients of variation for total testosterone
ranged from 4% to 12% and 9% to 11% for the assays done by Coming Nichols and from
3% to 13% and 9% to 14%, respectively for assays done by Endocrine Sciences Esoterix
(283-285). Blood samples from a subsample of 51 postmenopausal women were selected
to determine the stability of these hormones in serum by analyzing serum samples both at
baseline and after 3.5 years of storage at –190°C. The correlations between the two
testosterone measures was r=0.99 (P<0.001) (285).
Reproductive heath
Participants completed a self administered questionnaire that assessed their
reproductive health. Women were asked about their age at menarche and if at age 25
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years periods were regular or irregular. Age at natural menopause was determined by
asking “how old were you at the time of your last natural menstrual period”.
Hysterectomy status was also assessed, as well as type of hysterectomy (abdominal or
vaginal) and age at hysterectomy. Women who reported a history of hysterectomy were
further asked about the reasons why they underwent a hysterectomy (fibroids or bleeding,
pelvic pain or internal scarring, dropping or bulging out of female organs, surgical repair
for leakage of urine and other reasons). This was used to represent indication for
oophorectomy among women who had hysterectomy concomitant with bilateral
oophorectomy. Hormone therapy use, duration, indication, route of administration and
years since stopping HT use were also assessed. Oral contraceptive use was evaluated by
asking “have you ever taken birth control pills” with a response of “yes” indicative of
ever use. The number of pregnancies and live births were also obtained from all
participants.

Power calculation
The same assumption used in the NHANES III prospective study of the incidence
of CVD in diabetic women was employed. Based on SOF study having an accrual
interval of 2 years, and additional follow-up of approximately 18 years, and given that we
have an exposed group of 124 women and 383 unexposed women, We will be able to
detect true hazard ratios (relative risks) of failure for unexposed subjects relative to
exposed subjects of 0.716 or 1.442 with probability (power) 0.8. The Type I error
probability associated with this test of the null hypothesis that the exposed and unexposed
survival curves are equal is 0.05.(277).
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Figure 3.1 Detectable alternative relative risk based on a fixed sample size in the
SOF

Statistical Analysis
Descriptive statistics
Descriptive statistics such as frequencies, percentages and means were calculated
and used to describe the study participants according to diabetes and oophorectomy
status. The four mutually exclusive groups were as follows: no history of diabetes or
oophorectomy, history of diabetes without oophorectomy, no history of diabetes but with
oophorectomy, and history of both diabetes and oophorectomy. For categorical variables,
comparisons among groups were measured using the 2 test while comparisons for
continuous variables (namely sex hormones) were tested using analysis of variance
(ANOVA) as well as analyses of Covariance with adjustment for age and BMI which was
limited to women with diabetes. In instances when quantitative measures were skewed,
they were normalized by natural log transformation and when normality was still not
achieved by this procedure, a non-parametric test such as the Kruskal-Wallis test was
employed.
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Prevalent Cardiovascular disease
The risk of cardiovascular disease given diabetes status, was assessed using
logistic regression models using the SURVEYLOGISTIC procedure in SAS version 9.3
(SAS institute, Cary, NC) (287) which is suitable for analyzing NHANES data since it
incorporates the complex sampling design and sampling weights. Failure to account for
the clustered design, which incorporates differential probabilities of selection, introduces
bias into the parameter estimates leading to overstating of statistical significance. Since
the outcome (prevalent CVD) was dichotomous (that is the dependent variable takes on
only two values: 1 for the probability of success and 0 for the probability of failure),
logistic regression was appropriate to use to predict the risk of prevalent CVD
conditioned on a set of categorical, discrete and continuous predictors. Adjusted odds
ratios (OR) and 95% confidence intervals (CIs) for risk factors were also calculated with
alpha being set at 0.05. No adjustments in P values were made for multiple comparisons
and a two sided value was calculated. An a priori selection of confounders was made a
priori based on the literature. Four models with progressive degrees of adjustments were
employed in the analysis. Model 1 was adjusted for sociodemographic factors. Model 2
added reproductive factors to model 1, while model 3 was further adjust for
anthropometric measures and health behavioral/lifestyle factors. Finally, model 4 was
adjusted for lipid measurements. These analyses were further limited to diabetics with
women who had a history of diabetes being the referent as women with both diabetes and
oophorectomy were compared to them. Additionally, the effect of age at oophorectomy
on risk of CVD in diabetic women was further assessed.
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Incident cardiovascular disease
Participants in the SOF study who were alive and not lost to follow-up at the
second visit were included in this analysis. Women with prevalent cardiovascular disease
were excluded. Although incident cardiovascular disease was assessed, the date at which
the event occurred was not provided in the public released data. In the light of this a
discrete-time logistic model was employed (288).
This proportional odds model assumes that times are indeed discrete and not
continuous. Briefly, this model proposes that the conditional probability Pit that an
individual i has an event at time t, given that the event has not already occurred, is related
to the covariates by the logistic regression equation (288).

Time takes on only positive integer values (t = 1, 2, 3 . . .) which begins at some natural
starting point (t = 1). The observation continues until time it, at which point either an
event occurs or the observation is censored (288). The term αt which represents a set of
constants when unspecified is analogous to the baseline hazard in the proportional hazards
model and can vary from one point to another. When the time intervals become
progressively smaller the logistic model converges to the proportional hazards model
(288). Using partial likelihood, the above logistic model implies that the ratio of the odds
of any two individuals does not depend on time but may vary with covariates. Here the
constant terms αt are treated as nuisance parameters and only estimates for βk are
calculated (288). On the other hand, the standard maximum likelihood estimation which
can also handle large numbers of time dependent covariates does produce estimates for αt
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together with the other parameters in the model. The partial likelihood method was
chosen because if a participant who had an event was to miss a clinic visit, this event
would not be recorded until the next visit. Since the basic assumption of the model is that
the events really happened in the discrete time they were reported, a bias may be
introduced when estimating the dependence of the hazard on time. However estimates of
βk from both the partial and maximum likelihood methods are always comparable (288).
The following confounders, which were chosen a priori, were controlled in
multivariable models: age, race, education, body mass index, age at menopause,
hypertension, hysterectomy status, parity, hormone therapy use, cigarette smoking, waistto-hip ratio and physical activity. Lipids were not measured in the African American
cohort and therefore were not included in the multivariable model. Adjusted odds ratios
and 95% confidence intervals for risk these factors were calculated. Further analyses
were restricted to only diabetic women. All analyses met the minimum of 10 outcome
events per predictor variable rule (289). The goodness-of-fit of all statistical models was
determined by means of log-likelihood ratio test.
To assess the possibility of a dose-response association of age at natural
menopause or bilateral oophorectomy on the incidence of cardiovascular disease among
diabetics and nondiabetic women, logistic b-spline regression was implemented (290).
Unlike categorization of a continuous variable which introduces cut-point bias and
misclassification, splines (which are smooth continuous lines or curves) use the full range
of data to estimate the shape of the association between a continuous variable and a
dichotomous outcome (290, 291). Briefly, in this model the odds ratio for each value of a
predictor x, with respect to a reference value xref is calculated as
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where n is the number of degrees of freedom of the spline expansion, βi is the coefficient
of the ith spline basis function estimated by the logistic regression and si(x) is the value of
the ith spline basis function at x (290). The 95% confidence intervals are also calculated
based on asymptotic normality of the estimates. Akaike information criterion (AIC) was
used to determine the goodness of fit of the model. The final model chosen was quadratic
spline with three knots at the 25th, 50th and 75th percentiles of age at menopause. Knots
represent thresholds in a risk factor where the probability of an event is assumed or
expected to suddenly change (290, 291).

Cardiovascular disease Mortality
In the analysis of time to event, frequencies of incident CVD mortality were
described. The Kaplan-Maier method, also known as the product-limit estimator, which is
a non-parametric test, was used to estimate the risk of cardiovascular mortality during
follow up in both NHANES III and the SOF study. Survival curves were then produced
to graphically depict incident events with differences among groups assessed by means of
the Log-Rank test. Although Kaplan-Maier methods cannot consider the effects of
covariates on time to event, multivariable methods such as the semi-parametric Cox
proportional hazards regression may be employed to overcome this limitation. Again, to
assess the effect of complex sampling on the results, the SURVEYPHREG procedure in
SAS was used for NHANES III while the non-survey PHREG procedure was employed
for analysis using SOF data.
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The same method of adjustment for confounders in the logistic regression models
were employed with adjusted hazard ratios and 95% confidence intervals calculated.
However, because plasma lipids measures were measured only in a subsample of
participants in the SOF study, they were not included in the multivariable models. A two
tailed probability value less than 0.05 was considered statistically significant. In the SOF
study analysis, the proportionality assumption was tested using cumulative sums of
martingale residuals with a Kolmogorov-type supremum test and visually inspecting plots
of Schoenfeld residuals versus time. However since these analyses cannot be
accomplished with the survey procedure, the assumption of proportional hazards in
NHANES III was assessed by introducing a time dependent coefficient in the Cox
models. Subgroup analyses were conducted which were restricted to diabetics,
investigating the moderating effect of oophorectomy on CVD mortality.
The time scale for all survival analyses was age in years. The advantages of using
age instead of years since enrollment is that it has a more straight forward interpretation
of mortality as it is free of the confounding effect of age which is intrinsically taken into
account as a measure of survival time (292). Additionally, since no intervention was used
in these prospective studies, modeling mortality rate as a function of time since
enrollment is not interesting because we would be modeling mortality as a function of
study duration, instead of the aging process (292). Furthermore, estimates of survival
probabilities at every age in groups that are homogeneous according to the risk factors
can be easily obtained (292).
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CHAPTER FOUR

RESULTS

Characteristics of the study sample

The Third National Health and nutritional examination Survey, 1988-1994
Demographic characteristics of the 3,324 postmenopausal women are presented in
table 4.1, with descriptive statistics survey weighted. The average age of participants was
63.1 (median 62.3) years. Approximately, 83% were non-Hispanic whites, while nonHispanic blacks made up 9.2% of women recruited for the study. Almost a third of
survey participants (27.3%) were diabetics, 46% had undergone a hysterectomy and 25%
report a history of bilateral oophorectomy. A quarter of women (24.3%) who reported a
history of physician diagnosed diabetes were not on either insulin or oral hypoglycemic
drugs. Among women with a hysterectomy, 46.3% reported ovarian conservation.
Additionally, the prevalence of bilateral oophorectomy did not differ by diabetes status
(p=0.303). The median age at bilateral oophorectomy was 42.3 years. Hypertension was
reported in 42.65% of all participants while 11.2% of women were living 130% below
the federal poverty level. With regards to hormone therapy use, 44.9% of women with
oophorectomy were current users compared to 25.6% of women with hysterectomy and
9.2% of women with natural menopause.
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Table 4.1 Characteristics of study population, the third National Health and Nutrition Examination Survey (1988-1994)

No Diabetes/
oophorectomy
(N = 1695)

Diabetes w/o
oophorectomy
(N =812)

Oophorectomy
w/o diabetes
(N = 506)

Diabetes and
oophorectomy
(N= 211)

P value*

P value¶

63.9 (62.8-64.9)

64.0 (62.8-65.2)

61.3 (59.6-63.0)

59.9 (57.4-62.3)

0.001
0.001

0.003
0.071

Non-Hispanic White

83.5

76.3

86.3

84.7

Non-Hispanic Black

7.8

12.6

9.3

10.8

Other

8.7

11.2

4.4

4.5

College degree or higher

29.7

24.9

30.3

21.0

0.155

0.436

PIR ≤ 130% poverty line (%)

10.3

15.2

8.8

13.4

0.006

0.606

0.664

0.815

0.001

0.420

0.012

0.028

0.113

0.611

Characteristics
Age (years)
Race/Ethnicity (%)
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Smoking status (%)
former
Current

26.6
19.7

29.9
15.3

25.2
19.9

27.9
17.4

Age at menarche (years)
< 12

16.9

22.8

20.7

26.0

12 -14
>14

65.5
17.6

60.6
16.7

65.8
13.5

66.9
7.1

Parity
None

16.3

12.7

21.9

15.7

1 - 2 live births

35.7

33.2

37.1

36.9

3 - 4 live births

31.5

30.3

28.0

31.4

≥ 5 live births

16.5

23.7

13.0

16.0

31.7

26.4

36.5

29.1

Ever use of oral contraceptives (%)

Current Hormone therapy use (%)

14.7

11.6

45.9

42.7

0.001

0.001

Sedentary lifestyle (%)

37.2

44.8

37.0

47.2

0.015

0.526

93.2 (92.2-94.3)
0.90 (0.89-0.91)

98.7 (97.2-100.1)
0.94 (0.93-0.95)

92.2 (90.3-94.1)
0.89 (0.88-0.90)

98.6 (95.7-101.6)
0.91 (0.89-0.93)

0.001
0.001

0.988
0.017

0.001

0.210

Waist Circumference (cm)
Waist to Hip Ratio
BMI (kg/m2)
< 25.0

38.7

27.6

44.4

21.9

25.0 - 29.9
≥ 30.0

34.8
26.5

34.7
37.6

30.7
25.0

31.5
46.6

56.3 (55.2-57.5)

51.7 (49.8-53.7)

58.3 (55.9-60.7)

52.7 (50.1-55.4)

0.001

0.529

Triglycerides (mg/dl)

127.5 (122.8-132.4)

176.2 (164.9-188.4)

133.4 (124.6-142.8)

194.8 (176.9-214.7)

0.001

0.043

Total Cholesterol (mg/dl)

227.3 (224.0-230.1)

239.8 (235.1-244.5)

231.3 (225.4-237.2)

241.6 (233.9-249.2)

0.001

0.698

C-reactive Protein (mg/dl)

0.32 (0.30-0.34)

0.46 (0.42-0.50)

0.36 (0.32-0.40)

0.52 (0.44-0.61)

0.001

0.181

Glycohemoglobin (%)

5.41(5.37-5.46)

6.49 (6.29-6.69)

5.34 (5.29-5.38)

6.36 (6.11-6.61)

0.001

0.438

White blood cell count

6.52 (6.38-6.66)

7.25 (7.05-7.45)

6.69 (6.49-6.90)

7.46 (7.09-7.85)

0.001

0.302

Hypertension (%)
Family history of diabetes (%)

38.9
41.0

54.6
51.4

37.9
48.6

48.7
57.6

0.001
0.001

0.283
0.340

Family history of Heart Attack (%)

14.9

12.5

19.6

29.3

0.001

0.001

Angina pectoris (%)

1.1

2.2

1.6

2.6

0.352

0.782

Stroke (%)
Coronary Heart disease (%)

3.4
5.2

7.8
10.0

5.0
7.4

8.6
14.5

0.001
0.001

0.740
0.190

Cardiovascular disease (%)

7.5

16.0

10.6

20.0

0.001

0.264

HDL Cholesterol (mg/dl)
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Values are survey weighted mean (95% Confidence interval), or percentages for continuous or categorical variables, respectively
*
¶

P value comparing all four categories
P value for subgroup analyses restricted to only women with diabetes

Diabetics compared to non-diabetics were more likely to be African Americans (12.1%
vs. 8.1%), have lower socioeconomic status (14.7% vs. 9.9%), no high school education
(21.9% vs. 17.3%), live a more sedentary lifestyle (45.5% vs. 37.2%), obese (40% vs.
26.2%), hypertensive (53% vs. 38.7%), report earlier age at menarche (23.6% vs. 17.8%),
and higher prevalence of stroke (8% vs. 3.8%). Furthermore, in diabetic women, those
with a history of oophorectomy were younger (59.9 vs. 64.0 years), more likely to have
an earlier (<11 years) at menarche (26% vs. 22.8%), and were more often current users of
hormone therapy (42.7% vs. 11.6%) and have a family history of myocardial infarction
(28.4% vs. 12.2%) compared to those with intact ovaries. On the other hand, diabetic
women without oophorectomy had a higher WHR (0.94 vs. 0.91, p= 0.017) as measured
by waist to hip ratio but no difference in waist circumference were found. While a greater
proportion of diabetics had prevalent CHD and CVD, no differences were found with
regards to oophorectomy status. Other baseline differences among diabetic women with
and without oophorectomy did not attain statistical significance.
In non-diabetic, women who had an oophorectomy were more likely to be younger (61.3
vs. 63.9) African Americans (9.3% vs. 7.8%), current users of HT (45.9% vs. 14.7%) and
reach menopause earlier (<45 years) (60.5% vs. 30.5%),
Notably, women with diabetes and oophorectomy were more likely and to have a
family history of myocardial infarction (29.3% vs. 12.5%) compared to those diabetic
women who did not undergo oophorectomy. A similar observation was also found in
nondiabetics, where women with oophorectomy were more likely to have a family
history of diabetes (48.6% vs. 41.0%) and heart attack (19.6% vs. 14.9%).
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The National Health and Nutritional Examination Survey, 1999-2010
Characteristics of NHANES 1999-2010 participants according to oophorectomy
and diabetes status are illustrated in table 4.2. The survey-weighted average age of the
6,375 postmenopausal women sampled from the six waves of national survey data was
61.5 years. More than a third of participants (37.5%) were obese, with 25.1% having
sedentary lifestyles and 37.7% having metabolic syndrome (defined by the National
Cholesterol Education Program’s Adult Treatment Panel III criteria). Oophorectomy was
performed in 27.5% of women, with the mean age at surgery reported as 43 years.
Women with bilateral oophorectomy were more likely to be current smokers (20.1% vs.
16.5%), to have had no college education (55.3% vs. 49.4%), to have had an earlier age
(<50 years) at menopause (83% vs. 58.3%), and ever users of hormone therapy (75.9%
vs. 39.2%), hypertensive (56.4% vs. 49.6%).
As in the earlier survey, nondiabetic women with oophorectomy were more likely
to have a family history of myocardial infarction (21.6% vs. 15.9%), compared to women
with intact ovaries. While no statistically significant effect of ovarian status was found
with regards to lipid profiles, women with oophorectomy had higher levels of systemic
inflammation markers namely C-reactive proteins (0.59 vs. 0.49 mg/dl).
Approximately 17% of participants were diabetic and of this number 21.9% were
on insulin therapy while 68.3% were currently taking anti-hyperglycemic agents.
Diabetic women were more likely to have central adiposity as measured by waist
circumference (107 vs. 96 cm, p=0.001), be obese (55.9% vs. 33.8%), hypertensive
(75.5% vs. 46.6%), non-Hispanic blacks (16% vs. 8.8%), have no college education
(62.3% vs. 48.7%), living at or below the federal poverty level (24.7% vs. 17.4%), older
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age (≥ 55 years) at menopause (12.7 % vs. 9.6%), never users of hormone therapy (61.3%
vs. 48.6%), higher levels of C-reactive proteins (0.65 vs. 0.49 mg/dl, p=0.001) and a
family history of myocardial infarction (17.3% vs. 7.4%). Furthermore, diabetics had
relatively worse lipid profiles. Converse to what has been reported in previous studies,
non diabetics were more likely to be smokers compared to diabetics with (18.3 vs.
13.8%) being current smokers.
The impact of age at oophorectomy in diabetic women was next analyzed (Table
4.3). A greater proportion of women with both diabetes and oophorectomy reported a
history of cardiovascular disease compared to those with diabetes only. On the other
hand, when oophorectomy was performed after age 45 the likelihood of CHD or CVD
was reduced compared to diabetic women with no oophorectomy. Women with
oophorectomy before age 45 also had a family history of heart attack more often than
women with oophorectomy after age 45 or no oophorectomy (30.6% vs. 20.9% vs.
18.2%)
The same analyses of age at oophorectomy were repeated among nondiabetics
(table 4.4). Women who had oophorectomy before age 45 years had a worse CVD risk
profile than those who had oophorectomy at age 45 years or after. For instance, women
with early oophorectomy were likely to be younger, African American, obese, current
smokers and have no college education, sedentary lifestyles, lower HDL cholesterol
levels and higher C-reactive protein levels. While a greater proportion of women with
oophorectomy before age 45 years reported a family history of diabetes and heart attack,
those who had oophorectomy at 45 years or after were found to have more CHD and
CVD at baseline, an observation that maybe in part be driven by their older age status.
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Table 4.2 Characteristics of study population, National Health and Nutrition Examination Survey (1999-2010)
Characteristics

Age (years)

No Diabetes/
Diabetes w/o Oophorectomy Diabetes and
oophorectomy oophorectomy w/o diabetes Oophorectomy
N = 3689
N =1034
N = 1283
N = 369
61.0 (0.3)
64.9 (0.5)
60.3 (0.6)
65.6 (0.6)

Race/Ethnicity (%)

P value
0.001
0.001
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Non-Hispanic White

78.8

63.9

82.9

75.2

Non-Hispanic Black

8.6

16.8

8.7

14.2

Mexican American

4.0

7.8

2.8

3.9

Other

8.6

11.5

5.6

6.7

Some College degree or higher

52.8

39.3

47.1

33.8

0.001

Living at or below poverty line (%)

17.5

25.6

17.2

22.5

0.001

Smoking status (%)

0.004

former

27.5

30.0

28.9

29.9

Current

17.2

13.0

21.1

15.9

Age at menarche (years)

0.429

< 12

18.9

20.8

20.6

24.4

12 -14

66.7

64.5

66.0

60.4

>14

14.4

14.7

13.4

15.3

Parity
None

0.001
25.4

26.7

26.5

26.9

1 - 2 live births

37.2

28.3

35.5

31.5

3 - 4 live births

27.3

27.7

30.3

28.6

≥ 5 live births

10.1

17.3

7.8

13.0

Age at menopause

45.7 (0.2)

46.4 (0.4)

40.9 (0.3)

41.5 (0.6)

0.001

Ever use of Hormone therapy (%)

41.1

29.2

79.1

61.6

0.001

Sedentary lifestyle (%)

24.6

25.7

26.6

23.8

0.549

95.5 (0.3)

106.8 (0.7)

95.9 (0.5)

107.7 (0.9)

0.001

Waist Circumference (cm)
2

BMI (kg/m )

0.001
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< 25.0

35.9

17.7

33.3

18.0

25.0 - 29.9

30.6

27.2

32.0

24.1

≥ 30.0

33.5

55.1

34.7

57.9

HDL Cholesterol (mg/dl)

60.1 (0.4)

52.7 (0.6)

60.8 (0.6)

52.1 (1.0)

0.001

Total Cholesterol (mg/dl)

215.0 (0.9)

203.4 (1.9)

217.5 (1.5)

200 (3.7)

0.001

C-reactive Protein (mg/dl)

0.23 (0.1-0.5)

0.36 (0.2-0.8)

0.29 (0.1-0.7)

0.43 (0.2-0.8)

0.001

Glycohemoglobin

5.42 (5.2-5.7)

6.57 (6.0-7.5)

5.39 (5.2-5.6)

6.42 (5.9-7.4)

0.001

Hypertension (%)

44.7

74.5

51.7

77.9

0.001

Family history of diabetes (%)

35.5

57.9

39.6

57.2

0.001

Family history of Heart Attack (%)

15.4

18.2

20.5

26.4

0.001

Coronary Heart disease (%)

6.5

16.4

9.7

19.5

0.001

Cardiovascular disease (%)

9.5

23.1

12.9

28.4

0.001

Values are survey weighted mean (Standard error), median (interquartile range) or percentages for continuous or categorical
variables, respectively

Table 4.3 Characteristics of diabetic women according to age at oophorectomy,
National Health and Nutrition Examination Survey (1999-2010)
Characteristics
Age (years)
Race/Ethnicity (%)
Non-Hispanic White
Non-Hispanic Black
Mexican American
Other
Some College degree or higher
Living at or below poverty line (%)
Smoking status (%)
former
Current
Age at menarche (years)
< 12
12 -14
>14
Age at menopause
Ever use of Hormone therapy (%)
Nulliparous
Sedentary lifestyle (%)
Waist Circumference (cm)
BMI (kg/m2)
< 25.0
25.0 - 29.9
≥ 30.0
HDL Cholesterol (mg/dl)
Total Cholesterol (mg/dl)
C-reactive Protein (mg/dl)
Glycohemoglobin
Hypertension (%)
Family history of diabetes (%)
Family history of Heart Attack (%)
Coronary Heart disease (%)
Cardiovascular disease (%)

No BSO
N =1034
64.9 (0.5)

BSO < 45
N = 207
63.8 (0.9)

BSO ≥ 45
N = 162
68.0 (0.6)

P value
0.004

0.001
63.9
16.8
7.8
11.5
39.3
25.6

74.0
15.4
4.0
6.6
32.7
23.7

76.9
12.5
3.8
6.9
35.4
20.9

30.0
13.0

28.9
19.7

31.3
10.9

20.8
64.5
14.7
46.4 (0.4)
29.2

26.7

29.6
54.5
15.9
35.2 (0.6)
64.5
30.2

17.2
68.4
14.4
49.9 (0.4)
57.6
22.4

25.7
106.8 (0.7)

28.8
107.3 (1.3)

17.1
108.3 (0.8)

17.7
27.2
55.1
52.7 (0.6)
203.4 (1.9)
0.36 (0.2-0.8)
6.57 (6.0-7.5)
74.5
57.9
18.2
16.4
23.1

17.9
23.9
58.1
51.7 (1.2)
202.0 (4.7)
0.44 (0.2-0.8)
6.46 (5.9-7.5)
78.2
55.1
30.6
25.4
35.5

18.0
24.4
57.6
52.6 (1.2)
197.5 (3.0)
0.41(0.2-0.7)
6.39 (5.8-7.2)
77.5
60.0
20.9
11.6
18.9

0.329
0.522
0.324

0.111

0.001
0.001
0.442
0.057
0.556
0.910

0.773
0.408
0.477
0.591
0.649
0.707
0.010
0.007
0.001

Values are survey weighted mean (Standard error), median (interquartile range) or percentages
for continuous or categorical variables, respectively. BSO: Bilateral salpingo oophorectomy
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Table 4.4 Characteristics of non-diabetic women according to age at oophorectomy,
National Health and Nutrition Examination Survey (1999-2010)
Characteristics

Age (years)
Race/Ethnicity (%)
Non-Hispanic White
Non-Hispanic Black
Mexican American
Other
Some College degree or higher
Living at or below poverty line (%)
Smoking status (%)
former
Current
Age at menarche (years)
< 12
12 -14
>14
Age at menopause
Nulliparous
Ever use of Hormone therapy (%)
Sedentary lifestyle (%)
Waist Circumference (cm)
BMI (kg/m2)
< 25.0
25.0 - 29.9
≥ 30.0
HDL Cholesterol (mg/dl)
Total Cholesterol (mg/dl)
C-reactive Protein (mg/dl)
Hypertension (%)
Family history of diabetes (%)
Family history of Heart Attack (%)
Coronary Heart disease (%)
Cardiovascular disease (%)

No
oophorectomy
N = 3689
61.0 (0.3)

BSO < 45
N = 751

BSO ≥ 45
N = 532

57.1 (0.8)

65.3 (0.6)

78.8
8.6
4.0
8.6
52.8
17.5

83.4
9.7
2.8
4.1
43.4
18.7

82.2
7.1
2.8
7.9
53.0
14.7

27.5
17.2

26.6
27.2

32.6
11.3

P
value

0.001
0.001

0.001
0.277
0.001

0.496
18.9
66.7
14.4
45.7 (0.2)

21.4
64.3
14.3
35.6 (0.3)

19.3
68.8
11.9
49.5 (0.2)

41.1
24.6
95.5 (0.3)

82.1
28.8
96.8 (0.6)

74.4
23.2
94.4 (0.7)

0.001
0.001
0.048
0.020

35.9
30.6
33.5
60.1 (0.4)
215.0 (0.9)
0.23 (0.1-0.5)
44.7
35.5
15.4
6.5
9.5

29.5
34.0
36.4
59.8 (0.8)
217.6 (2.0)
0.31 (0.2-0.7)
47.7
42.1
22.0
9.3
12.4

39.3
28.9
31.9
62.4 (0.9)
217.3 (2.1)
0.27 (0.1-0.6)
58.2
35.6
18.1
10.4
13.8

0.028
0.349
0.001
0.001
0.025
0.002
0.004
0.006

Values are survey weighted mean (Standard error), median (interquartile range) or percentages
for continuous or categorical variables, respectively. BSO: Bilateral salpingo oophorectomy
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The Study of Osteoporotic Fractures
Descriptive statistics of both the Caucasian and African American cohorts are
presented in table 4.5 according to diabetes and oophorectomy status. Participants in this
cohort were relatively older than those in the NHANES study with the mean age of 71.8
years. Approximately 61% of women in this study had a high school education or less,
with 20.3% being obese. Additionally, 39.6% of study participants were hypertensive
while 10.3% reported being current smokers. African Americans made up 5.2% of the
entire cohort. The prevalence of hysterectomy, bilateral oophorectomy and diabetes was
28.2%, 21.7% and 7.2% respectively.
Uterine fibroid was the most frequently reported indication for surgery in women
with either hysterectomy (38.8%) or bilateral oophorectomy (45%). A greater proportion
of women with diabetes had undergone an oophorectomy than non-diabetic women (25.1
vs. 21.4). Furthermore, diabetics were more likely to be obese (36.4% vs.19%), African
American (11.7% vs. 4.7%), have no college education (71.8% vs. 60.9%), hypertensive
(54.8% vs. 38.4%) and had undergone a hysterectomy (32.6% vs. 27.9%), but were also
less likely to be either former (27.4% vs. 33.2%) or current (6.3% vs. 12%) hormone
therapy users compared to non-diabetics.
Among diabetic women, statistically significant differences between those with
intact ovaries and bilateral oophorectomy were found with regards to age at menopause,
parity, hormone therapy use and the prevalence of breast cancer.
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Table 4.5 Baseline characteristic of 7,950 postmenopausal women according to diabetes and bilateral oophorectomy
status, The Study of Osteoporotic Fractures
No diabetes

Diabetes

P value*

P value¶

Variables

No BSO
(n = 5794)

BSO
(n = 1582)

No BSO
(n = 430)

BSO
(n = 144)

Age (years)

71.9 (5.3)

71.2 (4.8)

72.4 (4.8)

71.5 (4.8)

0.001

0.053

African American race (%)

3.9

7.4

10.9

13.9

0.001

0.339

High school education or less (%)

59.8

64.9

70.2

76.4

0.001

0.155

0.001

0.414

0.293

0.221

2

Body Mass Index (Kg/m ) (%)
< 25.0

44.2

43.5

27.2

31.3

25.0 - 29.9

37.2

36.2

35.8

34.0

≥ 30.0

18.6

20.5

37.0

34.7
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Smoking status (%)
Never

60.4

58.6

61.1

57.6

Former

29.3

30.6

31.9

31.3

Current

10.3

10.8

7.0

11.1

Smoking (lifetime pack years)

26.4 (22.7)

27.8 (23.8)

28.9 (32.4)

34.8 (30.6)

0.020

0.223

Waist girth (cm)

82.6 (10.8)

83.2 (11.0)

90.2 (11.7)

90.5 (12.7)

0.001

0.840

Waist to hip ratio

0.81 (0.06)

0.81 (0.07)

0.85 (0.06)

0.85 (0.07)

0.001

0.893

Physical activity (total Kcal/week)
Age at menarche (%)

862.8 (3.3)

906.9 (3.4)

589.9 (3.8)

518.0 (4.3)

0.001
0.306

0.349
0.654

< 12 years

20.9

19.8

25.6

22.2

12 - 14 years

65.8

66.8

61.2

65.3

> 14 years

13.3

13.4

13.2

12.5
0.001

0.001

Age at menopause (%)

< 45 years

16.8

39.0

17.2

46.5

45 - 49 years

29.9

28.7

27.9

27.8

53.3

32.3

54.9

25.7

> 49 years
Parity
None

19.2

22.0

18.6

21.5

1 - 2 live births

41.1

43.2

38.1

45.8

3 - 4 live births
≥ 5 live births

30.0
9.7

27.6
7.2

30.7
12.6

25.7
6.9

Hormone therapy use

0.002

0.029

0.001

0.001
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Never

60.8

33.2

74.9

40.6

Former

30.8

41.6

21.6

44.8

Current

8.4

25.2

3.5

14.6

Hypertension

37.4

42.1

55.5

52.8

0.001

0.573

Angina
Myocardial infarction

8.5
5.4

11.3
6.1

16.5
10.9

13.2
11.8

0.001
0.001

0.343
0.773

Stroke

2.4

3.8

6.5

8.1

0.001

0.557

Breast Cancer

4.6

6.1

7.7

14.6

0.001

0.014

Serology measures of
HDL cholesterol (mg/dl)

53.5 (14.8)

56.2 (16.2)

46.6 (13.1)

49.3 (12.6)

0.002

0.515

LDL cholesterol (mg/dl)

154.6 (34.4)

146.4 (37.1)

155.0 (54.0)

135.2 (32.6)

0.071

0.252

Triglycerides (mg/dl)

156.9 (80.6)

174.5 (93.9)

249.4 (147)

252.3 (124)

0.001

0.949

Personal history of (%)

Values are displayed in percent or mean (Standard deviation)
*
P value comparing all four categories
¶
P value for subgroup analyses restricted to only women with diabetes
P values based on Chi-square test for categorical variables and ANOVA for normally distributed continuous variables

Sex-steroid hormones levels according to diabetes and oophorectomy status
Among the 894 women randomly selected from the Caucasian cohort in whom
measures of sex hormones were available, statistically significant differences were found
with regards to diabetes or ovarian status. Women with diabetes had lower SHBG (p=.001) and higher free testosterone (p =0.006), and percent free testosterone (p=0.001)
than non-diabetics. On the other hand, women with diabetes also had lower levels of
DHEAS. Furthermore, diabetic women had higher levels of estrone than non-diabetics.
Conversely levels of SHBG were lower in diabetic women compared to those without a
history of physician diagnosed diabetes (p=0.001).
Ovarian status influenced significantly the distribution of sex steroid hormones in
this postmenopausal cohort. As expected, total testosterone (p=0.001) and free
testosterone (p=0.001) were lower in women with bilateral oophorectomy than in women
with intact ovaries, while no differences were found in estradiol (p=0.218) or DHEAS
levels (p=0.266).
Ovarian status among diabetic women did profoundly influence sex hormone
levels (table 4.6). For instance, diabetic women with oophorectomy were observed to
have significantly elevated levels of both total testosterone and estradiol than diabetics
with intact ovaries, even after adjustment for age and BMI.
Finally no association between total testosterone (p=0.103), free testosterone
(p=0.456), total estradiol (p=0.4578), dehydroepiandrosterone sulfate (p=0.865),
bioavailable estradiol (p=0.235) or free estradiol (p=0.212) with incident cardiovascular
disease mortality was identified (table 4.7).
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Table 4.6 Hormone levels [median (IQR)] according to diabetes and bilateral oophorectomy status, the Study of Osteoporotic
Fractures

Oophorectomy and diabetes status
P value*

P value¶

P value§

12.0 (6.0-16.0)

0.001

0.012

0.016

1.2 (0.7-1.8)

1.8 (1.3-2.9)

0.001

0.071

0.301

1.4 (1.1-1.7)

1.1 (0.8-1.3)

1.8 (1.5-1.9)

0.001

0.152

0.142

47.0 (26.0-74.0)

45.0 (21.0-71.0)

39.5 (23.0-72.0)

46.0 (29.0-61.0)

0.692

0.987

0.834

Estradiol (pg/ml)

7.0 (5.0-9.0)

7.0 (6.0-10.0)

6.0 (4.0-10.0)

12.5 (6.5-23.0)

0.003

0.004

0.015

Estrone (pg/ml)

22.0 (15.5-29.0)

28.0 (22.0-32.0)

23.5 (14.0-36.0)

31.0 (14.0-55.0)

0.036

0.460

0.122

1.3 (1.0-1.9)

0.9 (.06-1.2)

1.6 (1.1-2.3)

0.8 (0.3-2.0)

0.001

0.854

0.502

No Diabetes or
Oophorectomy

Physician
diagnosed Diabetes

Bilateral
Oophorectomy

Oophorectomy&
Diabetes

(n = 646)

(n = 69)

(n = 162)

(n =17)

Total Testosterone (ng/dl)

20.0 (12.0-30.0)

21.0 (11.0-33.0)

12.0 (7.5-17.0)

Free Testosterone (pg/ml)

2.2 (1.2-3.5)

2.7 (1.6-4.1)

% Free testosterone

1.1 (0.9-1.4)

DHEAS (ug/dl)

Variables
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SHBG (ug/dl)
*

P value comparing all four categories based on ANOVA for normally distributed continuous variables after log transformation (total testosterone,
free testosterone, % free testosterone, estradiol, estrone and DHEAS) or Kruskal-Wallis test for non-normally distributed continuous variables
(SHBG).
¶
P value for subgroup analyses restricted to only women with diabetes based on t-test for normally distributed variables (Free testosterone, % Free
testosterone, estradiol and estrone) and Mann–Whitney U test for non-normally distributed variables (total testosterone, DHEAS and SHBG).
§
P value for subgroup analyses restricted to only women with diabetes adjusted for BMI, based on ANCOVA for normally distributed data and
rank analyses of covariance for non-normally distributed data.

Table 4.7: Association of free testosterone, total testosterone and dehydroepiandrosterone sulfate and risk of CVD
mortality, the Study of Osteoporotic Fractures
unadjusted
HR (95%CI)

Model 1
P value

HR (95%CI)

Model 2

P value

HR (95%CI)

Model 3
P value

HR (95%CI)

P value

Free Testosterone
Q1 (< 1.1 pg/ml)
Q2 (1.1 - 1.7 pg/ml)
Q3 (1.8 - 2.9 pg/ml)
Q4 (>2.9 pg/ml)
Risk per 1 SD increase

1.0 (Referent)
1.06 (0.66-1.70)
0.91 (0.57-1.46)
0.87 (0.55-1.40)
0.97 (0.82-1.16)

0.798
0.708
0.567
0.770

1.0 (Referent)
1.20 (0.75-1.92)
0.99 (0.62-1.59)
0.92 (0.57-1.47)
0.96 (0.81-1.14)

0.452
0.964
0.729
0.632

1.0 (Referent)
1.00 (0.57-1.74)
0.97 (0.60-1.69)
0.90 (0.52-1.58)
0.99 (0.80-1.22)

0.996
0.924
0.724
0.914

1.0 (Referent)
1.03 (0.59-1.82)
0.73 (0.41-1.33)
0.88 (0.50-1.57)
0.92 (0.73-1.15)

0.912
0.668
0.306
0.456

1.0 (Referent)
0.81 (0.47-1.40)
1.25 (0.74-2.11)
0.60 (0.33-1.09)
0.82 (0.66-1.03)

0.457
0.398
0.096
0.079

1.0 (Referent)
0.67 (0.37-1.18)
1.30 (0.76-2.23)
0.60 (0.32-1.10)
0.83 (0.66-1.04)

0.162
0.345
0.099
0.103

1.0 (Referent)
0.90 (0.53-1.52)
0.62 (0.36-1.09)
0.97 (0.57-1.64)
1.03 (0.84-1.24)

0.693
0.099
0.905
0.787

1.0 (Referent)
0.94 (0.55-1.62)
0.71 (0.40-1.27)
0.90 (0.52-1.58)
1.02 (0.84-1.24)

0.832
0.250
0.719
0.865

Total Testosterone
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Q1 (< 11.0 ng/dl)
Q2 (11.0 - 16.9 ng/dl)
Q3 (17.0 - 26.9 ng/dl)
Q4 (>26.9 ng/dl)
Risk per 1 SD increase

1.0 (Referent)
0.94 (0.59-1.50)
0.99 (0.63-1.56)
0.71 (0.43-1.18)
0.86 (0.71-1.06)

0.799
0.963
0.186
0.149

1.0 (Referent)
1.00 (0.63-1.60)
1.12 (0.71-1.77)
0.71 (0.43-1.17)
0.85 (0.71-1.03)

0.990
0.633
0.183
0.107

DHEA sulfate (ug/dl)
Q1 (< 25.0 ug/dl)
Q2 (25.0 - 42.9 ug/dl)
Q3 (43.0 - 71.9 ug/dl)
Q4 (>71.9 ug/dl)
Risk per 1 SD increase

1.0 (Referent)
1.05 (0.68-1.63)
0.53 (0.31-0.89)
0.80 (0.50-1.26)
0.90 (0.74-1.09)

0.832
0.016
0.343
0.257

1.0 (Referent)
1.09 (0.70-1.69)
0.57 (0.34-0.97)
0.98 (0.61-1.56)
0.99 (0.81-1.19)

0.707
0.036
0.921
0.889

MODEL 1; adjusted for age, education
MODEL 2; adjusted for Model 1 plus age at menopause bilateral oophorectomy status, hysterectomy status, parity and estrogen use
MODEL 3, adjusted for Model 2 BMI, waist hip ratio, hypertension, prevalent CVD, diabetes smoking status, and physical activity

Prevalent cardiovascular disease in NHANES

Among participants in NHANES III, a greater proportion of prevalent
cardiovascular disease (20%) was found in oophorectomized women with diabetes.
Diabetes increased the risk of both coronary heart disease and cardiovascular disease as
expected. On the other hand, oophorectomy overall did not increase the CHD or CVD
risk statistically (table 4.8).The increased in cardiovascular disease risk in
oophorectomized women with diabetes was influenced by timing of oophorectomy,
however. Women who had this surgical procedure before age 45 years had a twofold
increased odds for both CHD (OR: 2.65, 95%CI: 1.08 - 6.52) and CVD (OR: 2.40, 95%
CI: 1.02 - 5.66) compared to women with no oophorectomy or diabetes.
In analyses restricted to women with diabetes, the risk of CVD with early
oophorectomy (< 45 years) remained elevated in age-adjusted models (OR: 2.40, 95%CI:
1.33-4.33). However, in multivariable adjusted models, the estimates became attenuated
with no statistically significant risk identified in diabetic women with oophorectomy
before age 45 years or diabetic women who had oophorectomy after age 45 years when
compared to women with diabetes only.
Similarly, in NHANES 1999-2010, the joint effect of diabetes and oophorectomy
on cardiovascular disease did not approach statistical significance, but once again,
diabetic women who had oophorectomy before age 45 years had elevated odds for
coronary heart disease (OR: 1.85, 95%CI: 1.15-2.97) and cardiovascular disease (OR:
2.11, 95%CI: 1.45-3.08) (table 4.9) when compared to women with no oophorectomy or
diabetes.
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Table 4.8 Odds of prevalent cardiovascular disease according to diabetes and oophorectomy status, Third National
Health and Nutrition Examination Survey (1988-1994)
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Coronary Heart

Cardiovascular

disease 1

disease 2

N

OR (95%CI)

OR (95%CI)

No oophorectomy/diabetes

1695

1 (Referent)

1 (Referent)

Diabetes

812

1.88 (1.06 - 3.33)

2.14 (1.42 - 3.21)

Oophorectomy

506

1.32 (0.75 - 2.30)

1.20 (0.71 - 2.03)

Diabetes and oophorectomy

211

1.83 (0.81 - 4.16)

1.72 (0.80 - 3.70)

Oophorectomy before age 45
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2.65 (1.08 - 6.52)

2.40 (1.02 - 5.66)

Oophorectomy at or after age 45

87

0.78 (0.19 - 3.29)

0.95 (0.34 - 2.67)

OR: Odds ratio CI: Confidence interval
1

Model adjusted for age, race, education, age at menopause, hormone therapy use, hysterectomy status, Body Mass Index, Hypertension, smoking
status, family history of Heart disease, physical activity and total Cholesterol.
2

Adjusted for 1 and age at menarche, HDL cholesterol and white blood cell count,

Table 4.9 Odds of prevalent cardiovascular disease according to diabetes and oophorectomy status, National Health
and Nutrition Examination Survey (1999-2010)
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Coronary Heart

Cardiovascular

disease

disease

N

OR (95%CI)

OR (95%CI)

No oophorectomy diabetes

3689

1 (Referent)

1 (Referent)

Diabetes

1034

1.93 (1.47-2.52)

1.86 (1.46-2.37)

Oophorectomy

1283

1.14 (0.78-1.66)

1.06 (0.78-1.44)

Diabetes and oophorectomy

369

1.42 (0.95 - 2.12)

1.63 (1.16 - 2.30)

Oophorectomy before age 45

207

1.85 (1.15-2.97)

2.11 (1.45-3.08)

Oophorectomy at or after age 45

162

0.77 (0.40-1.47)

0.98 (0.54-1.78)

OR: Odds ratio CI: Confidence interval
Model adjusted for age, race, , education, age at menarche, age at menopause, Hormone therapy use, hysterectomy status, Body Mass Index,
Hypertension, smoking status, family history of Heart disease, physical inactivity, total Cholesterol, HDL cholesterol and C-reactive protein,

In analyses restricted to diabetic women in NHANES 1999-2010, s significant interaction
was found between diabetes status and age at oophorectomy (p = 0.001). Oophorectomy
after age 45 on the other hand was associated with a reduction in cardiovascular disease
(OR: 0.49, 95%CI: 0.25-0.95) (table 4.10). Moreover, comparing diabetic women who
had oophorectomy before age 45 years to diabetic women who had this surgical
procedure after age 45 years, the odds of CVD was threefold higher among the former
(OR: 3.05, 95%CI: 1.64-5.67).

Table 4.10 Odds of prevalent cardiovascular disease among diabetics by age at
oophorectomy, National Health and Nutrition Examination Survey (1999-2010)
Coronary Heart
disease

Cardiovascular
disease

N

OR (95%CI)

OR (95%CI)

Diabetes without oophorectomy

1034

1 (Referent)

1 (Referent)

Diabetes and oophorectomy

207

1.10 (0.66-1.84)

1.50 (0.94-2.39)

162

0.33 (0.16-0.70)

0.49 (0.25-0.95)

3.35 (1.57-7.14)

3.05 (1.64-5.67)

before age 45
Diabetes and oophorectomy
at or after age 45
Diabetes & oophorectomy < 45 vs.
Diabetes & oophorectomy ≥45
OR: Odds ratio CI: Confidence interval
Model adjusted for age, race, , education, age at menarche, age at menopause, Hormone therapy use,
hysterectomy status, Body Mass Index, Hypertension, smoking status, family history of Heart disease,
physical inactivity, HDL cholesterol and hemoglobin A1c,.
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Incident cardiovascular disease in SOF study

During follow-up, 2,652 (38%) non fatal cases of angina, myocardial infarction,
stroke, congestive heart failure and other forms of heart diseases were documented in
6,976 women who were free of disease.
In analyses based on a discrete time logit model adjusted for age, the risk of
incident cardiovascular disease was elevated for women with diabetes (OR: 1.33
95%CI:1.16-1.51) as well as women with oophorectomy (OR:1.16, 95% CI:1.08-1.24) in
age adjusted models (table 4.11). After further adjustment for sociodemographic,
anthropometric measures, reproductive and health behavioral/lifestyle factors, only
diabetes was associated with incident CVD. A 9% reduced risk of CVD was observed
among women with both diabetes and oophorectomy, albeit this did not approach
statistical significant.
In analyses restricted to diabetic women, ovarian status appeared to influence
disease risk in fully adjusted models but again this association was not statistically
significance (OR: 0.78, 95%CI: 0.56-1.09). No interaction was present with respect to
either general obesity (P=0.099), nor central obesity as measured by waist circumference
(p=0.542) or waist to hip ratio (p=0.538).
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Table 4.11: The risk of incident non-fatal cardiovascular disease according to diabetes and bilateral oophorectomy status, the
Study of Osteoporotic Fractures

Age Adjusted

Multivariable adjusted ¶

N

OR (95%CI)

OR (95%CI)

No Diabetes & No Oophorectomy

5155

1 (Referent)

1 (Referent)

Diabetes without oophorectomy

343

1.33 (1.16-1.51)

1.20 (1.04-1.37)

Oophorectomy without diabetes

1364

1.16 (1.08-1.24)

1.04 (0.92-1.18)

Diabetes & Oophorectomy
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1.11 (0.88-1.41)

0.91 (0.70-1.20)

No Oophorectomy

343

1 (Referent)

1 (Referent)

Oophorectomy
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0.87 (0.66-1.14)

0.78 (0.56-1.09)

Variables
All Participants
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Diabetic women

¶

Adjusted for baseline self-reported measures of age, race, education, age at menopause, hysterectomy status, parity,
postmenopausal hormone use, BMI, waist hip ratio, hypertension, smoking status and physical activity

Age at natural or surgical menopause and risk of incident CVD in SOF study

The multivariable adjusted spline regression model showed a decreasing trend
in the odds for incident cardiovascular disease as menopausal age increased, an
observation which was present in women with or without diabetes. An early age at
oophorectomy or natural menopause was associated with an increased CVD risk which
attenuated with each year that menopause was delayed (Figure 4.1).

Figure 4.1 Odds ratio and 95%CI estimates for age at menopause and the incidence of
cardiovascular disease, the Study of Osteoporotic Fractures. The average age at natural
menopause (51 years) was used as reference value with odds ratio of 1.00. Model was adjusted
for diabetes and oophorectomy status, age, race, education, parity, postmenopausal hormone use,
BMI, waist to hip ratio, hypertension, smoking status and physical activity. Red curve: Odds
ratio, blue curve: upper limit of 95% confidence interval, green curve: lower limit of 95%
confidence interval,
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With the reported average age at menopause (51 years) as reference value, women who
reached menopause after this age appeared to have a statistically significant reduced risk
of incident cardiovascular disease.
On the other hand, oophorectomy after age 51 did not increase nor decrease the risk for
cardiovascular disease as the upper limit of the 95% confidence interval was always
above the null value (Odds ratio = 1.00) (figure 4.2).

Figure 4.2 Odds ratio and 95%CI estimates for age at bilateral oophorectomy and the incidence
of cardiovascular disease, the Study of Osteoporotic Fractures. The average age at natural
menopause (51 years) was used as reference value with odds ratio of 1.00. Model was adjusted
for diabetes and oophorectomy status, age, race, education, parity, postmenopausal hormone use,
BMI, waist to hip ratio, hypertension, smoking status and physical activity. Red curve: Odds
ratio, blue curve: upper limit of 95% confidence interval, green curve: lower limit of 95%
confidence interval,
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Cardiovascular disease Mortality

During a mean follow-up of 12.7 years, 1,395 deaths were documented with 46%
of all reported deaths attributed to CVD in NHANES III. Cardiovascular related mortality
rate was 17.7 per 1000 person years. CVD mortality was highest among women with
both diabetes and oophorectomy (20.9 per 1000 person years) (table 4.12). Having
diabetes or diabetes and oophorectomy predisposed women to increased cardiovascular
mortality (Figure 4.3). In age adjusted models, the risk of CVD mortality for participants
were as follows: diabetes and oophorectomy (HR: 2.49, 95%CI: 1.50-4.16), diabetes
without oophorectomy (HR: 1.74, 95%CI: 1.30-2.34) and oophorectomy without diabetes
(HR: 1.22, 95%CI: 0.84-1.79). In multivariable models with adjustments made for
race/ethnicity, education, body mass index, smoking status, total cholesterol,
hypertension, waist-to-hip ratio, age at menopause, hysterectomy, hormone therapy use,
family history of MI and physical activity, the risk of CVD death was still elevated in
women with both diabetes and oophorectomy (HR: 2.23, 95%CI: 1.25-3.99) as well as
diabetes without oophorectomy (HR: 1.79, 95%CI: 1.22-2.62), while that for women with
oophorectomy without diabetes did not attain statistical significance (HR:1.14, 95%CI:
0.65-2.00) (table 4:13). In analyses restricted to only diabetic women, oophorectomy did
not influence CVD mortality (HR: 1.44, 95%CI: 0.93-2.22). However compared to
women with diabetes and intact ovaries, diabetic women with oophorectomy before age
45 had a significantly elevated risk (HR: 1.92, 95%CI: 1.06-3.48).
The rate of mortality attributable to cardiovascular disease in the Study of
Osteoporotic Fractures, mortality after a mean follow up of 14.8 years was 14.6 per 1000
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person years. CVD mortality rates in women with diabetes without oophorectomy (28.9
per 1000 person years) and diabetes with oophorectomy (30.8 per 1000 person years)
were twice as high as the rate for the whole SOF population.

Table 4.12: Incidence of cardiovascular disease related mortality, NHANES III

(1988-1994)
N

Deaths

% Deaths

Mean followup (yrs)

Rate per 1000
person years

No Diabetes & No Oophorectomy

1695

356

15.3

12.05

17.4

Diabetes without oophorectomy

812

182

19.9

11.62

19.3

Oophorectomy without diabetes

506

94

15.5

12.64

14.7

Diabetes & Oophorectomy

211

52

22.0

11.76

20.9

Variables

Table 4.13: The risk of cardiovascular disease related mortality according to diabetes and
bilateral oophorectomy status, NHANES III (1988-1994)
Age Adjusted

Multivariable adjusted ¶

HR (95%CI)

HR (95%CI)

1 (Referent)

1 (Referent)

Diabetes without oophorectomy

1.74 (1.30-2.34)

1.79 (1.22-2.62)

Oophorectomy without diabetes

1.22 (0.84-1.79)

1.14 (0.65-2.00)

Diabetes & Oophorectomy

2.49 (1.50-4.16)

2.23 (1.25-3.99)

Variables
No Diabetes & No Oophorectomy
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Figure 4.3 Kaplan-Meier cumulative incidence estimates of fatal CVD events
among participants without a history of cardiovascular disease, NHANES (19881994)

Similar to the NHANES results, diabetic women with or without oophorectomy
had elevated risk for CVD mortality (Figure 4.4). Oophorectomy appeared to have an
adverse effect on women with diabetes. For instance, the risk of cardiovascular related
mortality was two-and-half fold in women with diabetes and oophorectomy while women
with diabetes but no oophorectomy had a twofold increased risk (table 4.14). Unlike
NHANES III in which age at oophorectomy in diabetic women influenced CVD
mortality risk, diabetic women in the SOF study who had oophorectomy before age 45
years had similar elevated risk as diabetic women who had oophorectomy at or after age
45 years when compared to women with neither oophorectomy nor diabetes.
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Additionally, in analyses restricted to diabetic women only, the risk of CVD mortality did
not statistically differ by oophorectomy status (HR: 1.39, 95%CI: 0.78-2.48) or age at
which oophorectomy was performed (p= 0.457).

Figure 4.4 Kaplan-Meier cumulative incidence estimates of CVD death in
participants without a history of heart disease, The Study of Osteoporotic Fractures.

131

Table 4.14: The risk of all cause and cardiovascular disease related mortality according to
diabetes and bilateral oophorectomy status, the Study of Osteoporotic Fractures
Age Adjusted

Multivariable adjusted ¶

N

HR (95%CI)

HR (95%CI)

All cause Mortality
No Diabetes & No Oophorectomy

5568

Diabetes without oophorectomy

383

1 (Referent)
1.85 (1.65-2.08)

1 (Referent)
1.72 (1.52-1.94)

Oophorectomy without diabetes

1465

1.11 (1.03-1.20)

1.04 (0.92-1.18)

Diabetes & Oophorectomy

124

2.32 (1.91-2.82)

2.17 (1.73-2.72)

Cardiovascular Disease Mortality
No Diabetes & No Oophorectomy

5568

Diabetes without oophorectomy

383

1 (Referent)
2.40 (2.01-2.88)

1 (Referent)
1.99 (1.65-2.39)

Oophorectomy without diabetes

1465

1.15 (1.01-1.31)

1.10 (0.90-1.35)

Diabetes & Oophorectomy

124

3.13 (2.30-4.26)

2.57 (1.18-3.67)

Variables

¶

Adjusted for baseline measures of age, education, age at menopause, hysterectomy status, parity,
postmenopausal hormone use, BMI, waist hip ratio, hypertension, prior history of cardiovascular
disease, diabetes, smoking status and physical activity

A summary of the estimates assessing the risk of cardiovascular disease in women with
and without diabetes, based on results from the third National Health and Nutritional
Examination Survey (1988-1994), the National Health and Nutritional Examination
Survey 1999-2010 and the Study of Osteoporotic Fractures are illustrated by figure 4.5
and figure 4.6. Women who had oophorectomy before age 45 were found to have
significantly increased risk for incident CVD compared to women without oophorectomy
(OR: 1.17, 95% CI: 1.04-1.37). Although early oophorectomy appeared to have an
increased risk for CVD related mortality, this did not approach statistical significance
(figure 4.7).
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Figure 4.5 Summary estimates of the risk of cardiovascular disease according to diabetes
and oophorectomy status
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Figure 4.6 Summary estimates of the risk of cardiovascular disease in women with diabetes
according to oophorectomy status as well as age at oophorectomy
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Figure 4.7 Summary estimates of the risk of cardiovascular disease in women according to
age at oophorectomy
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CHAPTER FIVE

DISCUSSION

Summary of findings

This is the first population based study to assess the effect of bilateral salpingo
oophorectomy on the risk of incident cardiovascular disease or cardiovascular disease
related mortality among diabetic women. Because androgen levels are increased in
diabetic women, we proposed that bilateral salpingo-oophorectomy would not be
associated with the increased CVD risk reported in non-diabetic women, and might
instead reduce the CVD in this at-risk population. Although diabetic women with
oophorectomy were found to have reduced levels of androgens, this analysis of 17,549
postmenopausal women from three different studies did not support an overall protective
effect of oophorectomy in diabetic women in reducing cardiovascular disease risk. This
observation was consistent when diabetic women with bilateral oophorectomy were
compared to either women with natural menopause without diabetes, or naturally
menopausal diabetic women.
Contrary to our a priori hypothesis, oophorectomy increased the risk of cardiovascular
disease mortality in diabetic women.
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Interestingly, the increased risk of adverse cardiovascular events in oophorectomized
diabetic women appeared to be limited to women who had oophorectomy before the
natural age average at menopause (51 years). Additionally, early age at natural
menopause, either natural or through surgical removal of the ovaries, predisposed women
to increased risk for non-fatal cardiovascular disease.

Discussions based on study hypotheses
Hypothesis One
When women end their reproductive years, there is an abrupt and profound
decline in estradiol production by the ovary, and the only remaining source of estrogens
is from androstenedione from the adrenals. By contrast, testosterone levels are relatively
unchanged through the menopausal transition (293), but are about 50% lower if the
ovaries are removed surgically
In the present study, older postmenopausal women in the Study of Osteoporotic
Fractures with bilateral oophorectomy were again found to have reduced levels of both
free and total testosterone. Earlier studies of androgen levels in postmenopausal women
were limited by both sample size and the use of assays with low sensitivity and poor
reliability (294, 295). However, liquid chromatography tandem mass spectrometry assays
–which are relatively accurate and provide precise measurements of sex steroid hormones
than prior immunoassay methods – confirm lower levels of testosterone levels in
postmenopausal women (38) and also among women with bilateral oophorectomy (296).
The ovary is known to produce testosterone. Laughlin et al (39), analyzed sex
steroid hormone levels in 684 women aged 50 to 89 years in the Rancho Bernardo Study,
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and reported reduced levels of both total and bioavailable testosterone by more than 40%
in women with bilateral oophorectomy compared to those with intact ovaries. This
association was independent of age and body mass index. Building on that observation,
Davison et al (253), in a cross-sectional study of 1,423 healthy women aged 18 to 79
years, demonstrated that levels of total testosterone, calculated free testosterone,
dehydroepiandrosterone sulfate, and androstenedione declined steeply with age.
Moreover, in women who were 55 years or older, those who reported a history of
bilateral oophorectomy had lower androgen levels (total and calculated free testosterone)
compared to similar aged women with intact ovaries. This study further demonstrated
that decline in testosterone levels begins before women arrive at menopause and that the
postmenopausal ovary is ongoing site of testosterone production (253). Measuring
androgens using ultrasensitive assays in 347 community-dwelling women aged 65 to 98
years enrolled in the Cardiovascular Health Study, Cappola et al (293), also reported that
women with bilateral oophorectomy had 23% lower total testosterone and 16% lower free
testosterone levels than those with at least one intact ovary, while estrogen use,
corticosteroid use, and low body mass index were independent predictors of the
relationship.
Several studies have identified biochemical and clinical hyperandrogenism in
women with diabetes mellitus (36, 82, 86), however the pathogenesis of this androgen
excess in diabetic women is not thoroughly understood. Furthermore, none of the studies
investigated androgen levels in diabetic women with oophorectomy. After showing that
diabetic women have lower levels of SHBG and elevated non SHBG bound testosterone
levels, Korytkowski et al (82), speculated that the ovaries are a source of excess
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androgens in postmenopausal diabetic women. While entirely plausible, no further
studies have yet attempted to test this theory. On the other hand, the adrenals may also
contribute to hyperandrogenemia in diabetic women. Stress-induced alterations in the
hypothalamic-pituitary-adrenal axis which leads to elevations in corticotrophin-releasing
factor and corticotrophin could drive an increase in androgen production (82), although,
DHEAS levels, an androgen produced by the adrenal cortex, were similar in diabetic and
non diabetic women in our study as in previous studies (82).
There are several potential mechanisms for the elevated levels of testosterone
postmenopausal diabetic women. In premenopausal women, luteinizing hormone (LH) is
known to drive the production of testosterone (297), and increased production of LH in
the menopause may stimulate the ovaries to produce more testosterone (35). Diabetic
women are insulin resistant, and hyperinsulinemia stimulates ovarian production of
testosterone while insulin resistance results in lower levels of SHBG (298), which
together may result in increased testosterone in diabetic women (36). Additionally, the
ovaries in diabetic women may have reduced ability to convert androgen to estrogen due
to reduction of ovarian aromatase activity (94). Evidence obtained from women with
polycystic ovary syndrome (PCOS), who are usually insulin resistant and at high risk for
glucose intolerance, further suggests an ovarian source of hyperandrogenemia in diabetic
women (93). Even when adrenal androgen secretion is suppressed by dexamethasone
administration, women with PCOS still exhibit higher androgen levels than normal
healthy women, suggestive of an ovarian origin of androgen excess (299, 300).
Moreover, elevations in luteinizing hormones coupled with hyperinsulinemia work
synergistically to increase ovarian enzymatic activity involved in the synthesis of
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testosterone precursors in women with PCOS (301). These observations are also
corroborated by evidence from in vitro studies in which cultured theca cells from PCOS
women showed increased androgen responsiveness to insulin (300).
In the present study, after adjusting for the effect of age and body mass index,
women with diabetes and bilateral oophorectomy, like non-diabetics, had lower levels of
total testosterone compared to diabetic women with no oophorectomy or naturally
menopausal women without oophorectomy. Taken together, these findings (which also
support the first hypothesis of the present study) are interesting since they suggest that
oophorectomy moderates levels of testosterone in diabetic women and consequentially
confirms an ovarian source of testosterone in postmenopausal diabetic women.
During the menopausal transition, androgen levels remain fairly stable while there
is a marked reduction in estradiol levels, resulting in a relatively higher androgenic
hormonal milieu in older women (253). It is possible that the prolong exposure to LH and
hyperinsulinemia which enhances androgen excess may alter plasma lipid profiles and
increase visceral adiposity accumulation to a greater extent in diabetic women, thereby
predisposing them to a higher cardiovascular disease risk (82). Accordingly, we
hypothesized that oophorectomy will moderate CVD risk in diabetic women by reducing
androgen levels. However, in multivariable models comparing diabetic women with
oophorectomy to diabetic women without oophorectomy or naturally menopausal women
with diabetes, no protective effect for oophorectomy was identified.
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Hypothesis Two
Contrary to our hypothesis, diabetic women with oophorectomy appeared to have
an increased risk for prevalent cardiovascular disease and cardiovascular related
mortality. Oophorectomy also appeared to be inversely associated with incident
cardiovascular disease in diabetic women, although the available sample size did not
provide sufficient statistical power to establish if this association truly exists. While the
risk of prevalent CVD was dependent on age at oophorectomy, CVD mortality was
independent of surgical removal of the ovaries. This perhaps portrays a complex
relationship between ovarian function and cardiovascular disease risk in diabetic women
that may not be explained simply by ovarian androgen loss. For example, a U-shaped
relationship between testosterone and CHD incidence was observed in a prospective,
population-based study of 639 postmenopausal women, with a mean age of 73.8 years
who were followed for a median of 12.3 years (266).
Low testosterone may signal systemic illness or an indication of subclinical heart
disease (266). The Multi-Ethnic Study of Atherosclerosis, which collected data on 1,947
postmenopausal women aged 45 to 84 years also reported a divergent influence of
testosterone on subclinical heart disease (302). While total and bioavailable testosterone
were positively associated with carotid artery intimal-medial thickness independent of
age, BMI, hypertension, smoking, HDL-cholesterol, LDL-cholesterol and insulin
sensitivity, bioavailable testosterone was inversely associated with presence of coronary
artery calcium (302). These results may suggest that an optimal range of testosterone may
exist for cardiovascular health in women (266).
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One important observation of notable significance is that the prevalence of current
hormone therapy use was four times higher in diabetic women with bilateral
oophorectomy compared to diabetic women without oophorectomy. Results from the
Women’s Health Initiative indicate that hormone therapy has an adverse effect on CVD
in women with diabetes (60, 303). The Estrogen Replacement and Atherosclerosis
randomized placebo-controlled trial of 250 postmenopausal women given conjugated
equine estrogen with or without medroxyprogesterone acetate, also showed that hormone
therapy influenced coronary heart disease progression significantly more in women with
diabetes than in women without diabetes (78). This may have driven the apparent
increased prevalent as well as incident cardiovascular related mortality risk in diabetic
women with oophorectomy. Strikingly, women with diabetes and oophorectomy tended
to be more likely to have a family history of myocardial infarction and diabetes which
may mean that such select populations may be a high risk population, although the
statistically non-significant reduced risk of incident CVD in the SOF study seems to
contradict this concept.

Hypothesis Three
Age at oophorectomy seems to moderate the risk of CVD among diabetic women
without ovaries since the elevated risk of CVD was limited to diabetic women with
oophorectomy at an earlier age. CVD risk was threefold in diabetic women who had an
oophorectomy before age 45 compared to diabetic women who underwent this surgical
procedure after age 45 years (p interaction = 0.001). Additionally the spline regression
demonstrated that bilateral oophorectomy performed before the average age at natural
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menopause increased CVD risk in women with or without diabetes. Conversely,
oophorectomy after the average age at natural menopause did not indicate risk or benefit
to cardiovascular health in either diabetic or non-diabetic women. This observation was
contrary to that observed for age at menopause whereby menopause after age 51 was
associated with a statistically significant reduced risk of incident CVD.
. A family history of heart disease was more common among younger diabetic
women who had oophorectomy. Our interpretation of these data is that oophorectomy
was performed more often in younger women who inherited a risk factor for heart
disease. One possibility is the Metabolic Syndrome with PCOS and anovulation. In
PCOS women who had developed diabetes, dysfunctional uterine bleeding may have led
to hysterectomy with/or without oophorectomy at a young age in this group of women
with insulin resistance and heart disease risk. This interpretation of the data would
explain the similar CVD risk in women with hysterectomy and oophorectomy compared
to those with hysterectomy alone in the WHI study(59), since dysfunctional uterine
bleeding may have resulted in hysterectomy with or without oophorectomy, depending on
the surgeon and the patient’s preference.
It is also possible that the disruption in ovarian function that accompanies
oophorectomy in younger women influences their CAD risk. Women who have
premature/early physiological menopause have been reported to have more coronary
atherosclerosis and an increased risk of CHD (41, 42, 47, 48). In a meta-analysis, Atsma
et al (41), reported a 27% increased risk of cardiovascular disease in women who had
early natural menopause compared to women who had menopause at or after age 51
years. Similarly, an early age at menopause among 35,616 naturally postmenopausal
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women in the Nurses' Health Study was associated with a 42% increased risk of CVD
events (46). Additionally, each one year decrease in age at menopause was associated
with a 3% increased risk of CVD (46).
On the other hand, the clinical evidence that oophorectomy leads to an elevated
CVD risk is both limited and controversial. Some studies have reported an increased risk
of CVD events in women who underwent oophorectomy before age 45 years (or the
average age at natural menopause) who did not use postmenopausal estrogen therapy (5153). However, others have not found the CVD risk to increase in women who underwent
oophorectomy without hormone therapy use before age 45 years; an observation which is
consistent even when the referent group was women with natural menopause (55) or
women with hysterectomy but ovarian conservation (59). Some studies have even argued
that post-surgical use of estrogens in women who have oophorectomy at an early age may
not protect against the progression of atherosclerosis. The Los Angeles Atherosclerosis
Study, which assessed the cross-sectional relationship between years since bilateral
oophorectomy and common carotid artery intima-media thickness in 269 women aged 45
to 60, reported that bilateral oophorectomy was associated with increasing atherosclerosis
independent of high density lipoprotein or low density lipoprotein cholesterol (297).
Interestingly, 90 percent of women with oophorectomy (at an average age of 40 years)
had a history of hormone therapy use, which suggests that postsurgical estrogen use may
not entirely compensate for the loss of estrogen or loss of the overall imbalance of
multiple sex hormones that occur when the ovaries are removed (297).
Although the appropriate age at which oophorectomy should be performed
remains controversial, some have even recommend oophorectomy for all women over the
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age of 40 years who undergo hysterectomy (304). While ovarian cancer is a rare disease
affecting 1.4% of women, CVD is the leading cause of morbidity and mortality in
women, and among diabetic women, heart disease accounts for 68% of all deaths (102,
305). Parker et al (304), in their Markov decision analytic model, reported that removal
of the ovaries in women younger than 65 years at the time of hysterectomy increased
their risk of coronary heart disease mortality while a clear benefit of hysterectomy with
ovarian conservation was observed. However after age 65 years, no difference in CHD
events was found in women with or without oophorectomy. The probability of surviving
to age 80 years after hysterectomy at ages 50 to 54 varied from 62.5% for ovarian
conservation without estrogen therapy to 53.9% for oophorectomy without estrogen
therapy (304). Similar to results from the spline regression, this decision analysis did not
find any age at which oophorectomy when performed, provided a protective effect for
coronary events.
Several mechanisms may exist through which bilateral oophorectomy increases
the risk of CVD in women. Bilateral salpingo oophorectomy causes additional hormonal
changes beyond those of natural menopause. In our spline regression analyses,
oophorectomy at the time of hysterectomy in premenopausal women was associated with
adverse cardiovascular health in both diabetic and non-diabetic women even when
postmenopausal hormone use is taken into account. The mechanism by which
oophorectomy elevates cardiovascular disease risk in both diabetic and non-diabetic
women may be related to an adverse cardiovascular risk profile among women who
undergo this surgical procedure (57-59). The abrupt cessation of ovarian function as a
consequence of bilateral oophorectomy resulting in decreased endogenous estrogens is
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suggested to adversely influence lipid profiles in premenopausal women, although this
has not been consistent across all studies (190). Among premenopausal women who
underwent bilateral oophorectomy, a sudden significant increase in total and LDL
cholesterol levels was observed three months post-surgery, together with a decrease in
HDL cholesterol (306-308). Plasma triglycerides did not change after surgery but
estrogen administration was reported to reverse these atherogenic changes in lipid profile
(306, 307). Punnonen et al (309), studying 25 women with bilateral oophorectomy
followed for up to 7 months, reported no increase in serum cholesterol but an increase in
serum triglycerides after surgery which peaked at 1 month and declined to pre-operative
levels after 6 months. It should be noted that these changes in lipid profile towards a
more atherogenic profile have also been reported in women transitioning naturally
through menopause (310).
Another mechanism by which bilateral oophorectomy may influence CVD risk is
through changes in body composition including fat distribution. Animal studies report
that bilateral oophorectomy increases abdominal fat (250-252), which can be reversed
with estrogen therapy (HT) (251, 252). In the third National Health and Nutritional
Examination Survey (311), obese women who underwent bilateral oophorectomy before
40 years of age had an increased risk of mortality, with the lack of HT use compounding
this effect. Since circulating estrogens suppress and androgens stimulate visceral fat
accumulation (234, 253), and nearly all the estrogens in cycling women are from the
ovary, early bilateral oophorectomy may predispose women to adverse cardiovascular
health by increasing abdominal fat and its production of adipokines.
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Assessing large artery stiffening, a biomarker of vascular aging which predisposes
women to CVD events, Gavin et al (312), reported that carotid artery compliance was
lower in women with hysterectomy alone and in women with both hysterectomy and
bilateral oophorectomy when compared to women with no hysterectomy. Interestingly,
this greater arterial stiffening with hysterectomy in estrogen-deficient postmenopausal
women aged 46 to 80 years was not related to an adverse CVD risk profile (312).
Additionally, no differences in traditional CVD risk factors (adiposity, blood pressure,
lipoproteins, glucose, and insulin) were identified between women with hysterectomy and
those without (312). This study (297), challenges the assumption that an adverse CVD
risk profile is the culprit for the elevated risk in CVD among oophorectomized women,
but offers another biological mechanism by which hysterectomy with bilateral
oophorectomy may influence women’s cardiovascular health.
Other population studies have also reported no difference in CVD risk profile in
women with and without oophorectomy with some even suggesting that women who
have oophorectomy have better CVD risk profiles. A Norwegian study (313) including
326 women with oophorectomy and 1,630 age-matched women reported that except for a
greater waist circumference, women with oophorectomy had a more favorable coronary
heart disease risk profile, including lower Framingham risk scores, more physical
activity, lower levels of total cholesterol, higher levels of high-density lipoprotein
cholesterol, lower systolic blood pressure, and lower body mass index. Results from the
studies by Gavin et al (312) and Michelsen et al (313) seem to contradict the data in the
present study (and other previously described observational studies) in which women in
NHANES and SOF studies with oophorectomy (with or without diabetes) were found to
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have adverse cardiovascular risk profile. Self-selection of women seeking risk-reducing
salpingo-oophorectomy (313), changes in lifestyle after surgery, survival and selection
bias (312), may explain why oophorectomy was associated with no difference or a
favorable CVD profile in women with oophorectomy compared to age matched women
with intact ovaries. For example, Gavin et al (312), included only women (with or
without oophorectomy) who were normotensive, nonsmokers, nondiabetic and not taking
any lipid lowering therapy, while Michelsen et al (313) sampled women from families
with hereditary breast and/or ovarian cancer who had undergone risk-reducing salpingooophorectomy after genetic counseling and were also more likely to establish a healthier
lifestyle.

Addressing the conundrum about oophorectomy and women’s long term health

A debate exists regarding the risks and benefits of prophylactic bilateral
oophorectomy at the time of hysterectomy. This debate has resulted in several revisions
in practice guidelines and recommendations. In 1999, the American College of
Obstetricians and Gynecologists stated that, “prophylactic oophorectomy should be based
not only on the patient’s age but also on other factors that weigh individual risk for
developing ovarian cancer against the loss of ovarian function” (204). However this
recommendation was revised in 2008 to “strong consideration should be given to
retaining normal ovaries in premenopausal women who are not at increased genetic risk
of ovarian cancer…Given the risk of ovarian cancer in postmenopausal women, ovarian
removal at the time of hysterectomy should be considered for these women” (314). Some
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authors have argued that since there is no effective screening method for ovarian cancer,
prophylactic oophorectomy at the time of hysterectomy is a good option to prevent
subsequent ovarian cancer which has 22,240 new cases each year (315, 316). They
further argue that prophylactic oophorectomy is associated with a 80–90% and 50–60%
reduced risk of ovarian and breast cancer, respectively (317). In high risk women (for
example BRCA mutation carriers), these estimates are higher with oophorectomy being
associated with an 85% reduction in BRCA1-associated gynecologic cancer risk as well
as a 72% reduction in BRCA2-associated breast cancer risk (318).
Proponents of ovarian conservation at the time of hysterectomy argue that despite
the protective effect of oophorectomy on the development of breast and ovarian cancer,
it has detrimental effects on long term health by increasing the risk of all cause mortality
(28%), lung cancer (45%), coronary heart disease (33%), stroke (62%), osteoporosis and
bone fractures (50%), cognitive impairment (60%) and Parkinsonism (80%) (317). These
estimates may even vary depending on the reference population, the age at
oophorectomy, and the use of postoperative hormone therapy (317). The cumulative
lifetime mortality rate from ovarian cancer for women after hysterectomy for benign
disease is usually reported be 1.4% or 1 in 70 (305). However, figure may be misleading
since this estimate is limited to women with BRCA1 or BRCA2 mutations or other highrisk germ-line mutations. In the general female population, the cumulative lifetime
mortality from ovarian cancer after hysterectomy for benign disease is 0.47%, or fewer
than one in 200 (305). Sightler et al (319) asserted that performing prophylactic
oophorectomy in women undergoing hysterectomy for benign conditions at age 40 or
older would prevent 1,000 women from getting ovarian cancer each year nationwide.
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Ovarian cancer is the fifth leading cause of death in women, and the leading cause of
death from all gynecologic cancers in the United States (316). Although ovarian cancer
results in more than 14,030 deaths each year (316), 401,495 women die of cardiovascular
disease annually (102). Moreover, no substantial reduction in ovarian cancer mortality is
observed when oophorectomy is performed before age 65 since ovarian cancer is a
relatively uncommon cause of death in this age group, especially when women with
documented germ-line mutations and pedigrees with high risk for ovarian cancer are not
considered (304). National estimates show that among women who undergo
hysterectomy, the prevalence of concurrent oophorectomy is 38% in those aged 18 to 44
and 78% among women aged 55 to 64 years (304). Parker et al (304), demonstrated that
hysterectomy with ovarian conservation does reduce the risk of ovarian cancer, with this
protective effect persisting for about 20 years. Therefore reducing a woman’s risk of
ovarian cancer with oophorectomy appears to be outweighed by the increasing likelihood
of cardiovascular disease events as well as other chronic conditions (320). In light of this
information the decision to remove otherwise healthy ovaries at the time of hysterectomy
for benign disease should be approached with great caution especially in younger women
since the risk of ovarian cancer in women less than 65 years is minimal compared to
cardiovascular diseases.

Strengths and limitations
This study has several notable strengths. A major one is the approach of three
different samples and study designs to investigate the effect of bilateral oophorectomy on
cardiovascular health in diabetic women, with serum measures of sex hormones
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evaluated to enhance the biological plausibility of study findings. Additionally, the use of
large population-based nationally representative samples/cohort of postmenopausal
women increases the generalizability of the findings. These prospective studies were also
of sufficient size and duration (> 18 years) to allow associations with incident
cardiovascular outcomes to be assessed with good precision. Furthermore, total
testosterone was measured by radioimmunoassay after extraction and aluminum oxide
column chromatography which exhibits good precision, sensitivity, and high accuracy
comparable to liquid chromatography-tandem mass spectrometry, in measuring female
androgen concentrations, (297).
However several limitations should be acknowledged. A component of our study
used a cross-sectional design, which precluded the determination of temporality.
Furthermore, a single measure of sex hormones was used to characterize each woman’s
hormonal status. Current hormone levels may not adequately reflect earlier levels and a
single measure maybe imprecise to some degree (286). However, some studies have
demonstrated that a single measurement for plasma sex hormones can reliably categorize
average levels over at least a three year period in postmenopausal women, with intraclass correlation coefficients (0.88, 95%CI:0.84-0.93) not varying by age or time since
menopause (321). In contrast to the NHANES studies which defined diabetes using
fasting glucose criteria and an oral glucose tolerance test, the SOF study utilized selfreported diabetes mellitus or use of anti-diabetic drugs to diagnose women with diabetes.
To add to that, the number of women with cardiovascular disease may be underestimated
since information was obtained by self-report of physician diagnosis. Using such criteria
may have missed women with subclinical diabetes or CVD. Nevertheless, a significant

151

association was found with regards to prevalent and incident cardiovascular disease. In
the SOF study, adjustment for lipids in multivariable models was not feasible since only a
subsample of women had measures of cholesterol and triglycerides.
Moreover, there is the potential for misclassifications of age at menopause and
oophorectomy status due to imprecise recall of events occurring many years before study
enrollment and that were not confirmed by medical record review. Women’s accuracy in
recalling age at oophorectomy seems to surpass recall age at natural menopause with less
variance over time; however the accuracy of reported ovarian removal has been observed
to be low when compared to medical records (sensitivity:64% and positive predictive
value of 100%) (42, 322). If misclassification by ovarian status was present, it would be
expected to bias the finding of this study towards the null. However, since significant
effects were identified in all three studies, the probability of such misclassification
occurring may be small. Survivor bias may have influenced results especially those from
the SOF study since follow-up began long after women underwent oophorectomy.
Analytical methods, such as inverse probability weighting to account for competing risks,
were not employed because it has been shown in many instances that this selection bias is
not severe unless survival is very low in the sampled population (323). Finally, the
presence of confounding by indication for gynecological surgery which may predispose
some women to a high risk of CVD events cannot be ruled out in the present study. In
studies that accounted for the indication of bilateral oophorectomy in multivariable
models, no difference with regards to CVD was found between women whose indication
for surgery was prophylactic or for benign conditions (52, 311). ). It should be noted,
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however, that accounting for confounding by indication using this strategy can only work
to the extent that these indications are accurately measured.

Conclusion and recommendations
While recent years have seen substantial advancements in prevention, early
diagnosis and treatment, CVD remains the major cause of death for U. S. adults.
However, the prevalence of diabetes, the most important CVD risk factor, is
skyrocketing, and imparts a greater risk of CVD in women than men. While the classic
risk factors for CVD are similar in both sexes, the hormonal environment, its change with
aging, and its connection to body composition differ drastically. Nonetheless, knowledge
of how these hormonal differences affect cardiovascular disease in women remains
fragmentary. Regrettably, investigations into androgen effects on cardiovascular health in
diabetic women are sparse and lacking. Although contentious, current experimental and
epidemiologic data suggest that increased testosterone levels may have adverse effects on
women’s cardiovascular health. Testosterone may have adverse effect on coronary
vasculature by increasing macrophage acetylated LDL uptake as well as adhesion of
monocytes to the vascular endothelium. However, it is unclear whether these effects
occur in vivo. Additionally, testosterone has been found to increase lipogenesis in
visceral fat deposits in women.
This present study identified lower levels of total testosterone in diabetic women
with bilateral oophorectomy than in those with intact ovaries, but did not find a
statistically significant association of free or total testosterone with cardiovascular
mortality. Additionally, no protective effect of reduced ovarian testosterone following
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oophorectomy in postmenopausal diabetic women was observed. The main findings of
this study do not of course, diminish the important role that androgens may play in
cardiovascular health in postmenopausal diabetic women, since hyperandrogenemia is
associated with dyslipidemia, hyperinsulinemia, insulin resistance, and increased
abdominal fat accumulation, all of which contribute to increasing the risk of
cardiovascular disease. Whether androgens adversely affect CVD risk in diabetic women
requires more research. Longitudinal investigations are needed into the effect of
testosterone on the progression of atherosclerosis in women and to establish the
mechanisms by which testosterone affects vascular walls as well as determine
testosterone thresholds at which CVD risk is increased. From a clinical perspective, this
will aid in identifying high risk postmenopausal women.
Oophorectomy before the average age at natural menopause was found to be
associated with an increase risk for cardiovascular events in women with or without
diabetes. This result that is consistent with some previous observational and clinical
investigations. This study draws attention to the fact that at no age in a woman’s life does
oophorectomy provide a positive effect on cardiovascular health. Overall, our results
convincingly refute the hypothesis that oophorectomy has a protective effect for CVD in
women with diabetes. The finding that a strong family history of heart disease, more so
than diabetes, might be linked to this CVD risk, and requires further study.
Prophylactic oophorectomy at the time of hysterectomy is a complex decision
requiring that the patient and physician consider multiple factors. Concerns about ovarian
cancer prevention should be balanced with the increased risk of cardiovascular disease
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and all cause mortality especially among premenopausal women who are at low risk for
gynecological cancers.
In conclusion, despite significant advances in preventive and interventional
cardiology, cardiovascular disease remains and will continue to be the most important
healthcare challenge in industrialized nations due to the increasing obesity epidemic and
sedentary lifestyle. The prevalence of CVD is greater in women and since women have a
longer longevity than men, they will bear the greatest burden of morbidity and disability
related with CVD. Diabetes mellitus amplifies adverse cardiovascular disease outcomes
more in women than men. Furthermore, diabetic women have poorer outcomes after
coronary interventions such as percutaneous coronary intervention and coronary artery
bypass grafting. The prevalence of diabetes is increasing in the United States. In the light
of this, it is important and prudent that we understand and identify underlying factors that
predispose diabetic women to cardiovascular events to aid in early detection of high risk
women in a timely fashion who may benefit from pharmacologic management of their
risk factors beyond lifestyle modification. This will have a major impact on
cardiovascular health in diabetic women by reducing morbidity and mortality, decreasing
healthcare costs, and improving quality of life.
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